Aromatic molecules for use in treatment of pathological conditions
Bisallyl ethers with specific aromatic ring configurations offer a solution to inhibit cell proliferation and enhance Notch signaling, effectively treating conditions like cancer and immune disorders.
Patent Information
- Application Number
- JP2024126422
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-08-24
- Filing Date
- 2024-08-01
- Publication Date
- 2024-11-26
AI Technical Summary
Existing treatments for pathological conditions such as cancer, skin disorders, and immune system-related disorders lack effective compounds that can inhibit cell proliferation or enhance the Notch signaling pathway to address hyperproliferative disorders and malignancies.
Development of bisallyl ethers composed of two 6-membered aromatic rings, one unsubstituted or substituted benzyl and the other optionally substituted with heteroatoms, which exhibit anti-proliferative and Notch-enhancing activities.
These compounds effectively inhibit cell proliferation and enhance the Notch signaling pathway, providing therapeutic benefits for various pathological conditions including cancer, skin disorders, and immune system-related disorders.
Smart Images

Figure 2024164040000001 
Figure 2024164040000002 
Figure 2024164040000003
Abstract
Description
[Technical field]
[0001] The present invention relates to novel compounds and their use as therapeutic agents in human and veterinary medicine. The compounds of the present invention can be used to treat pathological conditions including cancer, skin disorders, muscle disorders, lung disorders, disorders of the hematopoietic system, including the blood system, and disorders related to the immune system. [Background technology]
[0002] The present invention is directed to novel molecules that exhibit significant biological activity on cells of human and animal origin. These compounds were found to affect the growth and survival of cancer cells and primary non-cancerous cells. In particular, molecules were identified that are capable of completely or partially inhibiting cell proliferation or of causing cell death. Furthermore, some compounds were found to affect cell signaling pathways, in particular the Notch signaling pathway. These molecules were found to enhance the Notch signaling pathway.
[0003] That is, the present invention relates to compounds as defined herein, characterized by antiproliferative activity, which can be used for the treatment of benign and malignant hyperproliferative disorders in human and veterinary medicine.In particular, the present invention relates to compounds as defined herein for the treatment of disorders of the hematopoietic system, including blood system, and immune system-related disorders, both related to myeloid and lymphoid malignancies, malignant and non-malignant disorders of the skin and mucous membranes, including hyperproliferative disorders of muscle, such as keratinization disorders, muscle hyperplasia and muscle hypertrophy, disorders of the neuroendocrine system, non-melanoma skin cancers, including squamous cell carcinoma and basal cell carcinoma, hyperproliferative disorders of the skin and mucous membranes, such as actinic keratosis, cancers and precancerous lesions, hyperproliferative disorders and cancers of the oral cavity and tongue, hyperproliferative disorders and cancers of the neuroendocrine system, such as medullary thyroid carcinoma, hyperproliferative disorders and cancers of the hematopoietic system, including blood system, such as leukemia and lymphoma, hyperproliferative disorders and cancers of the lung, breast, stomach, urogenital tract, including ovarian cancer, such as cervical cancer, and cancers in human and veterinary medicine.
[0004] Biological activity, such as the anti-proliferative activity of the claimed compounds, may be attributable to, but is not limited to, Notch signaling enhancing activity, i.e. the present invention also relates to compounds as defined herein characterized by Notch enhancing activity, which can be used for the treatment of pathological conditions responsive to Notch regulation, such as cancer, skin diseases, muscle disorders, disorders of the hematopoietic system, including the blood system, and immune system-related disorders in human and veterinary medicine. Summary of the Invention
[0005] The compounds of the present invention relate to bisallyl ethers composed of two 6-membered aromatic rings, where one of the aromatic rings is an unsubstituted or substituted benzyl ring and the other aromatic ring is an unsubstituted or substituted aryl ring, which optionally contains an N-atom, i.e., optionally a 6-membered heteroaromatic ring. All such bisallyl ether structures share the common feature of containing substituents at both para positions of the ether bond, where such substituents on the benzene ring, which cannot be heteroaromatic rings, are preferably non-polar residues and / or sterically undemanding residues. and such substituents on the aryl ring, which may optionally be a heteroaromatic ring, are preferably selected from structural units containing large amounts of heteroatoms.
[0006] A first aspect of the present invention relates to compounds of formula (I) and their salts and solvates:
[0007] [ka]
[0008] (In the formula, R 1 is C1-C 12 Preferably C4-C 12 Alkyl, C2-C 12 Preferably C4-C 12 Alkenyl, C2-C 12 Preferably C4-C 12 Alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C5-C 12Bicycloalkyl, C7-C 12 Bicycloalkenyl, C8-C 14 Tricycloalkyl, -OC1-C 12 Preferably -OC3-C 12 Alkyl, -OC2-C 12 Preferably -OC3-C 12 Alkenyl, -OC2-C 12 Preferably -OC3-C 12 Alkynyl, -OC3-C8 cycloalkyl, -OC5-C8 cycloalkenyl, -OC5-C 12 Bicycloalkyl, -OC7-C 12 Bicycloalkenyl, -OC8-C 14 Tricycloalkyl, -SC1-C 12 Preferably -SC3-C 12 Alkyl, -SC2-C 12 Preferably -SC3-C 12 Alkenyl, -SC2-C 12 Preferably -SC3-C 12 Alkynyl, -SC3-C8 cycloalkyl, -SC5-C8 cycloalkenyl, -SC5-C 12 Bicycloalkyl, -SC7-C 12 Bicycloalkenyl, -SC8-C 14 Tricycloalkyl, -NHR 7 Or -NR 7 R 8 (In the formula, R 7 and R 8 are C1-C 12 Preferably C3-C 12 Alkyl, C2-C 12 Preferably C3-C 12 Alkenyl, C2-C 12 Preferably C3-C 12 Alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C5-C 12 Bicycloalkyl, C7-C 12 Bicycloalkenyl, C8-C 14 tricycloalkyl or R 7 R 8can form a ring structure together with; wherein said ring structure containing an N atom is selected from a 3- to 8-membered cyclic structure or a 5- to 12-membered bicyclic structure, and wherein all said ring structures can further contain one or more heteroatoms independently selected from O, S and N in place of the carbon atoms contained in the ring structure, particularly wherein such substitution results in a residue containing at least twice the number of C atoms than heteroatoms independently selected from O, S and N); Here, R 1 , R 7 and R 8 All alkyl, alkenyl and alkynyl residues included in the definition may be linear or branched and may be unsubstituted or substituted with -F, -Cl, -Br, -I, -CN, -NCO, -NCS, -OH, -NH2, -NO2, =O, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C5-C 12 Bicycloalkyl, C7-C 12 Bicycloalkenyl, C8-C 14 substituted with one or more substituents independently selected from tricycloalkyl, -OC1-C5 alkyl such as -OCH3 linear or branched, -OC3-C5 cycloalkyl such as -O(cyclopropyl), -NH(C1-C5 alkyl) linear or branched, -N(C1-C5 alkyl)(C1-C5 alkyl), -NH(C3-C5 cycloalkyl) such as -NH(cyclopropyl), -N(C3-C5 cycloalkyl)(C3-C5 cycloalkyl), linear or branched -N(C1-C5 alkyl)(C3-C5 cycloalkyl); Here, R 1 , R 7 and R 8 When alkyl, alkenyl and alkynyl residues included in the definition are substituted with one or more substituents that are =O, such substitutions at =O are immediately cannot be one of the groups selected from C=O, S=O and N=O attached to an aromatic ring; 1 , R 7 and R 8All cyclic, bicyclic and tricyclic structures, including cycloalkyl, cycloalkenyl, bicycloalkyl, bicycloalkenyl and tricycloalkyl residues included in the definition of are unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, -CN, -NCO, -NCS, -OH, -NH2, -NO2, =O, C1-C5 alkyl such as linear or branched -CH3, -OC1-C5 alkyl such as linear or branched -OCH3, linear or branched -NH(C1-C5 alkyl), linear or branched -N(C1-C5 alkyl)(C1-C5 alkyl), -NH(C3-C5 cycloalkyl) such as -NH(cyclopropyl), -N(C3-C5 cycloalkyl)(C3-C5 cycloalkyl), linear or branched -N(C1-C5 alkyl)(C3-C5 cycloalkyl); Here, R 1 , R 7 and R 8 All alkyl, alkenyl and alkynyl residues included in the definition may contain, instead of a carbon atom, one or more heteroatoms independently selected from O, S and N, and where such substitution results in a residue containing at least twice the number of C atoms than heteroatoms independently selected from O, S and N, and where such substitution cannot be one of the groups selected from C=O, S=O and N=O directly attached to the aromatic ring; Here, R 1 , R 7 and R 8 All cycloalkyl, cycloalkenyl, bicycloalkyl, bicycloalkenyl and tricycloalkyl residues included in the definition of may contain one or more heteroatoms independently selected from O, S and N instead of carbon atoms, and where such a substitution results in a residue containing at least the same number of C atoms as heteroatoms independently selected from O, S and N; Here, R 1 , R 7 and R 8All alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, bicycloalkyl, bicycloalkenyl and tricycloalkyl residues included in the definition may be partially or fully halogenated, in particular fluorinated, more in particular perfluorinated; wherein bicyclic and tricyclic moieties include fused, bridged and spiro systems; and where R 1is preferably methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, isopropyl, sec-butyl, tert-butyl, tert-pentyl, tert-octyl, 3-pentyl, -CF3, -CF2CF3, -(CF2)2CF3, -CH(CF3)2, -CH2SCH3, -CH2CH2SCH3, -CH2SCH2CH3, -CH2CH2SCH2CH3, methoxymethyl, methoxyethyl, methoxypropyl, ethoxymethyl, ethoxyethyl, propoxymethyl, Dimethyl-aminomethyl, dimethyl-aminoethyl, diethyl-aminomethyl, ethyl-methyl-aminomethyl, cyclopropyl, methyl-cyclopropyl, ethyl-cyclopropyl, trifluoromethyl-cyclopropyl, perfluoroethyl-cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, bicyclopentyl, bicyclohexyl, bicycloheptyl, preferably norbornyl, bicyclooctyl, bicyclooctenyl, bicyclononyl, methylbicyclononyl, ada Mantyl, tricyclodecyl, oxiranyl, oxetanyl, tetrahydrofuranyl, methyltetrahydrofuranyl, trimethyltetrahydrofuranyl, tetrahydropyranyl, aziridinyl, N-methylaziridinyl, azetidinyl, N-methylazetidinyl, difluoroazetidinyl, pyrrolidinyl, N-methylpyrrolidinyl, piperidinyl, N-methylpiperidinyl, difluoropiperidinyl, thiiranyl, thietanyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, dioxanyl, pipera dithianly, dimethylpiperazinyl, dithianly, morpholinyl, N-methylmorpholinyl, thiomorpholinyl, N-methylthiomorpholinyl, oxa-azaspiroheptyl, N-methyloxa-azaspiroheptyl, azaspiroheptyl, N-methylazaspiroheptyl, thia-azaspiroheptyl, N-methylthia-azaspiroheptyl, difluorothia-azaspiroheptyl, azaspirooctyl, N-methylazaspirooctyl, oxa-azaspirooctyl, N-methyloxa -Azaspirooctyl, oxa-azaspirononyl, N-methyloxa-azaspirononyl, azaspirononyl, N-methylazaspirononyl, oxa-azaspirodecyl, N-methyloxa-azaspirodecyl, azaspirodecyl, N-methylazaspirodecyl, dihydro-oxazinyl, N-methyldihydro-oxazinyl, oxazolidinyl, N-methyloxazolidinyl, dioxolanyl, imidazolidinyl, N-methylimidazolidinyl, N,N-dimethylimidazolidinyl, azepanyl, N-methylazepanyl, azaspirohexyl, N-methylazaspirohexyl, oxa-azadispirodecyl, N-methyloxa-azadispirodecyl, azadispirodecyl, N-methylazadispirodecyl, oxa-azabicyclooctyl, N-methyloxa-aza azabicyclooctyl, azabicyclooctyl, N-methylazabicyclooctyl, azabicycloheptyl, N-methylazabicycloheptyl, azabicyclononyl, N-methylazabicyclononyl, azaadamantyl, -O(adamantyl), oxa-azabicyclononyl, N-methyloxa-azabicyclononyl, oxa-azabicycloheptyl, N-methyloxa-azabicycloheptyl, diazabicyclooctyl, N-methyldiazabicyclooctyl, N,N-dimethyldiazabicyclooctyl, diazabicycloheptyl, N-methyldiazabicycloheptyl, N,N-dimethyldiazabicycloheptyl; 4-oxocyclohexyl; 3-oxocyclopentyl; 2-oxocyclobutyl, 4-oxobicyclo[4.1.0]heptan-1-yl; and where R 1 is even more preferably C4-C 12 Alkyl, C4-C 12 Alkenyl, C4-C 12 are selected from alkynyl, cyclic, bicyclic and tricyclic residues, where the alkyl, alkenyl and alkynyl residues are preferably branched, including:
[0009] [ka]
[0010] R2 -R 5 are each independently -H, -F, -Cl, -Br, -I, -CN, -NCO, -NCS, -OH, -NH2, -NO2, linear or branched C1-C4 alkyl, linear or branched C2-C4 alkenyl, linear or branched C2-C4 alkynyl, C3-C6 cycloalkyl, -CH2(C3-C6 cycloalkyl), linear or branched -OC1-C3 alkyl, -O(cyclopropyl), linear or branched -NH(C1-C3 alkyl), linear or branched -N(C1-C3 alkyl)(C1-C 3 alkyl), -NH(cyclopropyl), -N(cyclopropyl)2, linear or branched -N(C1-C3 alkyl)(cyclopropyl); Here, R 2 -R 5 All alkyl, alkenyl, alkynyl and cycloalkyl residues included in the definition are unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, -CH3, -CF3, -OH and -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2; Here, R 2 -R 5 All alkyl, alkenyl, alkynyl and cycloalkyl residues included in the definition may contain one or more heteroatoms independently selected from O, S and N in place of a carbon atom, and wherein such substitution cannot be one of the groups selected from C=O and S=O directly attached to the aromatic ring; Here, R 2 -R 3 Each of R is preferably -H, 4 is preferably -H or -F, R 5is preferably -H, -F, -Cl, -Br, -CH3, -CF3, -CH=CH2, -C≡CH, -CH2OH, -CH2NHCH3, -OH, -OCH3, -OCF3, cyclopropyl, oxiranyl, -CH2-N-morpholinyl, -C(CH3)3, -CH2OCH3, -NO2, -CN, -NH2, -N(CH3)2, -OCH(CH3)2, -CH2NH2, -CH2N(CH3)2; where the substituent R 1 From R 5 The six-membered aromatic ring to which is attached is preferably selected from:
[0011] [ka]
[0012] X 1 -X 4 are N and CR independently of each other. 9 , C.R. 10 , C.R. 11 , C.R. 12 Selected from; R 9 -R 12 are each independently -H, -F, -Cl, -Br, -I, -CN, -NCO, -NCS, -OH, -NH2, -NO2, linear or branched C1-C4 alkyl, selected from linear or branched C2-C4 alkenyl, linear or branched C2-C4 alkynyl, C3-C6 cycloalkyl, -CH2(C3-C6 cycloalkyl), linear or branched -OC1-C3 alkyl, -O(cyclopropyl), linear or branched -NH(C1-C3 alkyl), linear or branched -N(C1-C3 alkyl)(C1-C3 alkyl), -NH(cyclopropyl), -N(cyclopropyl)2, linear or branched -N(C1-C3 alkyl)(cyclopropyl); Here, R 9 -R 12All alkyl, alkenyl, alkynyl and cycloalkyl residues included in the definition are unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, -CH3, -CF3, -OH and -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2; Here, R 9 -R 12 All alkyl, alkenyl, alkynyl and cycloalkyl residues included in the definition may contain one or more heteroatoms independently selected from O, S and N in place of a carbon atom, and wherein such substitution cannot be one of the groups selected from C=O and S=O directly attached to the aromatic ring; Here, R 9 -R 12 is preferably selected from -H, -F, -Cl, -Br, -CH3, -CF3, -OH, -OCH3, -OCF3, cyclopropyl, oxiranyl, -C(CH3)3, -N(CH3)2, -NH2, -CN, -CH2OCH3, -OCH(CH3)2, -CH2NH2, -CH2N(CH3)2, -CH2OH, -NO2, -CH2-N-morpholinyl; and wherein X defined in general formula (I) 1 -X 4 is preferably selected from:
[0013] [ka]
[0014] R 6 is -H, C1-C8 preferably C1-C4 alkyl, C2-C8 preferably C2- C4 alkenyl, C2-C8 preferably C2-C4 alkynyl, C3-C6 cycloalkyl, C5-C6 cycloalkenyl, C5-C 12 Bicycloalkyl, C7-C 12 Bicycloalkenyl, C8-C 14 tricycloalkyl, as well as aromatic and heteroaromatic residues, preferably 6-membered aromatic rings and 5- to 6-membered heteroaromatic rings; and wherein the bicyclic and tricyclic moieties include fused, bridged and spiro systems; Here, R 6 The cycloalkyl, cycloalkenyl, bicycloalkyl, bicycloalkenyl, tricycloalkyl, aromatic and heteroaromatic residues included in the definition of R are optionally linked via a C1 alkylene or C2 alkylene or C3 alkylene linker. 6 can be bonded to N; Here, R 6 All aromatic and heteroaromatic residues included in the definition are unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, -CN, -NCO, -NCS, -OH, -NH2, -NO2, linear or branched C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, cyclopropyl, -OC1-C3 alkyl such as linear or branched -OCH3, -O(cyclopropyl), linear or branched -NH(C1-C3 alkyl), linear or branched -N(C1-C3 alkyl)(C1-C3 alkyl), -NH(cyclopropyl), -N(cyclopropyl)2, linear or branched -N(C1-C3 alkyl)(cyclopropyl); Here, R 6 All alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, bicycloalkyl, bicycloalkenyl and tricycloalkyl residues, as well as alkylene linkers, included in the definition of are linear or branched and unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, -CN, -NCO, -NCS, -OH, -NH2, =O, linear or branched C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, cyclopropyl, -OC1-C3 alkyl such as linear or branched -OCH3, -O(cyclopropyl), linear or branched -NH(C1-C3 alkyl), linear or branched -N(C1-C3 alkyl)(C1-C3 alkyl), -NH(cyclopropyl), -N(cyclopropyl)2, linear or branched -N(C1-C3 alkyl)(cyclopropyl); Here, R 6 All alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, bicycloalkyl, bicycloalkenyl, tricycloalkyl and heteroaromatic residues, as well as alkylene linkers, included within the definition of may contain one or more heteroatoms independently selected from O, S and N in place of carbon atoms; Here, R 6 is preferably -H, -CH3, -CH2CH3, n-propyl, isopropyl, cyclopropyl, -CF3 and -CF2CF3, benzyl, tert-butyl, phenyl, cyclohexyl, 1-phenylethyl, 2,2-dimethyl-1-phenylpropyl, (1-naphthyl)-methyl, 4-methoxybenzyl, 4-trifluoromethylbenzyl, tetrahydropyranyl; Here, R 2 -R 6 and R 9 -R 12 All alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, bicycloalkyl, bicycloalkenyl, tricycloalkyl, aromatic and heteroaromatic residues included in the definition may be partially or fully halogenated, in particular fluorinated, more in particular perfluorinated; Y is -H, linear or branched C1-C6 alkyl, linear or branched C2-C6 alkenyl, linear or branched C2-C6 alkynyl, C3-C6 cycloalkyl, C5-C6 cycloalkenyl, -OH, linear or branched -OC1-C6 alkyl, linear or branched -OC2-C6 alkenyl, linear or branched -OC2-C6 alkynyl, -OC3-C6 cycloalkyl, -OC5-C6 cycloalkenyl, -CN, aromatic and heteroaromatic residues preferably 6-membered aromatic rings and 5- to 6-membered heteroaromatic rings, -S(O)R 13 and -S(O)R 13 (In the formula, R 13 is a linear or branched C1-C6 alkyl, a linear or branched C2-C6 alkenyl, a linear or branched C2-C6 alkynyl, a C3-C6 cycloalkyl, a C5-C6 cycloalkenyl , -CF3, and -C6H4CH3; wherein all cycloalkyl, cycloalkenyl, aromatic and heteroaromatic residues included in the definition of Y can be optionally linked to the N to which Y is attached via a C1 alkylene or C2 alkylene or C3 alkylene or -O- or -O-CH2- or -O-CH2-CH2- linker; wherein all aromatic and heteroaromatic residues included in the definition of Y are unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, -CN, -NCO, -NCS, -OH, -NH2, -NO2, linear or branched C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, cyclopropyl, -OC1-C3 alkyl such as linear or branched -OCH3, -O(cyclopropyl), linear or branched -NH(C1-C3 alkyl), linear or branched -N(C1-C3 alkyl)(C1-C3 alkyl), -NH(cyclopropyl), -N(cyclopropyl)2, linear or branched -N(C1-C3 alkyl)(cyclopropyl); wherein all alkyl, acyclic, ... Alkenyl, alkynyl, cycloalkyl and cycloalkenyl residues, as well as alkylene linkers, are linear or branched and unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, -CN, -NCO, -NCS, -OH, -NH2, =O, linear or branched C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, cyclopropyl, linear or branched -OC1-C3 alkyl such as -OCH3, -O(cyclopropyl), linear or branched -NH(C1-C3 alkyl), linear or branched -N(C1-C3 alkyl)(C1-C3 alkyl), -NH(cyclopropyl), -N(cyclopropyl)2, linear or branched -N(C1-C3 alkyl)(cyclopropyl); wherein all alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and heteroaromatic residues, as well as alkylene linkers, included within the definition of Y, can contain one or more heteroatoms independently selected from O, S and N in place of carbon atoms; wherein all alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aromatic and heteroaromatic residues, as well as alkylene linkers included in the definition of Y, may be partially or fully halogenated, in particular fluorinated, more in particular perfluorinated; wherein Y is preferably -H, -CH3, -CH2CH3, n-propyl, isopropyl, cyclopropyl, cyclohexyl, tetrahydropyranyl, -CF3, -CF2CF3, -OH, -OCH3, -OCH2CH3, -OCH2(cyclopropyl), -CN, -S(O)C(CH3), -S(O)2CH3, -S(O)2CF3, -S(O)2C6H4CH3, -OCH2C6H5 and -OC6H5; and R 6 is -H or -CH3 or benzyl, Y is preferably -OH, -OCH3, -OCH2CH3, -OCH2 (cyclopropyl); Here, Y is R 6 can form a ring structure together with the N atom of formula I, wherein said ring structure containing the N atom of formula I is selected from a 3-membered ring, a 4-membered ring, a 5-membered ring, a 6-membered ring, from a 5- to 12-membered bicyclic residue, from an 8- to 14-membered tricyclic residue, and from a heteroaromatic residue, wherein all rings, bicyclic, tricyclic and heteroaromatic residues can further contain one or more heteroatoms independently selected from O, S and N in place of carbon atoms contained in the ring structure, and wherein all rings, bicyclic, tricyclic and heteroaromatic residues are unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, -CN, -NCO, -NCS, -OH, -OCH3, -NH2, -NHCH3, -N(CH3)2, =O, -CH3, -CF3, morpholinyl; and wherein the bicyclic and tricyclic moieties include fused, bridged and spiro systems; where R containing the N atom of formula I 6The ring structure of Y taken together is preferably aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, difluoropiperidinyl, morpholinyl, morpholinylazetidinyl, hydroxyazetidinyl, azetidinonyl, azetidinyl , difluoroazetidinyl, azaspirohexyl, azaspiroheptyl, difluoroazaspiroheptyl, hydroxyazaspiroheptyl, methylhydroxyazaspiroheptyl, trifluoromethylhydroxyazaspiroheptyl, azaspirooctyl, azaspirononyl, oxa-azaspiroheptyl, oxa-azaspirooctyl, oxa-azaspirononyl, thia-azaspiroheptyl, oxazolidinyl, tetrahydro-oxazinyl, isoxazolidinyl, oxazinane, isoxazolidine, piperazine; and wherein R containing an N atom of formula I 6 The ring structure of Y taken together is even more preferably selected from:
[0015] [ka]
[0016] Z 1 and Z 2 is selected from the following groups:
[0017] [ka]
[0018] Here, Z 1 is selected from linear or branched C1-C3 alkyl, preferably -CH3, cyclopropyl, oxiranyl, N-methyl-aziridinyl, thiiranyl, -CN, -N3, -CF3, -CF2CF3, and wherein Z 2 are independently selected from -H and linear or branched C1-C3 alkyl, preferably -CH3, -CF3, -CF2CF3 (general formula Ia); Here, Z 1is preferably -CH3, -CF3, -CN, cyclopropyl; and / or wherein Z 2 is preferably -H, -CH3 and -CF3; for example:
[0019] [ka]
[0020] Or here, Z 1 and Z 2 Together, =O, =S, =NR 14 (general formula Ib); 14 is selected from -H, -OH, -OCH3, -CN, -S(O)C(CH3)3, -S(O)2CH3, -S(O)2CF3, linear or branched C1-C3 alkyl, preferably -CH3, cyclopropyl, -CF3, -CF2CF3, -CH2CF3, -C6H5, -CH2C6H5; Here, Z 1 and Z 2 are preferably =O, =NR 14 where R 14 is preferably selected from -H, -CH3, cyclopropyl, -OH, -OCH3, -CN:
[0021] [ka]
[0022] Or here, Z 1 and Z 2taken together form a cyclic residue including the carbon atom to which they are attached (general formula Ic); wherein the cyclic residue is selected from 3-, 4-, 5- and 6-membered rings, wherein all rings may optionally contain one or more heteroatoms independently selected from O, S and N in place of the carbon atoms contained in the ring structure; and wherein all rings are unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, -CN, -NCO, -NCS, -OH, -OCH3, -NH2, -NHCH3, -N(CH3)2, =O, -CH3 and -CF3; Here, Z 1 and Z 2 together preferably form a 3- or 4-membered cyclic residue including the carbon atom to which they are attached, wherein said cyclic residue is preferably selected from cyclopropyl, cyclobutyl, oxiranyl, oxetanyl, aziridinyl, azetidinyl and thietanyl; and wherein said cyclic residue is optionally substituted, preferably with -F, -OH, -OCH3, -NH2, -NHCH3, -N(CH3)2, =O, -CH3 and -CF3; and wherein said cyclic residue is even more preferably selected from:
[0023] [ka]
[0024] Here, Z 1 and Z 2 All alkyl and cyclic residues included in the definition may be partially or fully halogenated, in particular fluorinated, more in particular perfluorinated. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0025] R 1 -R 14 , X 1 -X 4 , Z 1 , Z 2The following preferred definitions of and Y may apply, optionally independently and / or in combination, to all aspects, including preferred and certain aspects, to all embodiments, including preferred and certain embodiments, and to all subgenera as defined herein. 1) R 1 preferably contains 4 or more, preferably 6 or more, even more preferably 7 or more carbon atoms; 2) R 1 is preferably selected from branched alkyl, alkenyl and alkynyl residues; 3) R 1 is preferably selected from cyclic, bicyclic and tricyclic structures, where the bicyclic and tricyclic moieties include fused, bridged and spiro systems; 4) R 1 preferably does not contain heteroatoms; 5) R 1 is preferably selected from cyclohexyl, norbornyl, bicyclooctyl, bicyclononyl, methylbicyclononyl, tricyclodecyl, most preferably adamantyl, such as 1-adamantyl and 2-adamantyl; 6) R 1 is preferably R 1 7) R 1 is preferably selected from tetrahydropyranyl, N-methylpiperidinyl, morpholinyl, 4-oxocyclohexyl, azabicycloheptyl, N-methylazabicycloheptyl, oxa-azabicycloheptyl, N-methyldiazabicycloheptyl, azabicyclooctyl, diazabicyclooctyl, N-methyldiazabicyclooctyl, oxa-azabicyclooctyl, azabicyclononyl, azaadamantyl and -O(adamantyl); 8) R 2 -R 5 Preferably, two, more preferably three, substituents independently selected from are -H, i.e., R 2 -R 5Preferably two, more preferably one, substituent independently selected from are different from -H; 9) R 2 -R 5 are different from -H and are located ortho to the ether bond, then these two substituents are preferably different from -F, -Cl, -Br, -I and -NO2, and more preferably different from each other; 10) X 1 -X 4 The ring atom composition defined by is preferably X 1 -X 4 All of the above are CR 9 , C.R. 10 , C.R. 11 , C.R. 12 or X 1 -X 4 One of them is N and the other three are CR 9 , C.R. 10 , C.R. 11 , C.R. 12 or X 1 -X 4 Two of them are N and the other two are CR. 9 , C.R. 10 , C.R. 11 , C.R. 12 i.e., the aromatic or heteroaromatic ring is selected from benzene, pyridine, pyrimidine, pyridazine and pyrazine; 11) R 9 -R 12 Preferably, two, or more preferably three, substituents independently selected from are -H, i.e., R 9 -R 12 Preferably two and more preferably one substituent independently selected from are different from -H; 12) R 9 -R 12 are different from -H and are located ortho to the ether bond, then these two substituents are preferably different from -F, -Cl, -Br, -I and -NO2, and more preferably different from each other; 13) Y is preferably selected from residues included in the general definition of Y that are linked via an oxygen atom to the N to which Y is attached.
[0026] A preferred aspect of the present invention relates to compounds of general formula (Ib) and salts and solvates thereof, wherein Z 1 and Z 2 are taken together as =O, and where R 6 and at least one of Y is different from H; and R 1 -R 5 , R 7 -R 13 and X 1 -X 4 is as defined in general formula (I), including the substituents and preferred definitions.
[0027] A further preferred aspect of the invention relates to compounds of general formula (I) and their salts and solvates, in which Y is selected from residues included in the general definition of Y, linked via an oxygen atom to the N to which Y is attached, and wherein Y is even more preferably -OH, -OCH3, -OCH2CH3, -OCH2(cyclopropyl), -OC6H5 and -OCH2C6H5; and R 1 -R 12 , R 14 , X 1 -X 4 , Z 1 and Z 2 is as defined in general formula (I), including the substituents and preferred definitions;
[0028] A further preferred aspect of the present invention relates to compounds of general formula (I) and salts and solvates thereof, wherein R 1 is R 1 and selected from residues containing 4 or more, preferably 6 or more, and even more preferably 7 or more carbon atoms, which are included in the general definition of and where R 1 does not contain heteroatoms, and where R 1is even more preferably selected from cyclic, bicyclic and tricyclic structures; and where R 1 is even more preferably selected from cyclohexyl, norbornyl, bicyclooctyl, bicyclononyl, methylbicyclononyl, tricyclodecyl and adamantyl; and where R 1 is most preferably adamantyl, and R 2 -R 6 , R 9 -R 14 , X 1 -X 4 , Z 1 , Z 2 and Y is as defined in general formula (I), including the substituents and preferred definitions.
[0029] A further preferred aspect of the present invention relates to compounds of general formula (I) and salts and solvates thereof, wherein R 1 is R 1 and selected from residues containing 4 or more, preferably 6 or more, and even more preferably 7 or more carbon atoms, which are included in the general definition of and where R 1 is R 1 and one or more, preferably one to two, heteroatoms independently selected from O, S and N in place of the carbon atoms contained in and where R 1 is even more preferably selected from cyclic, bicyclic and tricyclic structures, or 1 is selected from residues having cyclic, bicyclic and tricyclic structures; and where R 1is even more preferably selected from tetrahydropyranyl, N-methylpiperidinyl, morpholinyl, 4-oxocyclohexyl, azabicycloheptyl, N-methylazabicycloheptyl, oxa-azabicycloheptyl, N-methyldiazabicycloheptyl, azabicyclooctyl, diazabicyclooctyl, N-methyldiazabicyclooctyl, oxa-azabicyclooctyl, azabicyclononyl, aza-adamantyl and O-(adamantyl); and where R 1 is most preferably tetrahydropyranyl, N-methylpiperidinyl, morpholinyl, 4-oxocyclohexyl, azabicyclooctyl, aza-adamantyl and O-(adamantyl); and R 2 -R 14 , X 1 -X 4 , Z 1 , Z 2 and Y is as defined in general formula (I), including the substituents and preferred definitions.
[0030] A further preferred aspect of the invention relates to compounds of general formula (I) falling within the sub-genus defined herein, as well as salts and solvates thereof.
[0031] S.1 Z 1 and Z 2 is as defined in general formula (I), including the substituents and preferred definitions, with the proviso that Z 1 and Z 2 If there is no =O or =S together , In that case, R 1 -R 13 , X 1 -X 4 and Y is as defined in general formula (I), including the substituents and preferred definitions.
[0032] S.2 R 6is as defined in general formula (I), including the substituents and preferred definitions, with the proviso that R 6 is different from -H or linear unsubstituted or branched unsubstituted C1-C6 alkyl, In that case, R 1 -R 5 , R 7 -R 14 , X 1 -X 4 , Y, Z 1 and Z 2 is as defined in general formula (I), including the substituents and preferred definitions.
[0033] S.3 Y is as defined in general formula (I), including the substituents and preferred definitions, with the proviso that when Y is different from -H, linear unsubstituted or branched unsubstituted C1-C6 alkyl or -OH, In that case, R 1 -R 14 , X 1 -X 4 , Z 1 and Z 2 is as defined in general formula (I), including the substituents and preferred definitions.
[0034] S.4 Z 1 and Z 2 taken together is =O or =S and Y is -OH, In that case, R 6 is as defined in general formula (I), including the substituents and preferred definitions, with the proviso that R 6 is different from -H, And in that case, R 1 -R 5 , R 7 -R 12 and X 1 -X 4 is as defined in general formula (I), including the substituents and preferred definitions.
[0035] S.5 Z 1 and Z 2 Together, they are =O or =S, and R 6 is -H and Y is -H, linear unsubstituted or branched unsubstituted C1-C6 alkyl or -OH; Or Z 1 and Z 2 Together, they are =O or =S, and R 6 is -H or a linear unsubstituted or branched unsubstituted C1-C6 alkyl and Y is -H, a linear unsubstituted or branched unsubstituted C1-C6 alkyl; In that case, R 1 is C1-C 12 Preferably C1-C6 alkyl, C2-C 12 Preferably C2-C6 alkenyl, C2-C 12 Preferably, C2-C6 alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C5-C 12 Bicycloalkyl, C7-C 12 Bicycloalkenyl, C8-C 14 Tricycloalkyl, -OC1-C 12 Preferably, -OC1-C6 alkyl, -OC2-C 12 Preferably, -OC2-C6 alkenyl, -OC2-C 12 Preferably, -OC2-C6 alkynyl, -OC3-C8 cycloalkyl, -OC5-C8 cycloalkenyl, -OC5-C 12 Bicycloalkyl, -OC7-C 12 Bicycloalkenyl, -OC8-C 14 Tricycloalkyl, -SC1-C 12 Preferably, -SC1-C6 alkyl, -SC2-C 12 Preferably, -SC2-C6 alkenyl, -SC2-C 12 Preferably, -SC2-C6 alkynyl, -SC3-C8 cycloalkyl, -SC5-C8 cycloalkenyl, -SC5-C 12 Bicycloalkyl, -SC7-C 12 Bicycloalkenyl, -SC8-C 14 Tricycloalkyl, -NHR 7 Or -NR7 R 8 (In the formula, R 7 and R 8 are C1-C 12 Preferably C1-C6 alkyl, C2-C 12 Preferably C2-C6 alkenyl, C2-C 12 Preferably, C2-C6 alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C5-C 12 Bicycloalkyl, C7-C 12 Bicycloalkenyl, C8-C 14 tricycloalkyl or R 7 R 8 and together with the N atom can form a ring structure; wherein said ring structure containing the N atom is selected from a 3- to 8-membered ring structure or a 5- to 12-membered bicyclic structure, and all of said ring structures may contain O, S and / or aryl groups instead of carbon atoms contained in the ring structure. N); Here, all C1-C 12 Alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, norbornyl and adamantyl residues are linear or branched and are referred to herein as side substituents, and are -OH, -NH2, -NO2, =O, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C5-C8 cycloalkenyl, norbornyl and C5-C8 cycloalkenyl, including -OH, -NH2, -NO2, =O, 12 Bicycloalkyl, C7-C 12 C8-C including bicycloalkenyl, adamantyl 14and wherein all of said C1-C5 alkyl, -OC1-C5 alkyl, -OC3-C5 cycloalkyl, -O(cyclopropyl), -NH(C1-C5 alkyl), -N(C1-C5 alkyl)(C1-C5 alkyl), -NH(C3-C5 cycloalkyl), -NH(cyclopropyl), -N(C3-C5 cycloalkyl)(C3-C5 cycloalkyl), -N(C3-C5 cycloalkyl)(C3-C5 cycloalkyl), -N(C1-C5 alkyl)(C3-C5 cycloalkyl), -N(C1-C5 alkyl)(C3-C5 cycloalkyl), -N(C1-C5 alkyl)(C3-C5 cycloalkyl), 12 The alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, adamantyl or norbornyl residues may optionally further comprise one or more substituents independently selected from -F, -Cl, -Br, -I, -CN, -NCO, -NCS; and all C9-C 12 Alkenyl, C9-C 12 Alkynyl, -OC1-C 12 Alkyl, -OC2-C 12 Alkenyl, -OC2-C 12 Alkynyl, -SC1-C 12 Alkyl, -SC2-C 12 Alkenyl, -SC2-C 12 Alkynyl, and R 7 and R 8 All alkyl, alkenyl and alkynyl residues included in the definition may be linear or branched, unsubstituted or, as referred to herein as side substituents, may be -F, -Cl, -Br, -I, -CN, -NCO, -NCS, -OH, -NH2, -NO2, =O, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C5-C 12 Bicycloalkyl, C7-C 12 Bicycloalkenyl, C8-C 14substituted with one or more substituents independently selected from tricycloalkyl, -OC1-C5 alkyl such as -OCH3 linear or branched, -OC3-C5 cycloalkyl such as -O(cyclopropyl), -NH(C1-C5 alkyl) linear or branched, -N(C1-C5 alkyl)(C1-C5 alkyl), -NH(C3-C5 cycloalkyl) such as -NH(cyclopropyl), -N(C3-C5 cycloalkyl)(C3-C5 cycloalkyl), linear or branched -N(C1-C5 alkyl)(C3-C5 cycloalkyl); where all -OC3-C8 cycloalkyl, -OC5-C8 cycloalkenyl, -SC3-C8 cycloalkyl, -SC5-C8 cycloalkenyl residues as well as R 7 and R 8 All cycloalkyl and cycloalkenyl residues included in the definition of and in the selection of named side substituents, as well as R 1 , R 7 and R 8 All bicyclic and tricyclic structures, including bicycloalkyl, bicycloalkenyl and tricycloalkyl residues included in the definition of are unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, -CN, -NCO, -NCS, -OH, -NH2, -NO2, =O, -C1-C5 alkyl such as linear or branched -CH3, -OC1-C5 alkyl such as linear or branched -OCH3, linear or branched -NH(C1-C5 alkyl), linear or branched -N(C1-C5 alkyl)(C1-C5 alkyl), -NH(C3-C5 cycloalkyl) such as -NH(cyclopropyl), -N(C3-C5 cycloalkyl)(C3-C5 cycloalkyl), linear or branched -N(C1-C5 alkyl)(C3-C5 cycloalkyl); provided that they are distinct from adamantyl and norbornyl; Here, R 7 and R 8All alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, bicycloalkyl, bicycloalkenyl and tricycloalkyl residues included in the definition may contain one or more heteroatoms independently selected from O, S and N in place of carbon atoms; and where R 1 All alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, bicycloalkyl, bicycloalkenyl and tricycloalkyl residues included in the definition of R may contain, in place of carbon atoms, one or more heteroatoms independently selected from O, S and N, provided that combinations of said heteroatoms, optionally at terminal positions, are not limited to R 1 Unlike -CN, -NCO, -NCS and -N3 residues, which are not explicitly included in the definition of Here, R 1 , R 7 and R 8 All alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, bicycloalkyl, bicycloalkenyl and tricycloalkyl residues included in the definition may be partially or fully halogenated, in particular fluorinated, more in particular perfluorinated; wherein bicyclic and tricyclic moieties include fused, bridged and spiro systems; And in that case, R 2 -R 5 , R 9 -R 12 and X 1 -X 4 is as defined in general formula (I), including the substituents and preferred definitions.
[0036] S.6 Z 1 and Z 2 Together, they are =O or =S, and R 6 is -H and Y is -H, linear unsubstituted or branched unsubstituted C1-C6 alkyl or -OH; Or Z 1 and Z 2 Together, they are =O or =S, and R 6is -H or a linear unsubstituted or branched unsubstituted C1-C6 alkyl and Y is -H, a linear unsubstituted or branched unsubstituted C1-C6 alkyl; In that case, R 2 is selected from -CN, -NCO, -NCS, -OH, -NH2, -NO2, linear or branched C1-C4 alkyl, linear or branched C2-C4 alkenyl, linear or branched C2-C4 alkynyl, C3-C6 cycloalkyl, -CH2(C3-C6 cycloalkyl), linear or branched -OC1-C3 alkyl, -O(cyclopropyl), linear or branched -NH(C1-C3 alkyl), linear or branched -N(C1-C3 alkyl)(C1-C3 alkyl), -NH(cyclopropyl), -N(cyclopropyl)2, linear or branched -N(C1-C3 alkyl)(cyclopropyl); wherein all C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl and C3-C4 cycloalkyl residues are substituted with one or more substituents independently selected from -OH, -OCH3, -OCF3, -NH2, -NHCH3 and -N(CH3)2; wherein the C5-C6 cycloalkyl residue is unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, -CH3, -CF3, -OH, -OCH3, -OCF3, -NH2, -NHCH3 and -N(CH3)2; Here, R 2 All alkyl, alkenyl, alkynyl and cycloalkyl residues included in the definition may contain, instead of carbon atoms, one or more heteroatoms independently selected from O, S and N; and R 3 -R 5are independently selected from -H, -F, -Cl, -Br, -I, -CN, -NCO, -NCS, -OH, -NH2, -NO2, linear or branched C1-C4 alkyl, linear or branched C2-C4 alkenyl, linear or branched C2-C4 alkynyl, C3-C6 cycloalkyl, -CH2(C3-C6 cycloalkyl), linear or branched -OC1-C3 alkyl, -O(cyclopropyl), linear or branched -NH(C1-C3 alkyl), linear or branched -N(C1-C3 alkyl)(C1-C3 alkyl), -NH(cyclopropyl), -N(cyclopropyl)2, linear or branched -N(C1-C3 alkyl)(cyclopropyl); Here, R 3 -R 5 All alkyl, alkenyl, alkynyl and cycloalkyl residues included in the definition are unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, -CH3, -CF3, -OH and -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2; Here, R 3 -R 5 All alkyl, alkenyl, alkynyl and cycloalkyl residues included in the definition may contain, instead of carbon atoms, one or more heteroatoms independently selected from O, S and N; And in that case, R 1 , R 7 -R 12 and X 1 -X 4 is as defined in general formula (I), including the substituents and preferred definitions.
[0037] S.7 Z 1 and Z 2 Together, they are =O or =S, and R 6 is -H and Y is -H, linear unsubstituted or branched unsubstituted C1-C6 alkyl or -OH; Or Z 1 and Z 2 Together, they are =O or =S, and R6 is -H or a linear unsubstituted or branched unsubstituted C1-C6 alkyl and Y is -H, a linear unsubstituted or branched unsubstituted C1-C6 alkyl; In that case, X 1 is CR 9 and and R 9 is selected from -CN, -NCO, -NCS, -OH, -NH2, -NO2, linear or branched C1-C4 alkyl, linear or branched C2-C4 alkenyl, linear or branched C2-C4 alkynyl, C3-C6 cycloalkyl, -CH2(C3-C6 cycloalkyl), linear or branched -OC1-C3 alkyl, -O(cyclopropyl), linear or branched -NH(C1-C3 alkyl), linear or branched -N(C1-C3 alkyl)(C1-C3 alkyl), -NH(cyclopropyl), -N(cyclopropyl)2, linear or branched -N(C1-C3 alkyl)(cyclopropyl); wherein all C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl and C3-C4 cycloalkyl residues are substituted with one or more substituents independently selected from -OH, -OCH3, -OCF3, -NH2, -NHCH3 and -N(CH3)2; wherein the C5-C6 cycloalkyl residue is unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, -CH3, -CF3, -OH, -OCH3, -OCF3, -NH2, -NHCH3 and -N(CH3)2; Here, R 9 All alkyl, alkenyl, alkynyl and cycloalkyl residues included in the definition may contain, instead of carbon atoms, one or more heteroatoms independently selected from O, S and N; And in that case, R 1 -R 5 , R 7 , R 8 , R 10 -R 12 and X 2 -X 4is as defined in general formula (I), including the substituents and preferred definitions.
[0038] S.8 Z 1 and Z 2 Together, they are =O or =S, and R 6 is -H and Y is -H, linear unsubstituted or branched unsubstituted C1-C6 alkyl or -OH; Or Z 1 and Z 2 Together, they are =O or =S, and R 6 is -H or a linear unsubstituted or branched unsubstituted C1-C6 alkyl and Y is -H, a linear unsubstituted or branched unsubstituted C1-C6 alkyl; In that case, X 2 is CR 9 and and R 9 is selected from -CN, -NCO, -NCS, -OH, -NH2, -NO2, linear or branched C1-C4 alkyl, linear or branched C2-C4 alkenyl, linear or branched C2-C4 alkynyl, C3-C6 cycloalkyl, -CH2(C3-C6 cycloalkyl), linear or branched -OC1-C3 alkyl, -O(cyclopropyl), linear or branched -NH(C1-C3 alkyl), linear or branched -N(C1-C3 alkyl)(C1-C3 alkyl), -NH(cyclopropyl), -N(cyclopropyl)2, linear or branched -N(C1-C3 alkyl)(cyclopropyl); Here, all C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl and and the C3-C4 cycloalkyl residue is substituted with one or more substituents independently selected from -OH, -OCH3, -OCF3, -NH2, -NHCH3 and -N(CH3)2; wherein the C5-C6 cycloalkyl residue is unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, -CH3, -CF3, -OH, -OCH3, -OCF3, -NH2, -NHCH3 and -N(CH3)2; Here, R 9 All alkyl, alkenyl, alkynyl and cycloalkyl residues included in the definition may contain, instead of carbon atoms, one or more heteroatoms independently selected from O, S and N; And in that case, R 1 -R 5 , R 7 , R 8 , R 10 -R 12 , X 1 , X 3 and X 4 is as defined in general formula (I), including the substituents and preferred definitions.
[0039] S.9 Z 1 and Z 2 Together, they are =O or =S, and R 6 is -H and Y is -H, linear unsubstituted or branched unsubstituted C1-C6 alkyl or -OH; Or Z 1 and Z 2 Together, they are =O or =S, and R 6 is -H or a linear unsubstituted or branched unsubstituted C1-C6 alkyl and Y is -H, a linear unsubstituted or branched unsubstituted C1-C6 alkyl; In that case, X 3 is CR 9 and and R 9is selected from -CN, -NCO, -NCS, -OH, -NH2, -NO2, linear or branched C1-C4 alkyl, linear or branched C2-C4 alkenyl, linear or branched C2-C4 alkynyl, C3-C6 cycloalkyl, -CH2(C3-C6 cycloalkyl), linear or branched -OC1-C3 alkyl, -O(cyclopropyl), linear or branched -NH(C1-C3 alkyl), linear or branched -N(C1-C3 alkyl)(C1-C3 alkyl), -NH(cyclopropyl), -N(cyclopropyl)2, linear or branched -N(C1-C3 alkyl)(cyclopropyl); wherein all C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl and C3-C4 cycloalkyl residues are substituted with one or more substituents independently selected from -OH, -OCH3, -OCF3, -NH2, -NHCH3 and -N(CH3)2; wherein the C5-C6 cycloalkyl residue is unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, -CH3, -CF3, -OH, -OCH3, -OCF3, -NH2, -NHCH3 and -N(CH3)2; Here, R 9 All alkyl, alkenyl, alkynyl and cycloalkyl residues included in the definition may contain, instead of carbon atoms, one or more heteroatoms independently selected from O, S and N; And in that case, R 1 -R 5 , R 7 , R 8 , R 10 -R 12 , X 1 , X 2 and X 4 is as defined in general formula (I), including the substituents and preferred definitions.
[0040] S.10 Z 1 and Z 2 Together, they are =O or =S, and R 6is -H and Y is -H, linear unsubstituted or branched unsubstituted C1-C6 alkyl or -OH; Or Z 1 and Z 2 Together, they are =O or =S, and R 6 is -H or a linear unsubstituted or branched unsubstituted C1-C6 alkyl and Y is -H, a linear unsubstituted or branched unsubstituted C1-C6 alkyl; In that case, X 4 is CR 9 and and R 9 -CN, -NCO, -NCS, -OH, -NH2, -NO2, linear or is selected from branched C1-C4 alkyl, linear or branched C2-C4 alkenyl, linear or branched C2-C4 alkynyl, C3-C6 cycloalkyl, -CH2(C3-C6 cycloalkyl), linear or branched -OC1-C3 alkyl, -O(cyclopropyl), linear or branched -NH(C1-C3 alkyl), linear or branched -N(C1-C3 alkyl)(C1-C3 alkyl), -NH(cyclopropyl), -N(cyclopropyl)2, linear or branched -N(C1-C3 alkyl)(cyclopropyl); wherein all C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl and C3-C4 cycloalkyl residues are substituted with one or more substituents independently selected from -OH, -OCH3, -OCF3, -NH2, -NHCH3 and -N(CH3)2; wherein the C5-C6 cycloalkyl residue is unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, -CH3, -CF3, -OH, -OCH3, -OCF3, -NH2, -NHCH3 and -N(CH3)2; Here, R 9 All alkyl, alkenyl, alkynyl and cycloalkyl residues included in the definition may contain, instead of carbon atoms, one or more heteroatoms independently selected from O, S and N; And in that case, R 1-R 5 , R 7 , R 8 , R 10 -R 12 and X 1 -X 3 is as defined in general formula (I), including the substituents and preferred definitions.
[0041] S.11 Z 1 and Z 2 Together, they are =O or =S, and R 6 is -H and Y is -H, linear unsubstituted or branched unsubstituted C1-C6 alkyl or -OH; Or Z 1 and Z 2 Together, they are =O or =S, and R 6 is -H or a linear unsubstituted or branched unsubstituted C1-C6 alkyl and Y is -H, a linear unsubstituted or branched unsubstituted C1-C6 alkyl; In that case, X 1 , X 2 and X 3 are N, And in that case, R 1 -R 5 , R 7 -R 12 and X 4 is as defined in general formula (I), including the substituents and preferred definitions.
[0042] S.12 Z 1 and Z 2 Together, they are =O or =S, and R 6 is -H and Y is -H, linear unsubstituted or branched unsubstituted C1-C6 alkyl or -OH; Or Z 1 and Z 2 Together, they are =O or =S, and R 6is -H or a linear unsubstituted or branched unsubstituted C1-C6 alkyl and Y is -H, a linear unsubstituted or branched unsubstituted C1-C6 alkyl; In that case, X 1 , X 2 and X 4 are N, And in that case, R 1 -R 5 , R 7 -R 12 and X 3 is as defined in general formula (I), including the substituents and preferred definitions.
[0043] S.13 Z 1 and Z 2 Together, they are =O or =S, and R 6 is -H and Y is -H, linear unsubstituted or branched unsubstituted C1-C6 alkyl or -OH; Or Z 1 and Z 2 Together, they are =O or =S, and R 6 is -H or a linear unsubstituted or branched unsubstituted C1-C6 alkyl and Y is -H, a linear unsubstituted or branched unsubstituted C1-C6 alkyl; In that case, X 1 , X 3 and X 4 are N, And in that case, R 1 -R 5 , R 7 -R 12 and X 2 is as defined in general formula (I), including the substituents and preferred definitions.
[0044] S.14 Z 1 and Z 2 Together, they are =O or =S, and R 6 is -H and Y is -H, linear unsubstituted or branched unsubstituted C1-C6 alkyl or -OH; Or Z 1 and Z 2 Together, they are =O or =S, and R 6 is -H or a linear unsubstituted or branched unsubstituted C1-C6 alkyl and Y is -H, a linear unsubstituted or branched unsubstituted C1-C6 alkyl; In that case, X 2 , X 3 and X 4 are N, And in that case, R 1 -R 5 , R 7 -R 12 and X 1 is as defined in general formula (I), including the substituents and preferred definitions.
[0045] S.15 R 1 is as defined in general formula (I), including the substituents and preferred definitions, with the proviso that R 1 contains one or more heteroatoms independently selected from O, S and N, provided that said combination of heteroatoms in the terminal portion is different from -CN, -NCO, -NCS residues; In that case, R 2 -R 14 , X 1 -X 4 , Y, Z 1 and Z 2 is as defined in general formula (I), including the substituents and preferred definitions.
[0046] S.16 Z 1 and Z 2 is as defined in general formula (I), including the substituents and preferred definitions, with the proviso that Z 1 and Z 2 If there are no =O together, In that case, R 1 -R 14 , X 1 -X 4and Y is as defined in general formula (I), including the substituents and preferred definitions.
[0047] S.17 R 4 is as defined in general formula (I), including the substituents and preferred definitions, with the proviso that R 4 is different from -H or C1-C6 alkyl or C3-C6 cycloalkyl, wherein all said C1-C6 alkyl residues are linear or branched and unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, C1-C3 alkyl and -OC1-C3 alkyl; and wherein all said C3-C6 cycloalkyl residues are unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, C1-C3 alkyl and -OC1-C3 alkyl; and wherein all said alkyl and cycloalkyl residues may optionally be halogenated or perhalogenated; In that case, R 1 -R 5 , R 7 -R 14 , X 1 -X 4 , Y, Z 1 and Z 2 is as defined in general formula (I), including the substituents and preferred definitions.
[0048] S.18 Y is as defined in general formula (I), including the substituents and preferred definitions, with the proviso that when Y is different from -H or C1-C6 alkyl or C3-C6 cycloalkyl or -OH or -OC1-C6 alkyl, wherein all said C1-C6 alkyl residues are linear or branched and unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, C1-C3 alkyl and -OC1-C3 alkyl; and wherein all said C3-C6 cycloalkyl residues are unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, C1-C3 alkyl and -OC1-C3 alkyl; and wherein all said alkyl and cycloalkyl residues are optionally halogenated or may be perhalogenated; In that case, R 1 -R 14 , X 1 -X 4 , Z 1 and Z 2 is as defined in general formula (I), including the substituents and preferred definitions.
[0049] S.19 Z 1 and Z 2 Together, they are =O and R 6 is -H or C1-C6 alkyl or C3-C6 cycloalkyl and Y is -H or C1-C6 alkyl or C3-C6 cycloalkyl or -OH or -OC1-C6 alkyl; wherein all said C1-C6 alkyl residues are linear or branched and unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, C1-C3 alkyl and -OC1-C3 alkyl; and wherein all said C3-C6 cycloalkyl residues are unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, C1-C3 alkyl and -OC1-C3 alkyl; and wherein all said alkyl and cycloalkyl residues may optionally be halogenated or perhalogenated; In that case, R 1 is C1-C 12 Preferably C1-C6 alkyl, C2-C 12 Preferably C2-C6 alkenyl, C2-C 12 Preferably, C2-C6 alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C5-C 12Bicycloalkyl, C7-C 12 Bicycloalkenyl, C8-C 14 Tricycloalkyl, -OC1-C 12 Preferably, -OC1-C6 alkyl, -OC2-C 12 Preferably, -OC2-C6 alkenyl, -OC2-C 12 Preferably, -OC2-C6 alkynyl, -OC3-C8 cycloalkyl, -OC5-C8 cycloalkenyl, -OC5-C 12 Bicycloalkyl, -OC7-C 12 Bicycloalkenyl, -OC8-C 14 Tricycloalkyl, -SC1-C 12 Preferably, -SC1-C6 alkyl, -SC2-C 12 Preferably, -SC2-C6 alkenyl, -SC2-C 12 Preferably, -SC2-C6 alkynyl, -SC3-C8 cycloalkyl, -SC5-C8 cycloalkenyl, -SC5-C 12 Bicycloalkyl, -SC7-C 12 Bicycloalkenyl, -SC8-C 14 Tricycloalkyl, -NHR 7 Or -NR 7 R 8 (In the formula, R 7 and R 8 are C1-C 12 Preferably C1-C6 alkyl, C2-C 12 Preferably C2-C6 alkenyl, C2-C 12 Preferably, C2-C6 alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C5-C 12 Bicycloalkyl, C7-C 12 Bicycloalkenyl, C8-C 14 tricycloalkyl or R 7 R 8can form a ring structure together with the N atom, wherein said ring structure containing the N atom is selected from a 3- to 8-membered cyclic structure or a 5- to 12-membered bicyclic structure, and wherein all said ring structures can further contain one or more heteroatoms independently selected from O, S and N in place of carbon atoms contained in the ring structure; Here, all C1-C 12 Alkyl, C2-C 12 Alkenyl, C2-C 12 Alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C5-C 12 Bicycloalkyl, C7-C 12 Bicycloalkenyl and C8-C 14 Tricycloalkyl residues are linear or branched, and are referred to herein as side substituents, and include -OH, -NH2, -NO2, =O, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C5-C 12 Bicycloalkyl, C7-C 12 Bicycloalkenyl, C8-C 14 and wherein all of said C1-C1-C5 cycloalkyl, -OC4-C5 alkyl, -OC3-C5 cycloalkyl, such as -O(cyclopropyl), -NH(C1-C5 alkyl), -N(C1-C5 alkyl)(C1-C5 alkyl), -NH(C3-C5 cycloalkyl), such as -NH(cyclopropyl), -N(C3-C5 cycloalkyl)(C3-C5 cycloalkyl), -N(C1-C5 alkyl)(C3-C5 cycloalkyl), -N(C1-C5 alkyl)(C3-C5 cycloalkyl), -N(C1-C5 alkyl)(C3-C5 cycloalkyl), -N(C1-C5 alkyl)(C3-C5 cycloalkyl), 12 Alkyl, C2-C 12 Alkenyl, C 2-C 12 Alkynyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C5-C 12 Bicycloalkyl, C7-C 12 Bicycloalkenyl and C8-C 14The tricycloalkyl residue may optionally further include one or more substituents independently selected from -F, -Cl, -Br, -I, -CN, -NCO, -NCS; and all -OC1-C 12 Alkyl, -OC2-C 12 Alkenyl, -OC2-C 12 Alkynyl, -SC1-C 12 Alkyl, -SC2-C 12 Alkenyl, -SC2-C 12 Alkynyl, and R 7 and R 8 All alkyl, alkenyl and alkynyl residues included in the definition may be linear or branched, unsubstituted or, as referred to herein as side substituents, may be any of -F, -Cl, -Br, -I, -CN, -NCO, -NCS, -OH, -NH2, -NO2, =O, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, C5-C 12 Bicycloalkyl, C7-C 12 Bicycloalkenyl, C8-C 14 substituted with one or more substituents independently selected from tricycloalkyl, -OC1-C5 alkyl such as -OCH3 linear or branched, -OC3-C5 cycloalkyl such as -O(cyclopropyl), -NH(C1-C5 alkyl) linear or branched, -N(C1-C5 alkyl)(C1-C5 alkyl), -NH(C3-C5 cycloalkyl) such as -NH(cyclopropyl), -N(C3-C5 cycloalkyl)(C3-C5 cycloalkyl), linear or branched -N(C1-C5 alkyl)(C3-C5 cycloalkyl); Here, all -OC3-C8 cycloalkyl, -OC5-C8 cycloalkenyl, -OC5-C 12 Bicycloalkyl, -OC7-C 12 Bicycloalkenyl, -OC8-C 14 Tricycloalkyl, -SC3-C8 cycloalkyl, -SC5-C8 cycloalkenyl, -SC5-C 12 Bicycloalkyl, -SC7-C 12 Bicycloalkenyl, -SC8-C 14Tricycloalkyl residues, as well as R 7 and R 8 All cycloalkyl, cycloalkenyl, bicycloalkyl, bicycloalkenyl and tricycloalkyl residues included in the definition of and included in the selection of named side substituents are unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, -CN, -NCO, -NCS, -OH, -NH2, -NO2, =O, -C1-C5 alkyl such as linear or branched -CH3, -OC1-C5 alkyl such as linear or branched -OCH3, linear or branched -NH(C1-C5 alkyl), linear or branched -N(C1-C5 alkyl)(C1-C5 alkyl), -NH(C3-C5 cycloalkyl) such as -NH(cyclopropyl), -N(C3-C5 cycloalkyl)(C3-C5 cycloalkyl), linear or branched -N(C1-C5 alkyl)(C3-C5 cycloalkyl); Here, R 7 and R 8 All alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, bicycloalkyl, bicycloalkenyl and tricycloalkyl residues included in the definition may contain one or more heteroatoms independently selected from O, S and N in place of carbon atoms; and where R 1 All alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, bicycloalkyl, bicycloalkenyl, and tricycloalkyl residues included in the definition of R may contain one or more heteroatoms independently selected from O, S, and N in place of carbon atoms, provided that combinations of said heteroatoms at terminal positions are not limited to R 1 Unlike -CN, -NCO, -NCS and -OC1-C3 alkyl residues, unless expressly included in the definition of wherein bicyclic and tricyclic moieties include fused, bridged and spiro systems; And in that case, R 2 -R 5 , R 9 -R 12 and X1 -X 4 is as defined in general formula (I), including the substituents and preferred definitions.
[0050] S.20 Z 1 and Z 2 Together, they are =O and R 6 is -H or C1-C6 alkyl or C3-C6 cycloalkyl, and Y is -H or C1-C6 alkyl or C3-C 6 cycloalkyl or -OH or -OC1-C6 alkyl, wherein all said C1-C6 alkyl residues are linear or branched and unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, C1-C3 alkyl and -OC1-C3 alkyl; and wherein all said C3-C6 cycloalkyl residues are unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, C1-C3 alkyl and -OC1-C3 alkyl; and wherein all said alkyl and cycloalkyl residues may optionally be halogenated or perhalogenated; In that case, R 2 is selected from -F, -Cl, -Br, -I, -CN, -NCO, -NCS, -OH, -NH2, -NO2, linear or branched C1-C4 alkyl, linear or branched C2-C4 alkenyl, linear or branched C2-C4 alkynyl, C3-C6 cycloalkyl, -CH2(C3-C6 cycloalkyl), linear or branched -OC1-C3 alkyl, -O(cyclopropyl), linear or branched -NH(C1-C3 alkyl), linear or branched -N(C1-C3 alkyl)(C1-C3 alkyl), -NH(cyclopropyl), -N(cyclopropyl)2, linear or branched -N(C1-C3 alkyl)(cyclopropyl); Here, R 2All alkyl, alkenyl, alkynyl and cycloalkyl residues included in the definition are unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, -CH3, -CF3, -OH and -OCH3, -OCF3, -NH2, -NHCH3, -N(CH3)2; Here, R 2 All alkyl, alkenyl, alkynyl and cycloalkyl residues included in the definition may contain, instead of carbon atoms, one or more heteroatoms independently selected from O, S and N; And in that case, R 1 , R 3 -R 5 , R 7 -R 12 and X 1 -X 4 is as defined in general formula (I), including the substituents and preferred definitions.
[0051] S.21 Z 1 and Z 2 Together, they are =O and R 6 is -H or C1-C6 alkyl or C3-C6 cycloalkyl and Y is -H or C1-C6 alkyl or C3-C6 cycloalkyl or -OH or -OC1-C6 alkyl; wherein all said C1-C6 alkyl residues are linear or branched and unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, C1-C3 alkyl and -OC1-C3 alkyl; and wherein all said C3-C6 cycloalkyl residues are unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, C1-C3 alkyl and -OC1-C3 alkyl; and wherein all said alkyl and cycloalkyl residues may optionally be halogenated or perhalogenated; In that case, X 1 is CR 9 and and R9 is selected from -Cl, -Br, -I, CN, -NCO, -NCS, -OH, -NH2, -NO2, linear or branched C1-C4 alkyl, linear or branched C2-C4 alkenyl, linear or branched C2-C4 alkynyl, C3-C6 cycloalkyl, -CH2(C3-C6 cycloalkyl), linear or branched -OC1-C3 alkyl, -O(cyclopropyl), linear or branched -NH(C1-C3 alkyl), linear or branched -N(C1-C3 alkyl)(C1-C3 alkyl), -NH(cyclopropyl), -N(cyclopropyl)2, linear or branched -N(C1-C3 alkyl)(cyclopropyl); Here, R 9 All alkyl, alkenyl, alkynyl and cycloalkyl residues included in the definition are unsubstituted or substituted with -F, -Cl, -Br, -I, -CH3, -CF3, -OH and substituted with one or more substituents independently selected from -OCH3, -OCF3, -NH2, NHCH3, N(CH3)2; Here, R 9 All alkyl, alkenyl, alkynyl and cycloalkyl residues included in the definition may contain, instead of carbon atoms, one or more heteroatoms independently selected from O, S and N; And in that case, R 1 -R 5 , R 7 , R 8 , R 10 -R 12 and X 2 -X 4 is as defined in general formula (I), including the substituents and preferred definitions.
[0052] S.22 Z 1 and Z 2 Together, they are =O and R 6 is -H or C1-C6 alkyl or C3-C6 cycloalkyl and Y is -H or C1-C6 alkyl or C3-C6 cycloalkyl or -OH or -OC1-C6 alkyl; wherein all said C1-C6 alkyl residues are linear or branched and unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, C1-C3 alkyl and -OC1-C3 alkyl; and wherein all said C3-C6 cycloalkyl residues are unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, C1-C3 alkyl and -OC1-C3 alkyl; and wherein all said alkyl and cycloalkyl residues may optionally be halogenated or perhalogenated; In that case, X 2 is CR 9 and and R 9 is selected from -Cl, -Br, -I, CN, -NCO, -NCS, -OH, -NH2, -NO2, linear or branched C1-C4 alkyl, linear or branched C2-C4 alkenyl, linear or branched C2-C4 alkynyl, C3-C6 cycloalkyl, -CH2(C3-C6 cycloalkyl), linear or branched -OC1-C3 alkyl, -O(cyclopropyl), linear or branched -NH(C1-C3 alkyl), linear or branched -N(C1-C3 alkyl)(C1-C3 alkyl), -NH(cyclopropyl), -N(cyclopropyl)2, linear or branched -N(C1-C3 alkyl)(cyclopropyl); Here, R 9 All alkyl, alkenyl, alkynyl and cycloalkyl residues included in the definition are unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, -CH3, -CF3, -OH and -OCH3, -OCF3, -NH2, NHCH3, N(CH3)2; Here, R 9 All alkyl, alkenyl, alkynyl and cycloalkyl residues included in the definition may contain, instead of carbon atoms, one or more heteroatoms independently selected from O, S and N; And in that case, R 1 -R 5 , R7 , R 8 , R 10 -R 12 , X 1 , X 3 and X 4 is as defined in general formula (I), including the substituents and preferred definitions.
[0053] S.23 Z 1 and Z 2 Together, they are =O and R 6 is -H or C1-C6 alkyl or C3-C6 cycloalkyl and Y is -H or C1-C6 alkyl or C3-C6 cycloalkyl or -OH or -OC1-C6 alkyl; wherein all said C1-C6 alkyl residues are linear or branched and unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, C1-C3 alkyl and -OC1-C3 alkyl; and wherein all said C3-C6 cycloalkyl residues are unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, C1-C3 alkyl and -OC1-C3 alkyl; and wherein all said alkyl and cycloalkyl residues may optionally be halogenated or perhalogenated; In that case, X 3 is CR 9 and and R 9is selected from -Cl, -Br, -I, CN, -NCO, -NCS, -OH, -NH2, -NO2, linear or branched C1-C4 alkyl, linear or branched C2-C4 alkenyl, linear or branched C2-C4 alkynyl, C3-C6 cycloalkyl, -CH2(C3-C6 cycloalkyl), linear or branched -OC1-C3 alkyl, -O(cyclopropyl), linear or branched -NH(C1-C3 alkyl), linear or branched -N(C1-C3 alkyl)(C1-C3 alkyl), -NH(cyclopropyl), -N(cyclopropyl)2, linear or branched -N(C1-C3 alkyl)(cyclopropyl); Here, R 9 All alkyl, alkenyl, alkynyl and cycloalkyl residues included in the definition are unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, -CH3, -CF3, -OH and -OCH3, -OCF3, -NH2, NHCH3, N(CH3)2; Here, R 9 All alkyl, alkenyl, alkynyl and cycloalkyl residues included in the definition may contain, instead of carbon atoms, one or more heteroatoms independently selected from O, S and N; And in that case, R 1 -R 5 , R 7 , R 8 , R 10 -R 12 , X 1 , X 2 and X 4 is as defined in general formula (I), including the substituents and preferred definitions.
[0054] S.24 Z 1 and Z 2 Together, they are =O and R 6 is -H or C1-C6 alkyl or C3-C6 cycloalkyl and Y is -H or C1-C6 alkyl or C3-C6 cycloalkyl or -OH or -OC1-C6 alkyl; wherein all said C1-C6 alkyl residues are linear or branched and unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, C1-C3 alkyl and -OC1-C3 alkyl; and wherein all said C3-C6 cycloalkyl residues are unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, C1-C3 alkyl and -OC1-C3 alkyl; and wherein all said alkyl and cycloalkyl residues may optionally be halogenated or perhalogenated; In that case, X 4 is CR 9 and and R 9 is selected from -Cl, -Br, -I, CN, -NCO, -NCS, -OH, -NH2, -NO2, linear or branched C1-C4 alkyl, linear or branched C2-C4 alkenyl, linear or branched C2-C4 alkynyl, C3-C6 cycloalkyl, -CH2(C3-C6 cycloalkyl), linear or branched -OC1-C3 alkyl, -O(cyclopropyl), linear or branched -NH(C1-C3 alkyl), linear or branched -N(C1-C3 alkyl)(C1-C3 alkyl), -NH(cyclopropyl), -N(cyclopropyl)2, linear or branched -N(C1-C3 alkyl)(cyclopropyl); Here, R 9 All alkyl, alkenyl, alkynyl and cycloalkyl residues included in the definition are unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, -CH3, -CF3, -OH and -OCH3, -OCF3, -NH2, NHCH3, N(CH3)2; Here, R 9 All alkyl, alkenyl, alkynyl and cycloalkyl residues included in the definition may contain, instead of carbon atoms, one or more heteroatoms independently selected from O, S and N; And in that case, R 1 -R 5 , R7 , R 8 , R 10 -R 12 and X 1 -X 3 is as defined in general formula (I), including the substituents and preferred definitions.
[0055] S.25 Z 1 and Z 2 Together, they are =O and R 6 is -H or C1-C6 alkyl or C3-C6 cycloalkyl and Y is -H or C1-C6 alkyl or C3-C6 cycloalkyl or -OH or -OC1-C6 alkyl; wherein all said C1-C6 alkyl residues are linear or branched and unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, C1-C3 alkyl and -OC1-C3 alkyl; and wherein all said C3-C6 cycloalkyl residues are unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, C1-C3 alkyl and -OC1-C3 alkyl; and wherein all said alkyl and cycloalkyl residues may optionally be halogenated or perhalogenated; In that case, X 3 is N And in that case, R 1 -R 5 , R 7 -R 12 , X 1 , X 2 and X 4 is as defined in general formula (I), including the substituents and preferred definitions.
[0056] S.26 Z 1 and Z 2 Together, they are =O and R 6is -H or C1-C6 alkyl or C3-C6 cycloalkyl and Y is -H or C1-C6 alkyl or C3-C6 cycloalkyl or -OH or -OC1-C6 alkyl; wherein all said C1-C6 alkyl residues are linear or branched and unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, C1-C3 alkyl and -OC1-C3 alkyl; and wherein all said C3-C6 cycloalkyl residues are unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, C1-C3 alkyl and -OC1-C3 alkyl; and wherein all said alkyl and cycloalkyl residues may optionally be halogenated or perhalogenated; In that case, X 4 is N And in that case, R 1 -R 5 , R 7 -R 12 and X 1 -X 3 is as defined in general formula (I), including the substituents and preferred definitions.
[0057] S.27 Z 1 and Z 2 Together, they are =O and R 6 is -H or C1-C6 alkyl or C3-C6 cycloalkyl and Y is -H or C1-C6 alkyl or C3-C6 cycloalkyl or -OH or -OC1-C6 alkyl; wherein all said C1-C6 alkyl residues are linear or branched and unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, C1-C3 alkyl and -OC1-C3 alkyl; and wherein all said C3-C6 cycloalkyl residues are unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, C1-C3 alkyl and -OC1-C3 alkyl; and wherein all said alkyl and cycloalkyl residues may optionally be halogenated or perhalogenated; In that case, X 1 and X 2 are N, respectively. And in that case, R 1 -R 5 , R 7 -R 12 , X 3 and X 4 is as defined in general formula (I), including the substituents and preferred definitions.
[0058] S.28 Z 1 and Z 2 Together, they are =O and R 6 is -H or C1-C6 alkyl or C3-C6 cycloalkyl and Y is -H or C1-C6 alkyl or C3-C6 cycloalkyl or -OH or -OC1-C6 alkyl; wherein all said C1-C6 alkyl residues are linear or branched and unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, C1-C3 alkyl and -OC1-C3 alkyl; and wherein all said C3-C6 cycloalkyl residues are unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, C1-C3 alkyl and -OC1-C3 alkyl; and wherein all said alkyl and cycloalkyl residues may optionally be halogenated or perhalogenated; In that case, X 1 and X 3 are N, respectively. And in that case, R 1 -R 5 , R 7 -R12 , X 2 and X 4 is as defined in general formula (I), including the substituents and preferred definitions.
[0059] S.29 Z 1 and Z 2 Together, they are =O and R 6 is -H or C1-C6 alkyl or C3-C6 cycloalkyl and Y is -H or C1-C6 alkyl or C3-C6 cycloalkyl or -OH or -OC1-C6 alkyl; wherein all said C1-C6 alkyl residues are linear or branched and unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, C1-C3 alkyl and -OC1-C3 alkyl; and wherein all said C3-C6 cycloalkyl residues are unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, C1-C3 alkyl and -OC1-C3 alkyl; and wherein all said alkyl and cycloalkyl residues may optionally be halogenated or perhalogenated; In that case, X 1 and X 4 are N, respectively. And in that case, R 1 -R 5 , R 7 -R 12 , X 2 and X 3 is as defined in general formula (I), including the substituents and preferred definitions.
[0060] S.30 R 1 is as defined in general formula (I), including the substituents and preferred definitions, with the proviso that R 1 is different from C3-C8 cycloalkyl, wherein the C3-C8 cycloalkyl residue is unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, -CN, -NCO, -NCS, C1-C3 alkyl and -OC1-C3 alkyl; wherein the C3-C8 cycloalkyl residue may be optionally perhalogenated; and wherein said C3-C8 cycloalkyl residue is a C1-C8 cycloalkyl group on the same carbon atom that is attached to the phenyl ring as defined in general formula (I). 12 Alkyl, C2-C 12 Alkenyl, C2-C 12 substituted with a substituent selected from alkynyl, C3-C8 cycloalkyl or C5-C8 cycloalkenyl; wherein all said alkyl, alkenyl and alkynyl residues are linear or branched, unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, -CN, -NCO, -NCS and -OC1-C3 alkyl; wherein all said cycloalkyl and cycloalkenyl residues are unsubstituted or substituted with one or more substituents independently selected from -F, -Cl, -Br, -I, -CN, -NCO, -NCS, C1-C3 alkyl and -OC1-C3 alkyl; and wherein all said alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkenyl residues may optionally be perhalogenated; In that case, R 2 -R 14 , X 1 -X 4 , Y, Z 1 and Z 2 is as defined in general formula (I), including the substituents and preferred definitions.
[0061] In one aspect, the present invention relates to compounds of general formula (I) and salts and solvates thereof, wherein R 1 is adamantyl, and where Z 1 and Z 2is as defined in general formula (I), including general formula (Ia), general formula (Ib) and general formula (Ic), including substituents and preferred definitions, with the optional proviso that in the case of general formula (Ib), Z 1 and Z 2 are not combined to make =O, and where R 14 is as defined in general formula (Ib), including the substituents and preferred definitions, and where Y, R 2 -R 6 , R 9 -R 13 and X 1 -X 4 is as defined in general formula (I), including the substituents and preferred definitions; and wherein the compound shares the following structure (I-1):
[0062] [ka]
[0063] and wherein the compounds of structure (I-1) are preferred for use in human and veterinary medicine, in particular for medical uses according to the present invention, preferably for immune system related applications including immunotherapy as defined in the present invention and other immunotherapies, and for use in the treatment of immune system related disorders, skin diseases, muscle diseases, hyperproliferative disorders, and cancers including cancers of the hematopoietic and blood system such as leukemia and lymphoma, cancers of the skin, oral mucosa, tongue, lung, stomach, breast, cervix, ovary, and cancers of the neuroendocrine system. Examples include compounds XPW-0014, XPW-0028, XPW-0042, XPW-0182, XPW-0924, XPW-3038, XPW-3052, XPW-4633, XPW-4642 and XPW-4643.
[0064] In a further aspect, the present invention relates to compounds of formula (I) and salts and solvates thereof, wherein Y and R 6is as defined in general formula (I), including the substituents and preferred definitions, where Y is R 6 and together with Y and R form a ring structure, and such ring structure is 6 contains an O atom in place of one of the ring C atoms directly bonded to the N atom to which is bonded, and where Z 1 and Z 2 is as defined in general formula (I), including general formula (Ia), general formula (Ib) and general formula (Ic), including substituents and preferred definitions; and where R 14 In the general formula (Ib), including substituents and preferred definitions, As defined, and where R 1 -R 5 , R 7 -R 12 and X 1 -X 4 is as defined in general formula (I), including the substituents and preferred definitions; and wherein the compound shares the following structure (I-2):
[0065] [ka]
[0066] and wherein the compounds of structure (I-2) are preferred for use in human and veterinary medicine, in particular for medical use as described in the present invention, preferably for immune system related applications including immunotherapy as defined in the present invention and other immunotherapies, and for use in the treatment of immune system related disorders, skin diseases, muscle diseases, hyperproliferative disorders, and cancers including cancers of the hematopoietic and blood system such as leukemia and lymphoma, cancers of the skin, oral mucosa, tongue, stomach, breast, and cancers of the neuroendocrine system. Examples include compounds XPW-4637 and XPW-4638.
[0067] In a further aspect, the present invention relates to compounds of formula (I) and salts and solvates thereof, wherein Y is -S(O)R 13 and -S(O)R 13 is selected from and where R 1 is as defined in general formula (I), including the substituents and preferred definitions, where R 1 contains 4 or more, preferably 6 or more, carbon atoms, optionally independently substituted with heteroatoms selected from O, S and N as defined in general formula (I), and where Z 1 and Z 2 is as defined in general formula (I), including general formula (Ia), general formula (Ib) and general formula (Ic), including substituents and preferred definitions, and wherein R 14 is as defined in general formula (Ib), including the substituents and preferred definitions, and where R 2 -R 13 and X 1 -X 4 is as defined in general formula (I), including the substituents and preferred definitions; and wherein the compound shares the following structure (I-3):
[0068] [ka]
[0069] and wherein the compounds of structure (I-3) are preferred for use in human and veterinary medicine, in particular for medical uses according to the present invention, preferably for immune system related applications including immunotherapy as defined in the present invention and other immunotherapies, and for use in the treatment of immune system related disorders, skin diseases, muscle diseases, hyperproliferative disorders, and cancers including cancers of the hematopoietic and blood system such as leukemia and lymphoma, cancers of the skin, oral mucosa, tongue, lung, stomach, breast, cervix, ovary, and cancers of the neuroendocrine system. Examples include compounds XPW-0547, XPW-0548, XPW-0552, XPW-0560, XPW-0566, XPW-0574, XPW-0575, XPW-0576, XPW-0580, XPW-0588, XPW-0603, XPW-0604, XPW-0608, XPW-0616, XPW-2675, XPW-2676, XPW-2688, XPW-2703, XPW-2704, XPW-2708, XPW-2716, XPW-2732, XPW-2744, XPW-4633, and XPW-4642.
[0070] In a further aspect, the present invention relates to compounds of formula (I) and salts and solvates thereof, wherein Y is -OH, and where R 6 is as defined in general formula (I), including the substituents and preferred definitions, with the proviso that R 6 is different from -H, and where Z 1 and Z 2 is as defined in general formula (I), including general formula (Ia), general formula (Ib) and general formula (Ic), including substituents and preferred definitions; and where R 14 is as defined in general formula (Ib), including the substituents and preferred definitions, and where R 1 -R 5 , R 7 -R 12 and X 1 -X 4 is as defined in general formula (I), including the substituents and preferred definitions; and wherein the compound shares the following structure (I-4):
[0071] [ka]
[0072] and wherein the compounds of structure (I-4) are preferred for use in human and veterinary medicine, in particular for medical uses according to the present invention, preferably for immune system related applications including immunotherapy as defined in the present invention and other immunotherapies, and for use in the treatment of immune system related disorders, skin diseases, muscle diseases, hyperproliferative disorders, and cancers including cancers of the hematopoietic and blood system such as leukemia and lymphoma, cancers of the skin, oral mucosa, tongue, lung, stomach, breast, cervix, ovary, and cancers of the neuroendocrine system. Examples include compounds XPW-0182, XPW-0674, XPW-0675, XPW-0678, XPW-0679, XPW-0686, XPW-0700, XPW-0734, XPW-0742, XPW-1750, XPW-2805, XPW-2806, XPW-4612, XPW-4614 , XPW-4616, XPW-4617, XPW-4618, XPW-4619, XPW-4620, XPW-4621, XPW-4622, XPW-4626, XPW-4631, XPW-4632, XPW-4640, XPW-4644, XPW-4646 and XPW-4647.
[0073] In a further aspect, the present invention relates to compounds of formula (I) and salts and solvates thereof, wherein Y is -OCH3, and where R 1 is as defined in general formula (I), including the substituents and preferred definitions, wherein R 1 does not contain heteroatoms selected from O, S, and N, except that R 1 contains two or more carbon atoms, and where Z 1 and Z 2 is as defined in general formula (I), including general formula (Ia), general formula (Ib) and general formula (Ic), including substituents and preferred definitions; and where R 14 is as defined in general formula (Ib), including the substituents and preferred definitions, and where R 2 -R 6 , R9 -R 12 and X 1 -X 4 is as defined in general formula (I), including the substituents and preferred definitions; and wherein the compound shares the following structure (I-5):
[0074] [ka]
[0075] and wherein the compounds of structure (I-5) are - unless otherwise provided - preferred for use in human and veterinary medicine, in particular for medical uses as described in the present invention, preferably for immune system related applications including immunotherapy as defined in the present invention and other immunotherapies, and for use in the treatment of immune system related disorders, skin diseases, muscle diseases, hyperproliferative disorders, and cancers including cancers of the hematopoietic and blood system such as leukemia and lymphoma, cancer of the skin, oral mucosa, tongue, lung, stomach, breast. Examples include compounds XPW-0702, XPW-0706, XPW-0714, XPW-0716, XPW-0720, XPW-0728, XPW-2833, XPW-2834, XPW-2847, XPW-2848 and XPW-4605.
[0076] In a further aspect, the present invention relates to compounds of formula (I) and salts and solvates thereof, wherein R 6 is -H and Y is -OCH3; and where R 1 is as defined in general formula (I), including the substituents and preferred definitions, with the proviso that R 1 is selected from cyclic, bicyclic and tricyclic structures; and where Z 1 and Z 2 is as defined in general formula (I), including general formula (Ia), general formula (Ib) and general formula (Ic), including substituents and preferred definitions; and where R 14is as defined in general formula (Ib), including the substituents and preferred definitions, and where R 2 -R 5 , R 6 -R 12 and X 1 -X 4 is as defined in general formula (I), including the substituents and preferred definitions; and wherein the compound shares the following structure (I-6):
[0077] [ka]
[0078] and wherein the compounds of structure (I-6) are preferred for use in human and veterinary medicine, in particular for medical uses as described in the present invention, preferably for immune system related applications including immunotherapy as defined in the present invention and other immunotherapies, and for use in the treatment of immune system related disorders, skin diseases, muscle diseases, hyperproliferative disorders, and cancers including cancers of the hematopoietic and blood system such as leukemia and lymphoma, cancers of the skin, oral mucosa, tongue, lung, stomach, breast. Examples include compounds XPW-0706, XPW-0714, XPW-2833 and XPW-2834.
[0079] In a further aspect, the present invention relates to compounds of formula (I) and salts and solvates thereof, wherein Y and R 6 is as defined in general formula (I), including the substituents and preferred definitions, where Y is R 6 Together with and where R 1 is as defined in general formula (I), including the substituents and preferred definitions, where R 1 is selected from cyclic, bicyclic and tricyclic structures, with the proviso that R 1 contains zero or one heteroatom selected from O, S, N, and where Z1 , Z 2 and R 14 is as defined in general formula (Ib), including the substituents and preferred definitions, and where R 2 -R 5 , R 7 -R 12 and X 1 -X 4 is as defined in general formula (I), including the substituents and preferred definitions; and wherein the compound shares the following structure (I-7):
[0080] [ka]
[0081] and wherein the compounds of structure (I-7) are - unless otherwise provided - preferred for use in human and veterinary medicine, in particular for medical uses as described in the present invention, preferably for immune system related applications including immunotherapy as defined in the present invention and other immunotherapies, and for use in the treatment of immune system related disorders, skin diseases, muscle diseases, hyperproliferative disorders, and cancers including cancers of the hematopoietic and blood system such as leukemia and lymphoma, cancers of the skin, oral mucosa, tongue, lung, stomach, breast, ovary, and cancers of the neuroendocrine system. Examples include compounds XPW-0762, XPW-0770, XPW-0776, XPW-0784, XPW-0790, XPW-0798, XPW-0818, XPW-2890, XPW-2898, XPW-2904, XPW-2912, XPW-2918, XPW-2926, XPW-4576, XPW-4577, XPW-4578, XPW-4579, XPW-4580, XPW-4581, XPW-4583, XPW-4586, XPW-4589, XPW-4592 and XPW-4594.
[0082] In a further aspect, the present invention provides compounds of the general formula (Ia) and salts thereof, With respect to solvates, 1 is -CF3, and wherein Y is as defined in general formula (I), including the substituents and preferred definitions, with the proviso that, optionally, Y is different from -H; and where Z 2 is as defined in general formula (Ia), including the substituents and preferred definitions, and where R 1 -R 13 and X 1 -X 4 is as defined in general formula (I), including the substituents and preferred definitions; and wherein the compound shares the following structure (Ia-1):
[0083] [ka]
[0084] and wherein the compounds of structure (Ia-1) are - unless otherwise provided - preferred for use in human and veterinary medicine, in particular for medical uses as described in the present invention, preferably for immune system related applications including immunotherapy as defined in the present invention and other immunotherapies, and for use in the treatment of immune system related disorders, skin diseases, muscle diseases, hyperproliferative disorders, and cancers including cancers of the hematopoietic and blood system such as leukemia and lymphoma, cancers of the skin, oral mucosa, tongue, lung, stomach, breast, cervix, ovary, and cancers of the neuroendocrine system. Examples include compounds XPW-0014, XPW-0020, XPW-0028, XPW-0042, XPW-0182, XPW-4633, XPW-4642 and XPW-4643.
[0085] In a further aspect, the present invention relates to compounds of the general formula (Ia) and salts and solvates thereof, wherein Z 1 is -CF3, and where R 6 is as defined in general formula (I), including the substituents and preferred definitions, with the optional proviso that R 6 is different from -H, and where Z2 is as defined in general formula (Ia), including the substituents and preferred definitions, and where R 1 -R 5 , R 7 -R 13 , X 1 -X 4 and Y is as defined in general formula (I), including the substituents and preferred definitions; and wherein the compound shares the following structure (Ia-2):
[0086] [ka]
[0087] and wherein the compounds of structure (Ia-2) are - unless otherwise provided - preferred for use in human and veterinary medicine, in particular for medical uses as described in the present invention, preferably for immune system related applications including immunotherapy as defined in the present invention and other immunotherapies, and for use in the treatment of immune system related disorders, skin diseases, muscle diseases, hyperproliferative disorders, and cancers including cancers of the hematopoietic and blood system such as leukemia and lymphoma, cancers of the skin, oral mucosa, tongue, lung, stomach, breast, cervix, ovary, and cancers of the neuroendocrine system. Examples include compounds XPW-0014, XPW-0020, XPW-0028, XPW-0042, XPW-0182, XPW-4633, XPW-4642 and XPW-4643.
[0088] In a further aspect, the present invention relates to compounds of the general formula (Ia) and salts and solvates thereof, wherein Z 1 is -CF3, and where Y and R 6 are -H, respectively. and where R 1 is as defined in general formula (I), including the substituents and preferred definitions, with the optional proviso that R 1contains 5 or more, preferably 6 or more, carbon atoms, optionally independently substituted with heteroatoms selected from O, S and N as defined in general formula (I), and where Z 2 is as defined in general formula (Ia), including the substituents and preferred definitions, and where R 2 -R 5 , R 7 -R 12 and X 1 -X 4 is as defined in general formula (I), including the substituents and preferred definitions; and wherein the compound shares the following structure (Ia-3):
[0089] [ka]
[0090] and wherein the compounds of structure (Ia-3) are - unless otherwise provided - preferred for use in human and veterinary medicine, in particular for medical uses as described in the present invention, preferably for immune system related applications including immunotherapy as defined in the present invention and other immunotherapies, and for use in the treatment of immune system related disorders, skin diseases, muscle diseases, hyperproliferative disorders, and cancers including cancers of the hematopoietic and blood system such as leukemia and lymphoma, cancers of the skin, oral mucosa, tongue, lung, stomach, breast, ovary, and cancers of the neuroendocrine system. An example is the compound XPW-0014.
[0091] In a further aspect, the present invention relates to compounds of the general formula (Ia) and salts and solvates thereof, wherein Z 1 is -CN, and where R 1 is as defined in general formula (I), including the substituents and preferred definitions, and wherein R 1R contains 3 or more, preferably 6 or more, carbon atoms, optionally substituted independently with heteroatoms selected from O, S and N as defined in general formula (I), provided that R 1 does not contain heteroatoms selected from O, S and N, and where Z 2 is as defined in general formula (Ia), including the substituents and preferred definitions, and where R 2 -R 13 , X 1 -X 4 and Y is as defined in general formula (I), including the substituents and preferred definitions; and wherein the compound shares the following structure (Ia-4):
[0092] [ka]
[0093] and wherein the compounds of structure (Ia-4) are - unless otherwise provided - preferred for use in human and veterinary medicine, in particular for medical uses as described in the present invention, preferably for use in immune system related applications, including immunotherapy as defined in the present invention and other immunotherapies, and in the treatment of immune system related disorders, skin diseases, hyperproliferative disorders, and cancers, including cancers of the hematopoietic and blood system, such as leukemia, and cancers of the skin. An example is the compound XPW-0314.
[0094] In a further aspect, the present invention relates to compounds of formula (Ib) and salts and solvates thereof, wherein R 1 is as defined in general formula (I), including the substituents and preferred definitions, where R 1 contains six or more carbon atoms, optionally independently substituted with heteroatoms selected from O, S and N as defined in general formula (I), and wherein R 1 is selected from cyclic, bicyclic and tricyclic structures; and where R 5 is defined in general formula (I), including the substituents and preferred definitions. As described above, except that R 5 is different from -H and where Z 1 , Z 2 and R 14 is as defined in general formula (Ib), including the substituents and preferred definitions, and where R 2 -R 4 , R 6 -R 13 and X 1 -X 4 and Y is as defined in general formula (I), including the substituents and preferred definitions; and wherein the compound shares the following structure (Ib-1):
[0095] [ka]
[0096] and wherein the compounds of structure (Ib-1) are preferred for use in human and veterinary medicine, in particular for medical uses according to the present invention, preferably for immune system related applications including immunotherapy as defined in the present invention and other immunotherapies, and for use in the treatment of immune system related disorders, skin diseases, muscle diseases, hyperproliferative disorders, and cancers including cancers of the hematopoietic and blood system such as leukemia and lymphoma, cancers of the skin, oral mucosa, tongue, lung, stomach, breast, cervix, ovary, and cancers of the neuroendocrine system. Examples include compounds XPW-4575, XPW-4577, XPW-4578, XPW-4579, XPW-4580, XPW-4581, XPW-4583, XPW-4584, XPW-4585, XPW-4586, XPW-4587, XPW-4588, XPW-4589, XPW-4590, XPW-4591, XPW-4592, XPW-4593, XPW-4594 and XPW-4595.
[0097] In a further aspect, the present invention relates to compounds of formula (Ib) and salts and solvates thereof, wherein X 4 is N, and where R 1 is as defined in general formula (I), including the substituents and preferred definitions, where R 1 contains six or more carbon atoms, optionally independently substituted with heteroatoms selected from O, S and N as defined in general formula (I), and wherein R 1 is selected from cyclic, bicyclic and tricyclic structures; and where Z 1 , Z 2 and R 14 is as defined in general formula (Ib), including the substituents and preferred definitions, and where R 2 -R 13 , X 1 -X 3 and Y is as defined in general formula (I), including the substituents and preferred definitions; and wherein the compound shares the following structure (Ib-2):
[0098] [ka]
[0099] and wherein the compounds of structure (Ib-2) are preferred for use in human and veterinary medicine, in particular for medical uses according to the present invention, preferably for immune system related applications including immunotherapy as defined in the present invention and other immunotherapies, and for use in the treatment of immune system related disorders, skin diseases, muscle diseases, hyperproliferative disorders, and cancers including cancers of the hematopoietic and blood system such as leukemia and lymphoma, cancers of the skin, oral mucosa, tongue, lung, stomach, breast, cervix, ovary, and cancers of the neuroendocrine system. Examples include compounds XPW-4623, XPW-4624, XPW-4628, XPW-4629, XPW-4630, XPW-4631, XPW-4632, XPW-4634, XPW-4635, XPW-4636 and XPW-4644.
[0100] In a further aspect, the present invention relates to compounds of formula (Ib) and salts and solvates thereof, wherein Z 1 and Z 2 taken together are =O, and where Y is -OCH3; and where R 1 is as defined in general formula (I), including the substituents and preferred definitions, wherein R 1 does not contain heteroatoms selected from O, S, and N, except that R 1 contains two or more carbon atoms, and where R 2 -R 6 , R 9 -R 12 and X 1 -X 4 is as defined in general formula (I), including the substituents and preferred definitions; and wherein the compound shares the following structure (Ib-3):
[0101] [ka]
[0102] and wherein the compounds of structure (Ib-3) are - unless otherwise specified - for use in human and veterinary medicine, in particular for medical uses as defined in the present invention, preferably for immunotherapy as defined in the present invention. The present invention is preferred for use in immune system related applications, including immunotherapy and other immunotherapies, as well as in the treatment of immune system related disorders, skin disorders, muscle disorders, hyperproliferative disorders, and cancers, including cancers of the hematopoietic and blood system, such as leukemia and lymphoma, skin, oral mucosa, tongue, lung, stomach, and breast. Examples include compounds XPW-0702, XPW-0706, XPW-0714, XPW-0716, XPW-0720, XPW-0728, XPW-2833, XPW-2834, XPW-2847, XPW-2848 and XPW-4605.
[0103] In a further aspect, the present invention relates to compounds of formula (Ib) and salts and solvates thereof, wherein Y and R 6 is as defined in general formula (I), including the substituents and preferred definitions, where Y is R 6 Together with and where R 1 is as defined in general formula (I), including the substituents and preferred definitions, where R 1 is selected from cyclic, bicyclic and tricyclic structures, with the proviso that R 1 contains zero or one heteroatom selected from O, S, and N, and where Z 1 , Z 2 and R 14 is as defined in general formula (Ib), including the substituents and preferred definitions, and where R 2 -R 5 , R 7 -R 12 and X 1 -X 4 is as defined in general formula (I), including the substituents and preferred definitions; and wherein the compound shares the following structure (Ib-4):
[0104] [ka]
[0105] and wherein the compounds of structure (Ib-4) are - unless otherwise provided - preferred for use in human and veterinary medicine, in particular for medical uses as described in the present invention, preferably for immune system related applications including immunotherapy as defined in the present invention and other immunotherapies, and for use in the treatment of immune system related disorders, skin diseases, muscle diseases, hyperproliferative disorders, and cancers including cancers of the hematopoietic and blood system such as leukemia and lymphoma, cancers of the skin, oral mucosa, tongue, lung, stomach, breast, ovary, and cancers of the neuroendocrine system. Examples include compounds XPW-0762, XPW-0770, XPW-0776, XPW-0784, XPW-0790, XPW-0798, XPW-0818, XPW-2890, XPW-2898, XPW-2904, XPW-2912, XPW-2918, XPW-2926, XPW-4576, XPW-4577, XPW-4578, XPW-4579, XPW-4580, XPW-4581, XPW-4583, XPW-4586, XPW-4589, XPW-4592 and XPW-4594.
[0106] In a further aspect, the present invention provides compounds of the general formula (Ib) and salts thereof, With respect to solvates, 1 and Z 2 are taken together as =O, and where R 1 is adamantyl, and where R 5 is as defined in general formula (I), including the substituents and preferred definitions, with the proviso that R 5 is different from -H, and where Y, R 2 -R 4 , R 6 , R 9 -R 13 and X 1 -X 4 is as defined in general formula (I), including the substituents and preferred definitions; and wherein the compound shares the following structure (Ib-5):
[0107] [ka]
[0108] and wherein the compounds of structure (Ib-5) are preferred for use in human and veterinary medicine, in particular for medical uses according to the present invention, preferably for immune system related applications including immunotherapy as defined in the present invention and other immunotherapies, and for use in the treatment of immune system related disorders, skin diseases, muscle diseases, hyperproliferative disorders, and cancers including cancers of the hematopoietic and blood system such as leukemia and lymphoma, cancers of the skin, oral mucosa, tongue, lung, stomach, breast, cervix, ovary, and cancers of the neuroendocrine system. Examples include compounds XPW-4585, XPW-4586, XPW-4587, XPW-4591, XPW-4592 and XPW-4593.
[0109] In a further aspect, the present invention relates to compounds of formula (Ib) and salts and solvates thereof, wherein Z 1 and Z 2 are taken together as =O, and where R 1 is adamantyl, and where X 4 is N, and where R 2 -R 6 , R 9 -R 13 , X 1 -X 3 and Y is as defined in general formula (I), including the substituents and preferred definitions; and wherein the compound shares the following structure (Ib-6):
[0110] [ka]
[0111] and wherein the compounds of structure (Ib-6) are preferred for use in human and veterinary medicine, in particular for medical uses according to the present invention, preferably for immune system related applications including immunotherapy as defined in the present invention and other immunotherapies, and for use in the treatment of immune system related disorders, skin diseases, muscle diseases, hyperproliferative disorders, and cancers including cancers of the hematopoietic and blood system such as leukemia and lymphoma, cancers of the skin, oral mucosa, tongue, lung, stomach, breast, cervix, ovary, and cancers of the neuroendocrine system. Examples include compounds XPW-4623, XPW-4624, XPW-4628, XPW-4629, XPW-4630, XPW-4631, XPW-4632, XPW-4634, XPW-4635, XPW-4636 and XPW-4644.
[0112] In a further aspect, the present invention relates to compounds of formula (Ib) and salts and solvates thereof, wherein Z 1 and Z 2 taken together is =O, and where Y is -OH, and where R 6 is -H, and where R 1 is as defined in general formula (I), including the substituents and preferred definitions, where R 1 contains six or more carbon atoms, optionally independently substituted with heteroatoms selected from O, S and N as defined in general formula (I), and where R 5 is as defined in general formula (I), including the substituents and preferred definitions, with the proviso that R 5 is different from -H, and where R 2 -R 4 , R 7 -R 12 and X 1 -X 4 is as defined in general formula (I), including the substituents and preferred definitions; and wherein the compound shares the following structure (Ib-7):
[0113] [ka]
[0114] and wherein the compounds of structure (Ib-7) are preferred for use in human and veterinary medicine, in particular for medical uses according to the present invention, preferably for immune system related applications including immunotherapy as defined in the present invention and other immunotherapies, and for use in the treatment of immune system related disorders, skin diseases, muscle diseases, hyperproliferative disorders, and cancers including cancers of the hematopoietic and blood system such as leukemia and lymphoma, cancers of the skin, oral mucosa, tongue, lung, stomach, breast, cervix, ovary, and cancers of the neuroendocrine system. Examples include compounds XPW-4584, XPW-4587, XPW-4590 and XPW-4593.
[0115] In a further aspect, the present invention relates to compounds of formula (Ib) and salts and solvates thereof, wherein Z 1 and Z 2 taken together is =O, and where Y is -OH, and where R 6 is -H, and where X 4 is N, and where R 1 -R 5 , R 7 -R 12 and X 1 -X 4 is as defined in general formula (I), including the substituents and preferred definitions; and wherein the compound shares the following structure (Ib-8):
[0116] [ka]
[0117] and wherein the compounds of structure (Ib-8) are preferred for use in human and veterinary medicine, in particular for medical uses according to the present invention, preferably for immune system related applications including immunotherapy as defined in the present invention and other immunotherapies, and for use in the treatment of immune system related disorders, skin diseases, muscle diseases, hyperproliferative disorders, and cancers including cancers of the hematopoietic and blood system such as leukemia and lymphoma, cancers of the skin, oral mucosa, tongue, lung, stomach, breast, cervix, ovary, and cancers of the neuroendocrine system. Examples include compounds XPW-4623, XPW-4628, XPW-4630 and XPW-4636.
[0118] In a further aspect, the present invention relates to compounds of formula (Ib) and salts and solvates thereof, wherein Z 1 and Z 2 taken together is =O, and where Y is -OH, and where R 6 is -H, and where X 1 and X 2 are N, respectively. and where R 1 -R 5 , R 7 -R 12 , X 3 and X 4 is as defined in general formula (I), including the substituents and preferred definitions; and wherein the compound shares the following structure (Ib-9):
[0119] [ka]
[0120] and wherein the compounds of structure (Ib-9) are preferred for use in human and veterinary medicine, in particular for medical uses as described herein, preferably for immune system related applications including immunotherapy as defined herein and other immunotherapies, and for use in the treatment of immune system related disorders, skin diseases, muscle diseases, hyperproliferative disorders, and cancers including cancers of the hematopoietic and blood system such as leukemia and lymphoma, cancers of the skin, oral mucosa, tongue, lung, stomach, breast, cervix, ovary, and cancers of the neuroendocrine system. An example is the compound XPW-4625.
[0121] In a further aspect, the present invention relates to compounds of formula (Ib) and salts and solvates thereof, wherein Z 1 and Z 2 taken together is =O, and where Y is -OH, and where R 6 is -H, and where X 1 is N, and where X 4 CR 10 and where R 10 is as defined in general formula (I), including the substituents and preferred definitions, with the proviso that R 10 is different from -H, and where R 1 -R 5 , R 7 -R 9 , R 11 , R 12 , X 2 and X 3 is as defined in general formula (I), including the substituents and preferred definitions; and wherein the compound shares the following structure (Ib-10):
[0122] [ka]
[0123] and wherein the compounds of structure (Ib-10) are preferred for use in human and veterinary medicine, in particular for medical uses as described herein, preferably for immune system related applications including immunotherapy as defined herein and other immunotherapies, and for use in the treatment of immune system related disorders, skin diseases, muscle diseases, hyperproliferative disorders, and cancers including cancers of the hematopoietic and blood system such as leukemia and lymphoma, cancers of the skin, oral mucosa, tongue, lung, stomach, breast, cervix, ovary, and cancers of the neuroendocrine system. An example is the compound XPW-4639.
[0124] In a further aspect, the present invention relates to compounds of formula (Ib) and salts and solvates thereof, wherein Z 1 and Z 2 taken together is =O, and where Y is -CH3, and where R 6 is -CH3, and where R 1 is as defined in general formula (I), including the substituents and preferred definitions, where R 1 contains six or more carbon atoms, optionally independently substituted with heteroatoms selected from O, S and N as defined in general formula (I), and where R 5 is as defined in general formula (I), including the substituents and preferred definitions, where R 5 is different from -H, except that, optionally, R 5 Unlike -OCH3, and where R 2 -R 4 , R 7 -R 12 and X 1 -X 4 The substituents and preferred definitions are as defined in general formula (I), and wherein the compound shares the following structure (Ib-11):
[0125] [ka]
[0126] and wherein the compounds of structure (Ib-11) are - unless otherwise specified - preferred for use in human and veterinary medicine, in particular for medical use as described in the present invention, preferably for immune system related applications including immunotherapy as defined in the present invention and other immunotherapies, and for use in the treatment of immune system related disorders, skin diseases, muscle diseases, hyperproliferative disorders, and cancers including cancers of the hematopoietic and blood system such as leukemia and lymphoma, cancers of the skin, oral mucosa, tongue, lung, stomach, breast, and cancers of the neuroendocrine system. Examples include compounds XPW-4575, XPW-4585, XPW-4588, XPW-4591 and XPW-4595.
[0127] In a further aspect, the present invention relates to compounds of formula (Ib) and salts and solvates thereof, wherein R 1 is as defined in general formula (I), including the substituents and preferred definitions, where R 1 is selected from unsubstituted and substituted cycloalkyl and cycloalkenyl, where such rings contain 4 or more, preferably 6 or more, ring carbon atoms which cannot be substituted with heteroatoms selected from O, S and N; and where R 5 is as defined in general formula (I), including the substituents and preferred definitions, with the proviso that R 5 is different from -H, and where Z 1 , Z 2 and R 14 is as defined in general formula (Ib), including the substituents and preferred definitions, and where R 2 -R 4 , R 6 -R 13 , X 1 -X 4 and Y is as defined in general formula (I), including the substituents and preferred definitions; and wherein the compound shares the following structure (Ib-12):
[0128] [ka]
[0129] and wherein the compounds of structure (Ib-12) are preferred for use in human and veterinary medicine, in particular for medical uses according to the present invention, preferably for immune system related applications including immunotherapy as defined in the present invention and other immunotherapies, and for use in the treatment of immune system related disorders, skin diseases, muscle diseases, hyperproliferative disorders, and cancers including cancers of the hematopoietic and blood system such as leukemia and lymphoma, cancers of the skin, oral mucosa, tongue, lung, stomach, breast, cervix, ovary, and cancers of the neuroendocrine system. Examples include compounds XPW-4575, XPW-4577, XPW-4578, XPW-4579, XPW-4580, XPW-4581, XPW-4583, XPW-4584, XPW-4588, XPW-4589, XPW-4590, XPW-4594 and XPW-4595.
[0130] In a further aspect, the present invention relates to compounds of formula (Ib) and salts and solvates thereof, wherein Z 1 and Z 2 Let's get together =NR 14 and and where R 1 is as defined in general formula (I), including the substituents and preferred definitions, where R 1 is selected from cyclic, bicyclic and tricyclic structures, with the proviso that R 1 contains zero or one heteroatom selected from O, S, and N, and where R 14 is as defined in general formula (Ib), including the substituents and preferred definitions, and where R 2 -R 13 , X 1 -X 4and Y is as defined in general formula (I), including the substituents and preferred definitions; and wherein the compound shares the following structure (Ib-13):
[0131] [ka]
[0132] and wherein the compounds of structure (Ib-13) are - unless otherwise provided - preferred for use in human and veterinary medicine, in particular for medical uses as described in the present invention, preferably for immune system related applications including immunotherapy as defined in the present invention and other immunotherapies, and for use in the treatment of immune system related disorders, skin diseases, muscle diseases, hyperproliferative disorders, and cancers including cancers of the hematopoietic and blood system such as leukemia and lymphoma, cancer of the skin, oral mucosa, tongue and breast. Examples include compounds XPW-0832 and XPW-4574.
[0133] In a further aspect, the present invention relates to compounds of formula (Ib) and salts and solvates thereof, wherein Z 1 and Z 2 taken together is =O, and where Y is -OH, and where R 6 is -H, and where X 1 CR 11 and X 2 CR 8 and X 3 CR 9 and X 4 CR 10 and where R 1 is as defined in general formula (I), including the substituents and preferred definitions, where R 1 contains 4 or more, preferably 6 or more, carbon atoms, optionally independently substituted with heteroatoms selected from O, S and N as defined in general formula (I), provided that R 1contains 1 or 2 heteroatoms selected from O, S, and N; and where R 2 -R 5 and R 7 -R 12 is as defined in general formula (I), including the substituents and preferred definitions; and wherein the compound shares the following structure (Ib-14):
[0134] [ka]
[0135] and wherein the compounds of structure (Ib-14) are preferred for use in human and veterinary medicine, in particular for medical uses according to the present invention, preferably for immune system related applications including immunotherapy as defined in the present invention and other immunotherapies, and for use in the treatment of immune system related disorders, skin diseases, muscle diseases, hyperproliferative disorders, and cancers including cancers of the hematopoietic and blood system such as leukemia and lymphoma, cancers of the skin, oral mucosa, tongue, lung, stomach, breast, cervix, ovary, and cancers of the neuroendocrine system. Examples include compounds XPW-0661, XPW-0665, XPW-0667 and XPW-4613.
[0136] In a further aspect, the present invention relates to compounds of formula (Ib) and salts and solvates thereof, wherein Z 1 and Z 2 are taken together as =O, and where R 6 is -CH3, and where X 1 CR 11 and X 2 CR 8 and X 3 CR 9 and X 4 CR 10 and and where R 1 is defined in general formula (I), including the substituents and preferred definitions. where R1 is selected from cyclic, bicyclic and tricyclic structures, provided that R 1 contains 1 or 2 heteroatoms selected from O, S, and N; and where R 2 -R 5 , R 7 -R 13 and Y is as defined in general formula (I), including the substituents and preferred definitions; and wherein the compound shares the following structure (Ib-15):
[0137] [ka]
[0138] and wherein the compounds of structure (Ib-15) are preferred for use in human and veterinary medicine, in particular for medical uses as described in the present invention, preferably for immune system related applications including immunotherapy as defined in the present invention and other immunotherapies, and for use in the treatment of immune system related disorders, skin diseases, muscle diseases, hyperproliferative disorders, and cancers including cancers of the hematopoietic and blood system such as leukemia and lymphoma, cancers of the skin, oral mucosa, tongue, breast, ovary, and cancers of the neuroendocrine system. Examples include compounds XPW-0539, XPW-0541 and XPW-0679.
[0139] In a further aspect, the present invention relates to compounds of formula (Ic) and salts and solvates thereof, wherein Z 1 and Z 2 taken together form a cyclic residue including the carbon atoms to which they are attached, and wherein Z 1 and Z 2 is as defined in general formula (Ic), including the substituents and preferred definitions, and where R 6 is as defined in general formula (I), including the substituents and preferred definitions, with the optional proviso that R 6 is different from H, and where R1 -R 5 , R 7 -R 13 , X 1 -X 4 and Y is as defined in general formula (I), including the substituents and preferred definitions; and wherein the compound shares the following structure (Ic-1):
[0140] [ka]
[0141] and wherein the compounds of structure (Ic-1) are - unless otherwise provided - preferred for use in human and veterinary medicine, in particular for medical uses as described in the present invention, preferably for immune system related applications including immunotherapy as defined in the present invention and other immunotherapies, and for use in the treatment of immune system related disorders, skin diseases, muscle diseases, hyperproliferative disorders, and cancers including cancers of the hematopoietic and blood system such as leukemia and lymphoma, cancers of the skin, oral mucosa, tongue, lung, stomach, breast, cervix, ovary, and cancers of the neuroendocrine system. Examples include compounds XPW-0902, XPW-0916, XPW-0924, XPW-0930, XPW-3038 and XPW-3052.
[0142] In a further aspect, the present invention relates to compounds of formula (Ic) and salts and solvates thereof, wherein Z 1 and Z 2 taken together form a cyclic residue including the carbon atoms to which they are attached, and wherein Z 1 and Z 2 is as defined in general formula (Ic), including the substituents and preferred definitions, with the proviso that, optionally, said cyclic residue comprises one or more heteroatoms independently selected from O, S and N in place of the carbon atoms contained in the ring structure, and / or said cyclic residue is substituted with one or more substituents as defined in general formula (Ic); and where R 1 -R 13 , X1 -X 4 and Y is as defined in general formula (I), including the substituents and preferred definitions; and wherein the compound shares the following structure (Ic-2):
[0143] [ka]
[0144] and wherein the compounds of structure (Ic-2) are - unless otherwise provided - preferred for use in human and veterinary medicine, in particular for medical uses as described in the present invention, preferably for immune system related applications including immunotherapy as defined in the present invention and other immunotherapies, and for use in the treatment of immune system related disorders, skin diseases, muscle diseases, hyperproliferative disorders, and cancers including cancers of the hematopoietic and blood system such as leukemia and lymphoma, cancers of the skin, oral mucosa, tongue, lung, stomach, breast, cervix, ovary, and cancers of the neuroendocrine system. Examples include compounds XPW-0902, XPW-0916, XPW-0924, XPW-0930, XPW-3038 and XPW-3052.
[0145] In a further aspect, the present invention relates to compounds of formula (Ic) and salts and solvates thereof, wherein Z 1 and Z 2 taken together form a cyclic residue including the carbon atoms to which they are attached, and wherein Z 1 and Z 2 is as defined in general formula (Ic), including the substituents and preferred definitions, with the proviso that, optionally, said cyclic residue is a 4-membered ring, and where R 1 -R 13 , X 1 -X 4 and Y is as defined in general formula (I), including the substituents and preferred definitions; and wherein the compound shares the following structure (Ic-3):
[0146] [ka]
[0147] and wherein the compounds of structure (Ic-3) are - unless otherwise provided - preferred for use in human and veterinary medicine, in particular for medical uses as described in the present invention, preferably for immune system related applications including immunotherapy as defined in the present invention and other immunotherapies, and for use in the treatment of immune system related disorders, skin diseases, muscle diseases, hyperproliferative disorders, and cancers including cancers of the hematopoietic and blood system such as leukemia and lymphoma, cancers of the skin, oral mucosa, tongue, lung, stomach, breast, cervix, ovary, and cancers of the neuroendocrine system. Examples include compounds XPW-0902, XPW-0916, XPW-0924, XPW-0930, XPW-3038 and XPW-3052.
[0148] In a further aspect, the present invention relates to compounds of formula (Ic) and salts and solvates thereof, wherein Z 1 and Z 2 taken together form a cyclic residue including the carbon atoms to which they are attached, and wherein Z 1 and Z 2 is as defined in general formula (Ic), including the substituents and preferred definitions, and where Y and R 6 are -H, respectively. and where R 1 is as defined in general formula (I), including the substituents and preferred definitions, with the optional proviso that R 1 contains 5 or more, preferably 6 or more, carbon atoms, optionally independently substituted with heteroatoms selected from O, S and N as defined in general formula (I), and where R 2 -R 5 , R 7 -R 12 and X 1 -X 4 is as defined in general formula (I), including the substituents and preferred definitions; and wherein the compound shares the following structure (Ic-4):
[0149] [ka]
[0150] and wherein the compounds of structure (Ic-4) are - unless otherwise provided - preferred for use in human and veterinary medicine, in particular for medical uses as described in the present invention, preferably for immune system related applications including immunotherapy as defined in the present invention and other immunotherapies, and for use in the treatment of immune system related disorders, skin diseases, muscle diseases, hyperproliferative disorders, and cancers including cancers of the hematopoietic and blood system such as leukemia and lymphoma, cancers of the skin, oral mucosa, tongue, lung, stomach, breast, cervix, ovary, and cancers of the neuroendocrine system. Examples include compounds XPW-0916, XPW-0924 and XPW-3052.
[0151] In some embodiments, the following compounds shown in Tables 1 to 3 are expressly excluded from the scope of the invention.
[0152] The compounds in Table 1, specifically indicated by CAS Registry Number, have been identified by the inventors, who are skilled in the art. In the embodiment in which these compounds are included in the general formula (I) or any subgeneric formula defined herein, they are expressly excluded from the scope of the present invention in terms of compound protection. To the best of the inventors' knowledge, these compounds are not known for any medical use. That is, the present invention encompasses any medical use of the compounds in Table 1.
[0153] [Table 1-1]
[0154] [Table 1-2]
[0155] The compounds in Table 2, specifically indicated by CAS Registry Numbers, have been identified by the inventors, who are skilled in the art. In the embodiment in which these compounds are included in the general formula (I) or any subgeneric formula defined herein, they are expressly excluded from the scope of the present invention in terms of compound protection. To the best of the inventors' knowledge, these compounds are not known for any medical use as defined in the present invention. That is, the compounds in Table 2 are expressly included in the scope of the present invention in terms of medical use as defined in the present invention, particularly in the treatment of non-malignant or malignant hyperproliferative diseases.
[0156] [Table 2-1]
[0157] [Table 2-2]
[0158] The compounds in Table 3, specifically designated by CAS Registry Numbers, have been identified by the inventors, who are skilled in the art. In embodiments where these compounds are included in general formula (I) or any subgeneric formula defined herein, they are expressly excluded from the scope of the present invention with respect to compound protection. Furthermore, these compounds are, to the best of the inventors' knowledge, known for medical uses, which may in some embodiments be encompassed by medical uses as defined herein. That is, the compounds in Table 3 may be expressly excluded from the scope of the present invention with respect to compound protection and with respect to certain medical uses in some embodiments as defined herein.
[0159] [Table 3-1]
[0160] [Table 3-2]
[0161] [Table 3-3]
[0162] Specific examples of compounds falling within the scope of the compounds covered in pending application PCT / EP2018 / 054686 are claimed in the present application to have novel medical uses, in particular in muscle cells, keratinocytes and cells as well as in cervical cancer, cutaneous T-cell lymphoma, acute promyelocytic leukemia, acute myeloid leukemia, oral and tongue squamous cell carcinoma, epidermoid squamous cell carcinoma and lung squamous cell carcinoma cells. It has been determined that the compound has growth inhibitory properties against cells selected from and malignant cells. Thus, these compounds, together with their salts and solvates, are particularly suitable for the treatment of hyperproliferative muscle diseases, hyperproliferative skin diseases as defined herein, as well as for the treatment of cervical cancer, cutaneous T-cell lymphoma, acute promyelocytic leukemia, acute myeloid leukemia, epidermoid cancers such as non-melanoma skin cancer, cancer of the oral cavity, cancer of the tongue and lung cancer as defined herein.
[0163] Specific examples of compounds falling within the scope of compounds covered in pending application PCT / EP2018 / 054686 have been identified in the present application as having further novel medical uses, in particular growth inhibitory properties against cells and malignant cells selected from T-cell leukemia, B-cell leukemia, gastric cancer, breast cancer, ovarian cancer and medullary thyroid cancer. Thus, these compounds, together with their salts and solvates, are particularly suitable for the treatment of diseases of the hematopoietic system, including the blood system, such as T-cell leukemia, B-cell leukemia, as well as for the treatment of gastric cancer, breast cancer, ovarian cancer and cancers of the neuroendocrine system, as defined herein.
[0164] Novel medical uses identified herein for specific compounds falling within the scope of compounds covered by pending application PCT / EP2018 / 054686 are set out in Tables 4 and 5, where the medical indications are selected from the treatment of hyperproliferative muscle diseases (A), hyperproliferative skin diseases as defined herein (B), cervical cancer (C), cutaneous T-cell lymphoma (D), acute promyelocytic leukemia (E), acute myeloid leukemia (F), epidermoid carcinoma (G), cancer of the oral cavity (H), cancer of the tongue (I), lung cancer (J), T-cell leukemia (K), B-cell leukemia (L), gastric cancer (M), breast cancer (N), ovarian cancer (O) and cancer of the neuroendocrine system (P).
[0165] The following compounds described in PCT / EP2018 / 054686 are specifically claimed for the indicated medical uses:
[0166] [Table 4]
[0167] The following compounds described in PCT / EP2018 / 054686 are specifically claimed for the indicated medical uses:
[0168] [Table 5]
[0169] Illustrative examples of compounds falling within the scope of formula (I) are shown in Tables 6 to 54. The intermediate is designated "XPW-I."
[0170] [Table 6]
[0171] The above table constitutes an individual description of each of the compounds specifically set forth therein and of the salts and solvates thereof.
[0172] [Table 7]
[0173] The above table constitutes an individual description of each of the compounds specifically set forth therein and of the salts and solvates thereof.
[0174] [Table 8]
[0175] The above table constitutes an individual description of each of the compounds specifically set forth therein and of the salts and solvates thereof.
[0176] [Table 9]
[0177] The above table constitutes an individual description of each of the compounds specifically set forth therein and of the salts and solvates thereof.
[0178] [Table 10]
[0179] The above table constitutes an individual description of each of the compounds specifically set forth therein and of the salts and solvates thereof.
[0180] [Table 11]
[0181] The above table constitutes an individual description of each of the compounds specifically set forth therein and of the salts and solvates thereof.
[0182] [Table 12]
[0183] The above table constitutes an individual description of each of the compounds specifically set forth therein and of the salts and solvates thereof.
[0184] [Table 13]
[0185] The above table constitutes an individual description of each of the compounds specifically set forth therein and of the salts and solvates thereof.
[0186] [Table 14]
[0187] The above table constitutes an individual description of each of the compounds specifically set forth therein and of the salts and solvates thereof.
[0188] [Table 15]
[0189] The above table constitutes an individual description of each of the compounds specifically set forth therein and of the salts and solvates thereof.
[0190] [Table 16]
[0191] The above table constitutes an individual description of each of the compounds specifically set forth therein and of the salts and solvates thereof.
[0192] [Table 17]
[0193] The above table constitutes an individual description of each of the compounds specifically set forth therein and of the salts and solvates thereof.
[0194] [Table 18]
[0195] The above table constitutes an individual description of each of the compounds specifically set forth therein and of the salts and solvates thereof.
[0196] [Table 19]
[0197] The above table constitutes an individual description of each of the compounds specifically set forth therein and of the salts and solvates thereof.
[0198] [Table 20]
[0199] The above table constitutes an individual description of each of the compounds specifically set forth therein and of the salts and solvates thereof.
[0200] [Table 21]
[0201] The above table constitutes an individual description of each of the compounds specifically set forth therein and of the salts and solvates thereof.
[0202] [Table 22]
[0203] The above table constitutes an individual description of each of the compounds specifically set forth therein and of the salts and solvates thereof.
[0204] [Table 23]
[0205] The above table constitutes an individual description of each of the compounds specifically set forth therein and of the salts and solvates thereof.
[0206] [Table 24]
[0207] The above table constitutes an individual description of each of the compounds specifically set forth therein and of the salts and solvates thereof.
[0208] [Table 25]
[0209] The above table constitutes an individual description of each of the compounds specifically set forth therein and of the salts and solvates thereof.
[0210] [Table 26]
[0211] The above table constitutes an individual description of each of the compounds specifically set forth therein and of the salts and solvates thereof.
[0212] [Table 27]
[0213] The above table constitutes an individual description of each of the compounds specifically set forth therein and of the salts and solvates thereof.
[0214] [Table 28]
[0215] The above table constitutes an individual description of each of the compounds specifically set forth therein and of the salts and solvates thereof.
[0216] [Table 29]
[0217] The above table constitutes an individual description of each of the compounds specifically set forth therein and of the salts and solvates thereof.
[0218] [Table 30]
[0219] The above table constitutes an individual description of each of the compounds specifically set forth therein and of the salts and solvates thereof.
[0220] [Table 31]
[0221] The above table constitutes an individual description of each of the compounds specifically set forth therein and of the salts and solvates thereof.
[0222] [Table 32]
[0223] The above table constitutes an individual description of each of the compounds specifically set forth therein and of the salts and solvates thereof.
[0224] [Table 33]
[0225] The above table constitutes an individual description of each of the compounds specifically set forth therein and of the salts and solvates thereof.
[0226] [Table 34]
[0227] The above table constitutes an individual description of each of the compounds specifically set forth therein and of the salts and solvates thereof.
[0228] [Table 35]
[0229] The above table constitutes an individual description of each of the compounds specifically set forth therein and of the salts and solvates thereof.
[0230] [Table 36]
[0231] The above table constitutes an individual description of each of the compounds specifically set forth therein and of the salts and solvates thereof.
[0232] [Table 37]
[0233] The above table constitutes an individual description of each of the compounds specifically set forth therein and of the salts and solvates thereof.
[0234] [Table 38]
[0235] The above table constitutes an individual description of each of the compounds specifically set forth therein and of the salts and solvates thereof.
[0236] [Table 39]
[0237] The above table constitutes a separate description of each of the specifically indicated intermediates used in the synthesis of XPW-0001 through XPW-5062, as well as their salts and solvates. Such intermediates and their salts and solvates are also part of the present invention and are also within the scope of the process to produce the final compounds.
[0238] [Table 40]
[0239] The above table constitutes a separate description of each of the specifically indicated intermediates used in the synthesis of XPW-0001 through XPW-5062, as well as their salts and solvates. Such intermediates and their salts and solvates are also part of the present invention and are also within the scope of the process to produce the final compounds.
[0240] [Table 41]
[0241] The above table constitutes an individual description of each of the compounds specifically set forth therein and of the salts and solvates thereof.
[0242] [Table 42]
[0243] The above table constitutes an individual description of each of the compounds specifically set forth therein and of the salts and solvates thereof.
[0244] [Table 43]
[0245] The above table constitutes an individual description of each of the compounds specifically set forth therein and of the salts and solvates thereof.
[0246] [Table 44]
[0247] The above table constitutes an individual description of each of the compounds specifically set forth therein and of the salts and solvates thereof.
[0248] [Table 45]
[0249] The above table constitutes an individual description of each of the compounds specifically set forth therein and of the salts and solvates thereof.
[0250] [Table 46]
[0251] The above table constitutes an individual description of each of the compounds specifically set forth therein and of the salts and solvates thereof.
[0252] [Table 47]
[0253] The above table constitutes an individual description of each of the compounds specifically shown therein that are used as synthetic intermediates, as well as their salts and solvates. Such intermediates as well as their salts and solvates are also part of the invention and are also within the framework of the process to produce the final compounds.
[0254] [Table 48]
[0255] The above table constitutes an individual description of each of the compounds specifically shown therein that are used as synthetic intermediates, as well as their salts and solvates. Such intermediates as well as their salts and solvates are also part of the invention and are also within the framework of the process to produce the final compounds.
[0256] [Table 49]
[0257] The above table constitutes an individual description of each of the compounds specifically shown therein that are used as synthetic intermediates, as well as their salts and solvates. Such intermediates as well as their salts and solvates are also part of the invention and are also within the framework of the process to produce the final compounds.
[0258] [Table 50]
[0259] The above table constitutes an individual description of each of the compounds specifically shown therein that are used as synthetic intermediates, as well as their salts and solvates. Such intermediates as well as their salts and solvates are also part of the invention and are also within the framework of the process to produce the final compounds.
[0260] [Table 51]
[0261] The above table constitutes an individual description of each of the compounds specifically shown therein that are used as synthetic intermediates, as well as their salts and solvates. Such intermediates as well as their salts and solvates are also part of the invention and are also within the framework of the process to produce the final compounds.
[0262] [Table 52]
[0263] The above table constitutes an individual description of each of the compounds specifically shown therein that are used as synthetic intermediates, as well as their salts and solvates. Such intermediates as well as their salts and solvates are also part of the invention and are also within the framework of the process to produce the final compounds.
[0264] [Table 53]
[0265] The above table constitutes an individual description of each of the compounds specifically shown therein that are used as synthetic intermediates, as well as their salts and solvates. Such intermediates as well as their salts and solvates are also part of the invention and are also within the framework of the process to produce the final compounds.
[0266] [Table 54]
[0267] The above table constitutes an individual description of each of the compounds specifically shown therein that are used as synthetic intermediates, as well as their salts and solvates. Such intermediates as well as their salts and solvates are also part of the invention and are also within the framework of the process to produce the final compounds.
[0268] Also included are isomers, such as enantiomers or diastereomers or mixtures of isomers, salts, particularly pharma- ceutically acceptable salts, and solvates of the aforementioned compounds.
[0269] [Further definitions] "C1-C 12The term "alkyl" includes all isomers of the corresponding saturated aliphatic hydrocarbon groups containing from 1 to 12 carbon atoms; this includes methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, sec-pentyl, 3-pentyl, 2-methylbutyl, iso-pentyl, 2-methylbutan-2-yl, 3-methylbutan-2-yl, all hexyl isomers, all heptyl isomers, all octyl isomers, all nonyl isomers, all decyl isomers, all undecyl isomers, and all dodecyl isomers. "C2-C 12 The term "alkenyl" includes all isomers of the corresponding unsaturated olefinic hydrocarbon groups containing from 2 to 12 carbon atoms linked (i.e., including) by one or more double bonds; this includes vinyl, all propenyl isomers, all butenyl isomers, all pentenyl isomers, all hexenyl isomers, all heptenyl isomers, all octenyl isomers, all nonenyl isomers, all decenyl isomers, all undecenyl isomers, and all dodecenyl isomers. "C2-C 12 The term "alkynyl" includes all isomers of the corresponding unsaturated acetylenic hydrocarbon groups containing 2 to 12 carbon atoms linked by (i.e., including) one or more triple bonds; this includes ethynyl, all propynyl isomers, all butynyl isomers, all pentynyl isomers, all hexynyl isomers, all heptynyl isomers, all octynyl isomers, all nonynyl isomers, all decynyl isomers, all undecynyl isomers and all dodecynyl isomers. The term "alkynyl" also includes compounds with one or more triple bonds and one or more double bonds. The term "C3-C8 cycloalkyl" includes the corresponding saturated hydrocarbon groups containing from 3 to 8 carbon atoms arranged in a monocyclic ring structure; this includes cyclopropyl, cyclobutyl, etc. , cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. The term "C5-C8 cycloalkenyl" refers to any C5-C8 cycloalkenyl group, at least one of which is sp 3and corresponding unsaturated non-aromatic and non-heteroaromatic hydrocarbon groups which are hybridized and arranged in a monocyclic ring structure and contain from 5 to 8 carbon atoms linked (i.e., inclusive) by one or more double bonds; this includes all cyclopentenyl isomers, all cyclohexenyl isomers, all cycloheptenyl isomers, all cyclooctenyl isomers. "C5-C 12 The term "bicycloalkyl" includes corresponding saturated hydrocarbon groups containing from 5 to 12 carbon atoms arranged in a bicyclic ring structure; where these bicyclic ring structures include fused, bridged and spiro systems. "C7-C 12 The term "bicycloalkenyl" includes corresponding unsaturated non-aromatic and non-heteroaromatic hydrocarbon groups containing from 7 to 12 carbon atoms arranged in bicyclic ring structures and connected (i.e., including) by one or more double bonds; where these bicyclic ring structures include fused, bridged and spiro systems. "C8-C 14 The term "tricycloalkyl" includes corresponding saturated hydrocarbon groups containing from 8 to 14 carbon atoms arranged in a tricyclic ring structure; where these tricyclic ring structures include fused, bridged and spiro systems. R 1 The terms "cyclic", "bicyclic", "tricyclic", "cycloalkyl", "cycloalkenyl", "bicycloalkyl", "bicycloalkenyl" and "tricycloalkyl" mean that such cyclic, bicyclic or tricyclic moiety is attached by a chemical bond directly to the aromatic ring to which R is attached, and R 1 The terms "cyclic", "bicyclic", "tricyclic", "cycloalkyl", "cycloalkenyl", "bicycloalkyl", "bicycloalkenyl" and "tricycloalkyl" of the substituents of R are intended to mean that such cyclic, bicyclic or tricyclic moiety is linked by a chemical bond to R. 1 means that the group is directly bonded to one of the C, N, O, or S atoms contained in the 1 is cyclohexyl" means that the cyclohexyl residue is R 1 "R" means that the ring is bonded to an aromatic ring to which the1 is methyl, R 1 is substituted with cyclohexyl" means that the resulting -CH2 (cyclohexyl) residue is R 1 is bonded to an aromatic ring to which is bonded. When a carbon atom is replaced with a heteroatom selected from O, N, or S, the number of substituents on each heteroatom is adjusted according to its valence. For example, the -CR2- group can be replaced with -NR-, -NR2 + It may be substituted with -, -O- or -S- groups. The term "perhalogenated" refers to the exhaustive halogenation of the carbon scaffold; the corresponding residues include the corresponding perfluorinated, perchlorinated, perbrominated and periodated groups. Preferably, the term "perhalogenated" refers to a perfluorinated or perchlorinated group, more preferably a perfluorinated group.
[0270] The following contain definitions of terms used in this specification. The initial definition provided for a group or term herein applies to that group or term throughout the specification, unless otherwise indicated, either individually or as part of another group. The compounds of the present invention may form salts, which are also within the scope of the present invention. Reference to the compounds of the present invention herein is understood to include reference to their salts, unless otherwise indicated. The term "salt" as used herein refers to acidic and / or basic salts formed with inorganic and / or organic acids and bases. Zwitterions (internal or inner salts) are included in the term "salt" as used herein (and may be formed, for example, when a substituent contains an acid moiety, such as a carboxyl group, and an amino group). Quaternary ammonium salts, such as alkylammonium salts, are also included herein. Salts of compounds may be formed, for example, by reacting the compound with an equivalent amount of acid or base in a medium, such as a medium in which the salt precipitates, or in an aqueous medium with subsequent lyophilization. Exemplary salts resulting from the addition of an acid are acetates (acetic acid or trihaloacetic acids, e.g., trihaloacetic acids). (such as those formed with fluoroacetic acid), adipate, alginate, ascorbate, aspartate, benzoate, benzenesulfonate, bisulfate, borate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, chlorate, bromate, iodate Salts include, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate (such as those formed with sulfuric acid), sulfonate (such as those described herein), tartrate, thiocyanate, toluenesulfonate such as tosylate, undecanoate, and the like. Exemplary salts resulting from the addition of bases (e.g., formed when a substituent contains an acidic moiety such as a carboxyl group) include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (e.g., organic amines) such as benzathine, dicyclohexylamine, hydrabamine, N-methyl-D-glucamine, N-methyl-D-glucamide, tert-butylamine, and salts with amino acids such as arginine, lysine, etc. Basic nitrogen-containing groups may be quaternized with reagents such as lower alkyl halides (e.g., methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides), dialkyl sulfates (e.g., dimethyl, diethyl, dibutyl, and diamyl sulfate), long chain halides (e.g., decyl, lauryl, myristyl, and stearyl chloride, bromide, and iodide), aralkyl halides (e.g., benzyl and phenethyl bromide), and the like. The present invention also includes pharma- ceutically acceptable salts of the compounds described herein. As used herein, "pharma- ceutically acceptable salts" refers to derivatives of the disclosed compounds in which the parent compound is modified by converting an existing acid or base moiety into its salt form. Examples of pharma- ceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines, alkali or organic salts of acidic residues such as carboxylic acids, and the like. The pharma- ceutically acceptable salts of the present invention include conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. The pharma- ceutically acceptable salts of the present invention can be synthesized from the parent compound containing a basic or acidic moiety by conventional chemical methods. In general, such salts can be prepared by reacting these compounds in their free acid or base form with a stoichiometric amount of the appropriate base or acid in water or an organic solvent, or in a mixture of the two; generally, non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. A list of suitable salts can be found in Remington's Pharmaceutical Sciences, 17 th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418, and Journal of Pharmaceutical Science 1977, 66(2), each of which is incorporated herein by reference in its entirety. The phrase "pharmacologically acceptable" is used herein to refer to compounds, materials, compositions and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio. Furthermore, in the case of compounds of the invention which contain asymmetric carbon atoms or atropisomeric bonds, the invention relates to D-forms, L-forms and D,L mixtures, and also to diastereomeric forms, if one or more asymmetric carbon atoms or atropisomeric bonds are present. Those compounds of the invention which contain asymmetric carbon atoms or atropisomeric bonds and which occur as a rule as racemates, can be separated into optically active isomers in known manner, for example using optically active acids. However, it is also possible to use optically active starting materials from the start, in which case the corresponding optically active or diastereomeric compounds are obtained as final products. The compounds of the present invention also include tautomers. Tautomers result from the exchange of a single bond with an adjacent double bond with the concomitant migration of a proton. Tautomers include prototropic tautomers, which are isomeric protonation states with the same empirical formula and total charge. Examples of prototropic tautomers include ketone-enol pairs, amide-imidinic acid pairs, lactam-lactim pairs, amide-imidinic acid pairs, enamine-imine pairs, and cyclic forms in which protons can occupy more than one position of the heterocyclic ring system, such as 1H- and 3H-imidazole, 1H-, 2H- and 4H-1,2,4-triazole, 1H- and 2H-isoindole, and 1H- and 2H-pyrazole. Tautomers can be in equilibrium or sterically fixed in one form by appropriate substitution. The compounds described herein may be asymmetric (e.g., have one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated. Compounds of the present invention that contain asymmetrically substituted carbon atoms can be isolated in optically active or racemic forms. Methods on how to prepare optically active forms from optically active starting materials are known in the art, such as by resolution of racemic mixtures or by stereoselective synthesis. Many geometric isomers of olefins, C=N double bonds, and the like, may also exist in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomers. Compounds of the invention may also include all isotopes of atoms occurring in the intermediates or final compounds. Isotopes include atoms with the same atomic number but different mass numbers. For example, isotopes of hydrogen include tritium and deuterium. Also included are solvates and hydrates of the compounds of the invention, as well as solvates and hydrates of their pharma- ceutically acceptable salts. The term "compound," as used herein, unless otherwise indicated, is intended to include all stereoisomers, geometric isomers, tautomers, rotamers, and isotopes of the structures depicted. In some embodiments, the compounds may be provided as prodrugs. As used herein, the term "prodrug" refers to a compound that, upon administration to a subject, undergoes chemical conversion by metabolic or chemical processes to produce a compound of the invention or a salt and / or solvate thereof. In some embodiments, the compounds of the present invention and their salts are substantially isolated. "Substantially isolated" means that the compound is at least partially or substantially separated from the environment in which it was formed or detected. Partial separation can include, for example, a composition enriched in the compounds of the present invention. Substantial separation can include a composition that includes at least about 50% by weight, at least about 60% by weight, at least about 70% by weight, at least about 80% by weight, at least about 90% by weight, at least about 95% by weight, at least about 97% by weight, or at least about 99% by weight of the compounds of the present invention or their salts.
[0271] [Pharmaceutical Method] The compounds of the present invention have been found to have important pharmacological properties which can be used therapeutically. The compounds of the present invention can be used alone, in combination with each other or in combination with other active compounds. In some embodiments, compounds of the invention may exhibit growth inhibitory properties in hyperproliferative processes. The antiproliferative activity of the compounds falling within formulae (1a), (1b) and (Ic), respectively, was investigated in cells or cell lines derived from lesions of the hematopoietic system, including myeloid and lymphoid cell compartments (T and B cells), the neuroendocrine system, the cervix, breast, ovary, lung, gastrointestinal tract and mucosal epithelium, as well as skin epithelium and muscle. For this purpose, HL -60 cells, NB-4 cells, HH cells, RPMI-8402 cells, TANOUE cells, TT cells, HeLa cells, MDA-MB-231 cells, FU-OV-1 cells, LOU-NH91 cells, 23132 / 87 cells, CAL-27 cells, BHY cells, SCC-25 cells, A-431 cells, human primary epidermal keratinocytes (HPEK), and C2C12 cells were seeded into 96-well plates suitable for the fluorescence assay (CORNING #3598) at the following initial cell numbers: HL-60, 1000 cells per well; NB-4, 1000 cells per well; HH, 5000 cells per well; RPMI-8402, 5000 cells per well; TANOUE, 1500 cells per well; TT, 9000 cells per well; HeLa, 2000 cells per well; MDA-MB-231, 3000 cells per well; FU-OV-1, 3000 cells per well; L0U-NH91, 4000 cells per well; 23132 / 87, 2000 cells per well; CAL-27, 2000 cells per well; BHY, 1500 cells per well; SCC-25, 1500 cells per well; A-431, 700 cells per well; HPEK, 1000 cells per well; C2C12, 500 cells per well. Cells were treated for 5 days with the indicated final concentrations of compounds (diluted from 1000x stock solutions in DMSO to a final DMSO concentration of 0.1% v / v in HO (water for injection, WFI, Fisherscientific #10378939)) or with empty vehicle 0.1% v / v DMSO as control. Five days after the start of treatment, cells were subjected to the alamarBlue® proliferation assay (Bio-Rad Serotec GmbH, BUF012B) according to the manufacturer's protocol. Readings were taken on a multiwell plate reader in fluorescence mode, applying filters for excitation at 560 nm (bandwidth 10 nm) and emission at 590 nm (bandwidth 10 nm). Control treatments for growth inhibition with commercial compounds such as methotrexate (MTREX) and resveratrol (RES) were included in all plates. Some of the test compounds of the present invention were obtained as their salts and applied as such.The corresponding cases are shown in the "Specifications" columns of Tables 55 to 92 and given in full molecular formulae in Table 93. Assays were performed in two or more replicates of a single independent experiment, with six replicates each for all conditions. For every individual plate, the measured fluorescence intensity values of the compound-treated conditions were normalized to the corresponding equally weighted arithmetic mean of the fluorescence intensity values of the six DMSO-treated control wells to obtain a relative value to a baseline level of 1.0. Two independent outlier analyses were performed according to the method of Peirce and Chauvenet (Ross, Journal of Engineering Technology 2003, 1-12). Outliers identified by at least one method, but not more than one out of six per compound within a single experiment, were excluded from the calculations. Weighted arithmetic means (here AVE W The weighted arithmetic mean and corresponding standard deviation were calculated from the normalized values of all independent replicates of a single experiment, each containing six replicates. The weighted arithmetic mean and corresponding standard deviation were calculated according to the method of Bronstein et al. (Bronstein, Semendjajew, Musiol, Muehlig, Taschenbuch der Mathematik, 5th ed. 2001 (German), Publisher: Verlag Harri Deutsch, Frankfurt The standard deviation was calculated according to the method described by am Main and Thun and combined with the Gaussian error propagation associated with the calculation performed for normalization. The resulting standard deviation is referred to herein as the "combined standard deviation." If there was substantial variation in the normalized equally-weighted arithmetic means obtained from two independent replications, the number of independent replications was increased to more than two. In the case of four or more independent replications, a second outlier analysis was applied to all normalized equally-weighted arithmetic means, following the method of Peirce and Chauvenet described above. In some embodiments, the compounds of the invention can be growth inhibitors of hyperproliferative processes, including malignant and non-malignant hyperproliferative processes. In one embodiment, some compounds of the present invention were found to inhibit the growth of HL-60 cells (human acute myeloid leukemia cells), available from Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) under accession number ACC3. HL-60 cells were cultured in RPMI 1640 medium (Fisherscientific, #11554526) containing 10% fetal bovine serum (Fisher scientific, #15517589) at 37°C, 5% CO2. Compounds are considered as growth inhibitors of HL-60 cells if, at a reference concentration of 20 μM, the weighted arithmetic mean of the normalized fluorescence intensity values after addition of the corresponding binding standard deviation is ≤0.9 relative to an overall baseline level of 1.0, specifically ≤0.8, ≤0.7, ≤0.6, ≤0.4 and ≤0.2. The overall baseline level was calculated as the weighted arithmetic mean of all normalized values from the DMSO control measurements, similar to the calculations performed for the test compounds. The corresponding binding standard deviation with respect to the DMSO value is 1·10 -2 is less than. Following the above methodology, several molecules falling within the range of compounds defined herein by formulas (1a), (1b) and (1c), respectively, have been identified as growth inhibitors of HL-60 cells. The HL-60 growth inhibitors identified thus far relate to the compounds listed in Tables 55 and 56. The entries in Tables 55 and 56 are sorted by the corresponding weighted arithmetic mean of the compounds, without taking into account their respective standard deviations, and therefore falling within the activity ranges shown.
[0272] [Table 55-1]
[0273] [Table 55-2]
[0274] [Table 56]
[0275] The data in Table 55 relate to novel compounds and the data in Table 56 relate to novel medical uses of the compounds disclosed in PCT / EP2018 / 054686. In one embodiment, some compounds of the present invention were found to inhibit the growth of NB-4 cells (human acute promyelocytic leukemia cells), available from Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) under accession number ACC 207. NB-4 cells were cultured in RPMI 1640 medium (Fisherscientific, #11554526) containing 10% fetal bovine serum (Fisher scientific, #15517589) at 37°C, 5% CO2. Compounds are considered as growth inhibitors of NB-4 cells if, at a reference concentration of 20 μM, the weighted arithmetic mean of the normalized fluorescence intensity values after addition of the corresponding binding standard deviation is ≤0.9 relative to an overall baseline level of 1.0, specifically ≤0.8, ≤0.7, ≤0.6, ≤0.4 and ≤0.2. The overall baseline level was calculated as the weighted arithmetic mean of all normalized values from the DMSO control measurements, similar to the calculations performed for the test compounds. The corresponding binding standard deviation with respect to the DMSO value is 1·10 -2 is less than. Following the above methodology, several molecules falling within the range of compounds defined herein by formulas (1a), (1b) and (1c), respectively, have been identified as growth inhibitors of NB-4 cells. The NB-4 growth inhibitors identified thus far relate to the compounds listed in Tables 57 and 58. The entries in Tables 57 and 58 are sorted by the corresponding weighted arithmetic mean of the compounds, without taking into account their respective standard deviations, and therefore falling within the range of activity indicated.
[0276] [Table 57-1]
[0277] [Table 57-2]
[0278] [Table 58-1]
[0279] [Table 58-2]
[0280] The data in Table 57 relate to novel compounds and the data in Table 58 relate to novel medical uses of the compounds disclosed in PCT / EP2018 / 054686. In one embodiment, some compounds of the present invention were found to inhibit the growth of HH cells (human cutaneous T-cell lymphoma cells), available from Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) under accession number ACC 707. HH cells were cultured in RPMI 1640 medium (Fisherscientific, #11554526) containing 10% fetal bovine serum (Fisher scientific, #15517589) at 37°C, 5% CO2. Compounds are considered as HH cell growth inhibitors if, at a reference concentration of 20 μM, the weighted arithmetic mean of the normalized fluorescence intensity values after addition of the corresponding binding standard deviation is ≤0.9 relative to an overall baseline level of 1.0, specifically ≤0.8, ≤0.7, ≤0.6, ≤0.4 and ≤0.2. The overall baseline level was calculated as the weighted arithmetic mean of all normalized values from the DMSO control measurements, similar to the calculations performed for the test compounds. The corresponding binding standard deviation with respect to the DMSO value is 1·10 -2 is less than. According to the above method, several molecules falling within the scope of the compounds defined herein by formulas (1a), (1b) and (1c), respectively, have been identified as growth inhibitors of HH cells. The HH growth inhibitors identified thus far relate to the compounds listed in Tables 59 and 60. The entries in Tables 59 and 60 are classified by the corresponding weighted arithmetic mean of the compounds, without taking into account their respective standard deviations, and therefore falling within the activity ranges shown.
[0281] [Table 59-1]
[0282] [Table 59-2]
[0283] [Table 60-1]
[0284] [Table 60-2]
[0285] The data in Table 59 relate to novel compounds and the data in Table 60 relate to novel medical uses of the compounds disclosed in PCT / EP2018 / 054686. In one embodiment, some compounds of the present invention were found to inhibit the growth of RPMI-8402 cells (human T-cell acute lymphoblastic leukemia cells), available from Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) under accession number ACC 290. RPMI-8402 cells were cultured in RPMI 1640 medium (Fisherscientific, #11554526) containing 10% fetal bovine serum (Fisher scientific, #15517589) at 37°C, 5% CO2. Compounds are considered as growth inhibitors of RPMI-8402 cells if, at a reference concentration of 20 μM, the weighted arithmetic mean of the normalized fluorescence intensity values after addition of the corresponding binding standard deviation is ≤0.9 relative to an overall baseline level of 1.0, specifically ≤0.8, ≤0.7, ≤0.6, ≤0.4 and ≤0.2. The overall baseline level was calculated as the weighted arithmetic mean of all normalized values from the DMSO control measurements, similar to the calculation performed for the test compounds. The corresponding binding standard deviation with respect to the DMSO value is 1·10 -2 is less than. Following the above methodology, several molecules falling within the range of compounds defined herein by formulas (1a), (1b) and (1c), respectively, have been identified as growth inhibitors of RPMI-8402 cells. The RPMI-8402 growth inhibitors identified thus far relate to the compounds listed in Tables 61 and 62. The entries in Tables 61 and 62 are sorted by the corresponding weighted arithmetic mean of the compounds, without taking into account their respective standard deviations, and therefore falling within the activity ranges shown.
[0286] [Table 61-1]
[0287] [Table 61-2]
[0288] [Table 61-3]
[0289] [Table 62-1]
[0290] [Table 62-2]
[0291] [Table 62-3]
[0292] The data in Table 61 relate to novel compounds and the data in Table 62 relate to novel medical uses of the compounds disclosed in PCT / EP2018 / 054686. In one embodiment, some compounds of the present invention were found to inhibit the growth of TANOUE cells (human B-cell leukemia cells) available from Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) under accession number ACC 399. TANOUE cells were cultured in RPMI 1640 medium (Fisher scientific, #11554526) containing 10% fetal bovine serum (Fisher scientific, #15517589) at 37°C, 5% CO2. Compounds are considered as growth inhibitors of TANOUE cells if, at a reference concentration of 20 μM, the weighted arithmetic mean of the normalized fluorescence intensity values after addition of the corresponding binding standard deviation is ≦0.9 relative to an overall baseline level of 1.0, specifically ≦0.8, ≦0.7, ≦0.6, ≦0.4 and ≦0.2. The overall baseline level was calculated as the weighted arithmetic mean of all normalized values from the DMSO control measurements, similar to the calculations performed for the test compounds. The corresponding binding standard deviation with respect to the DMSO value is 1·10 -2 is less than. According to the above method, several molecules falling within the range of compounds defined herein by formulas (1a), (1b) and (1c), respectively, have been identified as growth inhibitors of TANOUE cells. The TANOUE growth inhibitors identified thus far relate to the compounds listed in Tables 63 and 64. The entries in Tables 63 and 64 are classified by the corresponding weighted arithmetic mean of the compounds, without taking into account their respective standard deviations, and therefore falling within the range of activity indicated.
[0293] [Table 63-1]
[0294] [Table 63-2]
[0295] [Table 63-3]
[0296] [Table 64-1]
[0297] [Table 64-2]
[0298] The data in Table 63 relate to novel compounds and the data in Table 64 relate to novel medical uses of the compounds disclosed in PCT / EP2018 / 054686. In one embodiment, some compounds of the present invention were found to inhibit the growth of TT cells (human medullary thyroid carcinoma cells), available from the American Type Culture Collection (ATCC) under accession number ATCC-CRL-1803. TT cells were cultured in F-12K medium (Fisher Scientific, #11580556, or ATCC, #ATCC-30-2004) containing 10% fetal bovine serum (Fisher Scientific, #15517589) at 37° C., 5% CO2. Compounds are shown to inhibit TT cell growth if, at a reference concentration of 20 μM, the weighted arithmetic mean of normalized fluorescence intensity values after addition of the corresponding combined standard deviation is 0.9 or less relative to an overall reference level of 1.0, specifically 0.8 or less, 0.7 or less, 0.6 or less, 0.4 or less, and 0.2 or less. Overall basal levels were calculated as the weighted arithmetic mean of all normalized values from the DMSO control measurements, similar to the calculation performed for the test compounds. The corresponding binding standard deviation for the DMSO values was 1·10 -2 is less than. According to the above method, several molecules falling within the range of compounds defined herein by formulas (1a), (1b) and (1c), respectively, have been identified as TT cell growth inhibitors. The TT growth inhibitors identified thus far relate to the compounds listed in Tables 65 and 66. The entries in Tables 65 and 66 are classified by the corresponding weighted arithmetic mean of the compounds, without taking into account their respective standard deviations, and therefore falling within the indicated activity ranges.
[0299] [Table 65-1]
[0300] [Table 65-2]
[0301] [Table 66]
[0302] The data in Table 65 relate to novel compounds and the data in Table 66 relate to novel medical uses of the compounds disclosed in PCT / EP2018 / 054686. In one embodiment, some compounds of the present invention were found to inhibit the growth of HeLa cells (human cervical adenocarcinoma cells), available from the American Type Culture Collection (ATCC) under accession number ATCC-CCL-2. HeLa cells were cultured in DMEM medium (Fisherscientific, #11584456) containing 10% fetal bovine serum (FisherScientific, #15517589) at 37° C., 5% CO2. Compounds are considered as growth inhibitors of HeLa cells if, at a reference concentration of 20 μM, the weighted arithmetic mean of the normalized fluorescence intensity values after addition of the corresponding binding standard deviation is ≦0.9 relative to an overall baseline level of 1.0, specifically ≦0.8, ≦0.7, ≦0.6, ≦0.4 and ≦0.2. The overall baseline level was calculated as the weighted arithmetic mean of all normalized values from the DMSO control measurements, similar to the calculations performed for the test compounds. The corresponding binding standard deviation with respect to the DMSO value is 1·10 -2 is less than. Following the above methodology, several molecules falling within the range of compounds defined herein by formulas (1a), (1b) and (1c), respectively, have been identified as growth inhibitors of HeLa cells. The HeLa growth inhibitors identified thus far relate to the compounds listed in Tables 67 and 68. The entries in Tables 67 and 68 are sorted by the corresponding weighted arithmetic mean of the compounds, without taking into account their respective standard deviations, and therefore falling within the activity ranges shown.
[0303] [Table 67]
[0304] [Table 68]
[0305] The data in Table 67 relate to novel compounds and the data in Table 68 relate to novel medical uses of the compounds disclosed in PCT / EP2018 / 054686. In one embodiment, some compounds of the present invention were found to inhibit the growth of MDA-MB-231 cells (human breast cancer cells) available from Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) under accession number ACC 732. MDA-MB-231 cells were cultured in Leibovitz's L-15 (phenol red free) medium (Fisher scientific, #11540556) containing 10% fetal bovine serum (Fisher scientific, #15517589) at 37° C. and 0% CO2. Compounds are classified as MDA-MB-23 if, at a reference concentration of 20 μM, the weighted arithmetic mean of normalized fluorescence intensity values after addition of the corresponding binding standard deviation is ≤0.9 relative to an overall reference level of 1.0, specifically ≤0.8, ≤0.7, ≤0.6, ≤0.4, and ≤0.2. 1 cell growth inhibitor. The overall basal level was calculated as the weighted arithmetic mean of all normalized values from the DMSO control measurements, similar to the calculation performed for the test compounds. The corresponding binding standard deviation for the DMSO values was 1·10 -2 is less than. Following the above methodology, several molecules falling within the range of compounds defined herein by formulas (1a), (1b) and (1c), respectively, have been identified as growth inhibitors of MDA-MB-231 cells. The MDA-MB-231 growth inhibitors identified thus far relate to the compounds listed in Tables 69 and 70. The entries in Tables 69 and 70 are sorted by the corresponding weighted arithmetic mean of the compounds, without taking into account their respective standard deviations, and therefore falling within the activity ranges shown.
[0306] [Table 69-1]
[0307] [Table 69-2]
[0308] [Table 69-3]
[0309] [Table 70-1]
[0310] [Table 70-2]
[0311] [Table 70-3]
[0312] The data in Table 69 relate to novel compounds and the data in Table 70 relate to novel medical uses of the compounds disclosed in PCT / EP2018 / 054686. In one embodiment, some compounds of the present invention were found to inhibit the growth of FU-OV-1 cells (human ovarian cancer cells) available from Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) under accession number ACC 444. FU-OV-1 cells were cultured in Ham's F-12 / DMEM (1:1) medium (Fisher scientific, #11514436) containing 10% fetal bovine serum (Fisher scientific, #15517589) and 1 mM sodium pyruvate (Fisher scientific, #11501871) at 37°C, 5% CO2. Compounds are considered as growth inhibitors of FU-OV-1 cells if, at a reference concentration of 20 μM, the weighted arithmetic mean of the normalized fluorescence intensity values after addition of the corresponding binding standard deviation is ≦0.9 relative to an overall baseline level of 1.0, specifically ≦0.8, ≦0.7, ≦0.6, ≦0.4 and ≦0.2. The overall baseline level was calculated as the weighted arithmetic mean of all normalized values from the DMSO control measurements, similar to the calculations performed for the test compounds. The corresponding binding standard deviation with respect to the DMSO value is 1·10 -2 is less than. According to the above method, several molecules falling within the scope of the compounds defined herein by formula (1b) have been identified as growth inhibitors of FU-OV-1 cells. The FU-OV-1 growth inhibitors identified thus far relate to the compounds listed in Tables 71 and 72. The entries in Tables 71 and 72 are sorted by the corresponding weighted arithmetic mean of the compounds, without taking into account their respective standard deviations, and therefore falling within the activity ranges shown.
[0313] [Table 71]
[0314] [Table 72]
[0315] The data in Table 71 relate to novel compounds and the data in Table 72 relate to novel medical uses of the compounds disclosed in PCT / EP2018 / 054686. In one embodiment, some compounds of the present invention are ng von Mikroorganismen und Zellkulturen GmbH (DSMZ) under accession number ACC 393. LOU-NH91 cells were cultured in RPMI 1640 medium (Fisherscientific, #11554526) containing 10% fetal bovine serum (Fisherscientific, #15517589) at 37°C and 5% CO2. Compounds are considered growth inhibitors of LOU-NH91 cells if, at a reference concentration of 20 μM, the weighted arithmetic mean of the normalized fluorescence intensity values after addition of the corresponding binding standard deviation is ≤0.9 relative to an overall baseline level of 1.0, specifically ≤0.8, ≤0.7, ≤0.6, ≤0.4 and ≤0.2. The overall baseline level was calculated as the weighted arithmetic mean of all normalized values from the DMSO control measurements, similar to the calculations performed for the test compounds. The corresponding binding standard deviation with respect to the DMSO value is 1·10 -2 is less than. According to the above methodology, several molecules falling within the range of compounds defined herein by formulas (1a), (1b) and (1c), respectively, have been identified as growth inhibitors of LOU-NH91 cells. The LOU-NH91 growth inhibitors identified thus far relate to the compounds listed in Tables 73 and 74. The entries in Tables 73 and 74 are sorted by the corresponding weighted arithmetic mean of the compounds, without taking into account their respective standard deviations, and therefore falling within the activity ranges shown.
[0316] [Table 73-1]
[0317] [Table 73-2]
[0318] [Table 74]
[0319] The data in Table 73 relate to novel compounds and the data in Table 74 relate to novel medical uses of the compounds disclosed in PCT / EP2018 / 054686. In one embodiment, some compounds of the present invention are available from Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) under accession number ACC 20123132 / 23132. It was found to inhibit the growth of 23132 / 87 cells (human gastric adenocarcinoma cells). 23132 / 87 cells were cultured in RPMI 1640 medium (Fisherscientific, #11554526) containing 10% fetal bovine serum (Fisherscientific, #15517589) at 37°C and 5% CO2. Compounds are considered as growth inhibitors of 23132 / 87 cells if, at a reference concentration of 20 μM, the weighted arithmetic mean of the normalized fluorescence intensity values after addition of the corresponding binding standard deviation is ≤0.9 relative to an overall baseline level of 1.0, specifically ≤0.8, ≤0.7, ≤0.6, ≤0.4 and ≤0.2. The overall baseline level was calculated as the weighted arithmetic mean of all normalized values from the DMSO control measurements, similar to the calculations performed for the test compounds. The corresponding binding standard deviation with respect to the DMSO value is 1·10 -2 is less than. Following the above methodology, several molecules falling within the range of compounds defined herein by formulas (1a), (1b) and (1c), respectively, have been identified as growth inhibitors of 23132 / 87 cells. The 23132 / 87 growth inhibitors identified thus far relate to the compounds listed in Tables 75 and 76. The entries in Tables 75 and 76 are sorted by the corresponding weighted arithmetic mean of the compounds, without taking into account their respective standard deviations, and therefore falling within the activity ranges shown.
[0320] [Table 75-1]
[0321] [Table 75-2]
[0322] [Table 76]
[0323] The data in Table 75 relate to novel compounds and the data in Table 76 relate to novel medical uses of the compounds disclosed in PCT / EP2018 / 054686. In one embodiment, some compounds of the present invention are disclosed in the Deutsche Sammlung von Mikroorganismen und Zellkulturen It was found to inhibit the growth of CAL-27 cells (human tongue squamous cell carcinoma cells) available from Fisher Scientific, Inc. under accession number ACC 446. CAL-27 cells were cultured in DMEM medium (Fisherscientific, #11584456) containing 10% fetal bovine serum (Fisherscientific, #15517589) at 37°C and 5% CO2. Compounds are considered as growth inhibitors of CAL-27 cells if, at a reference concentration of 20 μM, the weighted arithmetic mean of the normalized fluorescence intensity values after addition of the corresponding binding standard deviation is ≤0.9 relative to an overall baseline level of 1.0, specifically ≤0.8, ≤0.7, ≤0.6, ≤0.4 and ≤0.2. The overall baseline level was calculated as the weighted arithmetic mean of all normalized values from the DMSO control measurements, similar to the calculations performed for the test compounds. The corresponding binding standard deviation with respect to the DMSO value is 1·10 -2 is less than. Following the above methodology, several molecules falling within the range of compounds defined herein by formulas (1a), (1b) and (1c), respectively, have been identified as growth inhibitors of CAL-27 cells. The CAL-27 growth inhibitors identified thus far relate to the compounds listed in Tables 77 and 78. The entries in Tables 77 and 78 are sorted by the corresponding weighted arithmetic mean of the compounds, without taking into account their respective standard deviations, and therefore falling within the activity ranges shown.
[0324] [Table 77-1]
[0325] [Table 77-2]
[0326] [Table 78]
[0327] The data in Table 77 are for new compounds, and the data in Table 78 are for PCT / EP20 This application relates to novel medical uses of the compounds disclosed in US Pat. No. 18 / 054686. In one embodiment, some compounds of the present invention were found to inhibit the growth of BHY cells (human oral squamous cell carcinoma cells), available from Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) under accession number ACC 404. BHY cells were cultured in DMEM medium (Fisher scientific, #11584456) containing 10% fetal bovine serum (Fisher scientific, #15517589) at 37°C, 5% CO2. Compounds are considered as growth inhibitors of BHY cells if, at a reference concentration of 20 μM, the weighted arithmetic mean of the normalized fluorescence intensity values after addition of the corresponding binding standard deviation is ≦0.9 relative to an overall baseline level of 1.0, specifically ≦0.8, ≦0.7, ≦0.6, ≦0.4 and ≦0.2. The overall baseline level was calculated as the weighted arithmetic mean of all normalized values from the DMSO control measurements, similar to the calculation performed for the test compounds. The corresponding binding standard deviation with respect to the DMSO value is 1·10 -2 is less than. Following the above methodology, several molecules falling within the range of compounds defined herein by formulas (1a), (1b) and (1c), respectively, have been identified as growth inhibitors of BHY cells. The BHY growth inhibitors identified thus far relate to the compounds listed in Tables 79, 80 and 81. The entries in Tables 79, 80 and 81 are grouped by the corresponding weighted arithmetic mean of the compounds, without taking into account their respective standard deviations, and therefore falling within the activity ranges shown.
[0328] [Table 79-1]
[0329] [Table 79-2]
[0330] [Table 80]
[0331] [Table 81]
[0332] The data in Table 79 relate to novel compounds and the data in Tables 80 and 81 relate to novel medical uses of the compounds disclosed in PCT / EP2018 / 054686. In one embodiment, some compounds of the present invention were found to inhibit the growth of SCC-25 cells (human tongue squamous cell carcinoma cells), available from Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) under accession number ACC 617. SCC-25 cells were cultured in Ham's F-12 / DMEM (1:1) medium (FisherScientific, #11514436) containing 10% fetal bovine serum (FisherScientific, #15517589) and 1 mM sodium pyruvate (FisherScientific, #11501871) at 37° C., 5% CO2. Compounds are considered growth inhibitors of SCC-25 cells if, at a reference concentration of 20 μM, the weighted arithmetic mean of the normalized fluorescence intensity values after addition of the corresponding binding standard deviation is ≤0.9 relative to an overall baseline level of 1.0, specifically ≤0.8, ≤0.7, ≤0.6, ≤0.4 and ≤0.2. The overall baseline level was calculated as the weighted arithmetic mean of all normalized values from the DMSO control measurements, similar to the calculations performed for the test compounds. The corresponding binding standard deviation with respect to the DMSO value is 1·10 -2 is less than. Following the above methodology, several molecules falling within the range of compounds defined herein by formulas (1a), (1b) and (1c), respectively, have been identified as growth inhibitors of SCC-25 cells. The SCC-25 growth inhibitors identified thus far relate to the compounds listed in Tables 82 and 83. The entries in Tables 82 and 83 are sorted by the corresponding weighted arithmetic mean of the compounds, without taking into account their respective standard deviations, and therefore falling within the activity ranges shown.
[0333] [Table 82-1]
[0334] [Table 82-2]
[0335] [Table 83-1]
[0336] [Table 83-2]
[0337] The data in Table 82 relate to novel compounds and the data in Table 83 relate to novel medical uses of the compounds disclosed in PCT / EP2018 / 054686. In one embodiment, some compounds of the present invention were found to inhibit the growth of A-431 cells (human epidermoid squamous carcinoma cells), available from Cell Lines Service GmbH (CLS) under accession number 300112. A-431 cells were cultured in DMEM medium (Fisherscientific, #11584456) containing 10% fetal bovine serum (FisherScientific, #15517589) at 37° C., 5% CO2. Compounds are considered as growth inhibitors of A-431 cells if, at a reference concentration of 20 μM, the weighted arithmetic mean of the normalized fluorescence intensity values after addition of the corresponding binding standard deviation is ≦0.9 relative to an overall baseline level of 1.0, specifically ≦0.8, ≦0.7, ≦0.6, ≦0.4 and ≦0.2. The overall baseline level was calculated as the weighted arithmetic mean of all normalized values from the DMSO control measurements, similar to the calculation performed for the test compounds. The corresponding binding standard deviation with respect to the DMSO value is 1·10 -2 is less than. According to the above methodology, several molecules falling within the range of compounds defined herein by formulas (1a), (1b) and (1c), respectively, have been identified as growth inhibitors of A-431 cells. The A-431 growth inhibitors identified thus far relate to the compounds listed in Tables 84 and 85. The entries in Tables 84 and 85 are sorted by the corresponding weighted arithmetic mean of the compounds, without taking into account their respective standard deviations, and therefore falling within the activity ranges shown.
[0338] [Table 84-1]
[0339] [Table 84-2]
[0340] [Table 85-1]
[0341] [Table 85-2]
[0342] The data in Table 84 relate to novel compounds and the data in Table 85 relate to novel medical uses of the compounds disclosed in PCT / EP2018 / 054686. In one embodiment, some compounds of the present invention were found to inhibit the growth of human epidermal keratinocyte progenitor cells (HPEKp, pooled), available from CELLnTEC Advanced Cell Systems AG under accession number HPEKp. HPEKp cells were cultured in CnT-Prime epithelial culture medium (CELLnTEC, #CnT-PR, a well-defined, low calcium formulation, completely free of animal or human derived components) at 37° C., 5% CO2, without the addition of additional components. Compounds are considered as growth inhibitors of HPEKp cells if, at a reference concentration of 10 μM, the weighted arithmetic mean of the normalized fluorescence intensity values after addition of the corresponding binding standard deviation is ≦0.9 relative to an overall baseline level of 1.0, specifically ≦0.8, ≦0.7, ≦0.6, ≦0.4 and ≦0.2. The overall baseline level was calculated as the weighted arithmetic mean of all normalized values from the DMSO control measurements, similar to the calculations performed for the test compounds. The corresponding binding standard deviation with respect to the DMSO value is 1·10 -2is less than. Following the above methodology, several molecules falling within the range of compounds defined herein by formulas (1a), (1b) and (1c), respectively, have been identified as growth inhibitors of HPEKp cells. HPEKp growth inhibitors identified thus far relate to the compounds listed in Tables 86, 87 and 88. The entries in Tables 86, 87 and 88 are grouped by the corresponding weighted arithmetic mean of the compounds, without taking into account their respective standard deviations, and therefore falling within the activity ranges indicated.
[0343] [Table 86-1]
[0344] [Table 86-2]
[0345] [Table 86-3]
[0346] [Table 87-1]
[0347] [Table 87-2]
[0348] [Table 88]
[0349] The data in Table 86 are for new compounds, while the data in Tables 87 and 88 are for PC The present invention relates to novel medical uses of the compounds disclosed in T / EP2018 / 054686. In one embodiment, some compounds of the present invention were found to inhibit the growth of C2C12 cells (mouse myoblasts), available from Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) under accession number ACC 565. C2C12 cells were cultured in RPMI 1640 medium (Fisherscientific, #11554526) containing 10% fetal bovine serum (Fisher scientific, #15517589) at 37°C, 5% CO2. Compounds are considered as growth inhibitors of C2C12 cells if, at a reference concentration of 20 μM, the weighted arithmetic mean of the normalized fluorescence intensity values after addition of the corresponding binding standard deviation is ≦0.9 relative to an overall baseline level of 1.0, specifically ≦0.8, ≦0.7, ≦0.6, ≦0.4 and ≦0.2. The overall baseline level was calculated as the weighted arithmetic mean of all normalized values from the DMSO control measurements, similar to the calculations performed for the test compounds. The corresponding binding standard deviation with respect to the DMSO value is 1·10 -2 is less than. According to the above methodology, several molecules falling within the range of compounds defined herein by formulas (1a), (1b) and (1c), respectively, have been identified as growth inhibitors of C2C12 cells. The C2C12 growth inhibitors identified thus far relate to the compounds listed in Tables 89, 90 and 91. The entries in Tables 89, 90 and 91 are classified by the corresponding weighted arithmetic mean of the compounds, without taking into account their respective standard deviations, and therefore falling within the activity ranges shown.
[0350] [Table 89-1]
[0351] [Table 89-2]
[0352] [Table 90]
[0353] [Table 91]
[0354] The data in Table 89 relate to novel compounds and the data in Tables 90 and 91 relate to novel medical uses of the compounds disclosed in PCT / EP2018 / 054686.
[0355] In some embodiments, the compounds of the invention may be modulators, and in particular enhancers, of Notch signaling. Communication between cells via Notch signaling (reviewed in Kopan et al., Cell 2009, 137, 216-233; Bray, Nat. Rev. Mol. Cell Biol. 2016, 17, 722-735) consists in a first step mediated by two types of transmembrane proteins. Notch receptors are distributed throughout the plasma membrane of signal-receiving cells, while Notch ligands cover the membrane of signal-sending cells. Mechanistically, Notch signaling is activated by receptor-ligand interactions, which lead to the proteolytic release of the membrane-bound Notch receptor intracellular domain (NICD) into the interior of the signal-receiving cell. Subsequent translocation of NICD to the nucleus in turn leads to the transcriptional activation of certain cell-type-specific genes. Notch-mediated changes in the cell's previous gene expression program are manifested in compliant cellular changes that represent the cell's response to Notch signals. The activation level of Notch signaling can be reliably quantified in vitro by measuring the expression level of Notch-specific target genes. This can be achieved by quantifying the corresponding mRNA or protein of a specific Notch target gene. Alternatively, cells can be genetically modified to have a luciferase gene as an artificial Notch target gene, which is expressed depending on Notch activity. In this setting, the Notch signaling level can be quantified by measuring the bioluminescence value derived from luciferase. A similar Notch-reporter assay, i.e., a luciferase-based luminescence readout, was used herein to quantify the ability of the claimed compounds to enhance Notch signaling in cell lines. To this end, HeLa cells, available from the American Type Culture Collection (ATCC) under accession number ATCC-CCL-2, were transfected with FuGENE® HD (Promega, #E2311) as a transfection reagent to activate the Notch signaling cascade. Cells were transiently transfected for 24 h with expression vectors for a membrane-tethered form of the constitutively active intracellular domain of the human Notch receptor (hNotchΔE) (customized human analog of BPS Bioscience, Notch Pathway Reporter Kit #60509 component C) to monitor Notch signaling, firefly luciferase expressed under the control of a Notch-responsive promoter (CSL luciferase reporter vector from BPS Bioscience, Notch Pathway Reporter Kit #60509, component A not premixed with Renilla luciferase vector), and constitutively expressed Renilla luciferase (Promega, pRL-SV40, #E2231) in a Notch signaling-independent manner that included measuring the number of cells per sample. HeLa cells were cultured in DMEM medium (Fisherscientific, #11584456) containing 10% fetal bovine serum (Fisherscientific, #15517589). Transfections were performed in 100 mm culture dishes (StarLab, #CC7682-3394) with cells properly attached to the plate at 80-90% cell confluency in a total volume of 7 mL of medium. For each dish to be transfected, a transfection mix was prepared by adding 40 μL of hNotchlΔE expression vector (100 ng / μL), 80 μL of CSL luciferase reporter vector (40 ng), 4 μL of pRL-SV40-Renilla luciferase vector (10 ng / μL), and in the last step, 18.1 μL of FuGENE® HD to 238 μL of Opti-MEM (Fisherscientific, #10149832). After adding FuGENE® HD, the transfection mix was left to stand for 15 min at room temperature and then evenly distributed into the culture dishes. 24 h after transfection, the transfected cells were carefully detached from the dishes using 0.5 mM EDTA in PBS and seeded at 10000 cells per well into a 96-well plate suitable for luminescence reading (CORNING, #3610). Cells were then incubated for 20 hours with test compound at a final concentration of 10 μM (diluted from a 10 mM stock solution in DMSO to a final DMSO concentration of 0.1% v / v in HO (water for injection, WFI, Fisherscientific #10378939)) or with empty carrier 0.1% v / v DMSO as a control. Cells were then washed once with PBS and then lysed with 30 μL per well of Passive Lysis Buffer (Promega, #E194A, a component of the Dual-Luciferase® Reporter Assay System, #E1910) by gently shaking the plate on an orbital plate shaker for 20 minutes at room temperature.Immediately after lysis, first firefly and then Renilla luciferase levels were measured consecutively from the same well using a luminescence reader immediately after application of 15 μL per well of each of the corresponding enzyme substrates required to generate a luminescent signal (Promega, Dual-Luciferase® Reporter Assay System, #E1910). The suitability of the assay to monitor Notch signaling was controlled by additionally including a commonly accepted commercially available Notch inhibitor, namely DAPT, as a negative control and the reported Notch enhancer resveratrol (RES) as a positive control (Pinchot et al., Cancer 2011, 117, 1386-1398; Truong et al., Ann. Surg. Oncol. 2011, 18, 1506-1511; Yu et al., Mol. Cancer Ther. 2013, 12, 1276-1287). Both control compounds were tested at 10 μM as well. For each single experiment, measurements were performed in six replicates per compound. For all compounds, the experiment was repeated in at least three independent replicates. Notch reporter luciferase values were normalized by division through the corresponding individual Notch-independent Renilla value to eliminate the effect of absolute cell number variation between samples. For each individual plate, the equally weighted arithmetic mean (abbreviated here as AVE) of the six relevant Renilla-normalized DMSO control values within a single experiment was calculated to obtain a relative value to a baseline level of 1.0. A second normalization was performed on the basis of the α- and β-catenin binding. Statistical calculations were performed similarly to the proliferation assay described above. For this purpose, two independent outlier analyses were performed according to the method of Peirce and Chauvenet (Ross, Journal of Engineering Technology 2003, 1-12). Outliers identified by at least one method were excluded from the calculations, but not more than one out of six values per compound within a single experiment. Weighted arithmetic mean AVE for each compound Wwas calculated from the double normalized values of all independent replicates of a single experiment, each containing six replicates. The standard deviation corresponding to the weighted arithmetic mean was calculated according to the method described by Bronstein et al. (Bronstein, Semendjajew, Musiol, Muehlig, Taschenbuch der Mathematik, 5th Edition 2001 (German), Publisher: Verlag Harri Deutsch, Frankfurt am Main and Thun) and combined with the Gaussian error propagation associated with the calculations carried out for normalization. The resulting standard deviation is referred to herein as the "combined standard deviation". If there was substantial variation in the doubly normalized equally weighted arithmetic means obtained from three independent replications, the number of independent replications was increased to more than four. In the case of more than four independent replications, a second outlier analysis was applied to all doubly normalized equally weighted arithmetic means, following the method of Peirce and Chauvenet described above. Compounds are considered Notch signaling enhancing molecules, i.e. Notch signaling enhancers, if the weighted arithmetic mean of the luminescence values after subtracting the corresponding binding standard deviation is 1.1 or more relative to an overall basal level of 1.0, specifically 1.2 or more, 1.3 or more, 1.4 or more, 1.5 or more, 1.7 or more and 2.0 or more. The overall basal level was calculated as the weighted arithmetic mean of all double normalized values from the DMSO control measurements, similar to the calculation performed for the test compounds. The corresponding binding standard deviation with respect to the DMSO values is 1·10 -2 is less than. Following the above methodology, several molecules falling within the range of compounds defined herein by formulas (1b) and (1c), respectively, have been identified as Notch signaling enhancers. The Notch enhancers identified thus far relate to the compounds listed in Table 92. The entries in Table 92 are sorted by the corresponding weighted arithmetic mean of the compounds, without taking into account their respective standard deviations, and therefore falling within the range of activity indicated.
[0356] [Table 92-1]
[0357] [Table 92-2]
[0358] By the above methods, several other molecules were not identified as enhancers of Notch signaling. In some cases, the growth inhibitory properties correlate with the Notch enhancing properties, and in other cases, the growth inhibitory properties do not correlate with the Notch enhancing properties. The biological activity of the claimed compounds may be attributable to, but is not limited to, Notch signaling enhancing activity. The Notch regulating properties of the claimed compounds may be used as an alternative or in combination with mechanisms that provide anti-proliferative effects in medical therapy, preferably in the treatment of hyperproliferative disorders, including cancer and non-malignant hyperproliferative disorders.
[0359] In one aspect, the invention relates to the treatment of skin, skin adnexa, mucosa, mucosal adnexa, cornea, and epithelial tissues of all kinds. The term "skin" refers to tissues including the epidermis and dermis. The term "mucosa" refers to mucosal and submucosal tissues including oral, nasal, ocular, auricular, respiratory, genital, urinary, anal, and rectal mucosa. The term "adnexa" refers to tissues including hair follicles, hair, fingernails, toenails, and glands including sebaceous glands, sweat glands, e.g. apocrine or eccrine sweat glands, and mammary glands. In one embodiment, the invention relates to the treatment of non-melanoma skin cancers and precancerous lesions such as basal cell carcinoma (BCC), squamous cell carcinoma (SCC), sebaceous carcinoma, Merkel cell carcinoma, angiosarcoma, cutaneous B-cell lymphoma, cutaneous T-cell lymphoma, dermatofibrosarcoma, actinic keratosis (AK) or Bowen's disease (BD), as well as other squamous cell carcinomas and precancerous lesions, such as skin SCC, lung SCC, head and neck SCC, oral SCC, tongue SCC, esophageal SCC, cervical SCC, periocular SCC, thyroid SCC, penile SCC, vaginal SCC, prostate SCC and bladder SCC. In a further embodiment, the invention relates to the treatment of skin and mucosal disorders involving defective keratinization (keratosis) and / or abnormal keratinocyte proliferation, such as psoriasis, Darier's disease, lichen planus, lupus erythematosus, ichthyosis or common warts (senile). In a further embodiment, the present invention relates to the treatment of warts and HPV (human papillomavirus) associated warts, papillomas, HPV-associated papillomas, papillomatosis and HPV-associated papillomatosis, such as Verruca (plantar warts), Verruca plana (flat warts), Venus warts, and other warts associated with HPV (human papillomavirus). rruca filiformis (filamentous warts), mosaic warts, periungual warts, subungual warts, oral warts, genital warts, fibroepithelial papilloma, intraductal papilloma, intraductal papilloma, inverted papilloma, basal cell papilloma, flat papilloma, cutaneous papilloma, fibroangiopapilloma, plexus papilloma, nasal papilloma, pharyngeal papilloma, papillomatosis cutaneous carcinoid, papillomatosis cutaneous lymphatic, confluent and reticular papillomatosis or laryngeal papillomatosis (respiratory papillomatosis), herpes-related diseases such as herpes labialis, herpes genitalis, shingles, herpes cornea or Kaposi's sarcoma, as well as skin and mucosal diseases each associated with and / or caused by viral infections such as HPV-related cancers of the cervix, vulva, penis, vagina, anus, oropharynx, tongue and oral cavity, and skin and mucosal cancers. In a further embodiment, the present invention relates to the treatment of atopic dermatitis. In a further embodiment, the present invention relates to the treatment of acne. In a further embodiment, the present invention relates to the treatment of skin wounds, where the wound healing process is accelerated. In a further embodiment, the present invention relates to the treatment of cancers associated with and / or caused by viral infections, i.e. oncogenic viral infections, for example cancers associated with HBV and HCV (Hepatitis Virus B and C), such as liver cancer, cancers associated with EBV (Epstein-Barr Virus), such as Burkitt's lymphoma, Hodgkin's and non-Hodgkin's lymphoma and gastric cancer, cancers associated with HPV (Human Papillary Carcinoma Virus), such as cervical cancer, cancers associated with HHV (Human Herpes Virus), such as Kaposi's Sarcoma, and cancers associated with HTLV (Human T-Lymphotropic Virus), such as T-cell leukemia and T-cell lymphoma. A further aspect of the present invention relates to the treatment of immune system related disorders. As used herein, the term "immune system related disorder" refers to pathological conditions of the hematopoietic system, including the vasculature, in particular pathological conditions of immune cells belonging to the innate or acquired immune system. A further aspect of the present invention relates to therapeutic use in immune system related applications. The term "immune system related applications" as used herein applies to intervention in the proliferation, differentiation and / or activation of cell lineages of the hematopoietic system, including the vasculature, to modulate immune responses (immunomodulation). The term "immune system related applications" as used herein also applies to intervention in the cellular and non-cellular microenvironment of the site of action of immune cells, to support and / or enable immune cell performance. In particular, intervention as defined herein by the term "immune system related applications" relates to immune cells belonging to the innate or acquired immune system. That is, the compounds of the present invention may be used in immunotherapy alone or together with other immunotherapeutic methods or compounds, as immunological adjuvants, for example as vaccine adjuvants, or as immunotherapy adjuvants. As used herein, the term "immunotherapy" applies to activating immunotherapy in patients without immune deficiencies or with acquired or congenital immune deficiencies, as immune restoration to enhance the function of the immune system in response to pathogens such as cancer cells or pathologically transformed endogenous cells. The term "other immunotherapy" as used herein applies to vaccination, antibody therapy, cytokine therapy, the use of immune checkpoint inhibitors and immune response stimulants, as well as autologous transplantation of genetically modified or unmodified immune cells, which may be stimulated by intercellular signals, or signaling molecules, or antigens, or antibodies, i.e., adoptive immune cell transfer. The methods of use of the present invention in immune system related applications and other immunotherapeutic applications relate to in vivo, in vitro, and ex vivo uses, respectively. Specific examples include the activation and / or enhancement of the activation of peripheral T lymphocytes, including T helper cells and cytotoxic T cells, for example to enhance the immune response, in particular the stimulation of proliferation and / or production and / or secretion of cytokines and / or cytotoxic agents upon antigen recognition to amplify the immune response, the activation and / or enhancement of the activation of B lymphocytes, for example to amplify the immune response, in particular the stimulation of proliferation and / or antibody production and / or secretion, and also the activation and / or enhancement of peripheral T lymphocytes, in particular marginal zone B cells, cytotoxic T cells or T helper (Th) subpopulations, for example by modulating cell fate decisions during differentiation and / or immune cell development. for example, to enhance immune responses through increasing the numbers of specific immune cell subtypes, particularly to enhance the numbers of immune cells belonging to the T and B cell lineages, including Thl, Th2, Thl7 and regulatory T cells; or for use as an immune adjuvant, such as a vaccine adjuvant. Yet another aspect of the invention relates to the treatment of muscle disorders, including disorders of skeletal, cardiac and smooth muscle. In one embodiment, the present invention relates to the treatment of muscular dystrophy (MD). Specific examples include Duchenne MD, Becker MD, congenital MD, limb-girdle MD, facioscapulohumeral MD, Emery-Dreyfus MD, distal MD, myotonic MD or oculopharyngeal MD. In a further embodiment, the present invention relates to the treatment of hyperproliferative disorders of muscle, including myoblastoma, rhabdomyosarcoma and rhabdomyosarcoma, as well as muscle hyperplasia and muscle hypertrophy. In a further embodiment, the compounds of the invention may be used for muscle regeneration after pathological muscle degeneration or atrophy caused by trauma, muscle ischemia or inflammation, for example in muscle atrophy associated with aging, or muscle atrophy associated with diseases such as myositis and fibromyositis or polio. Yet another aspect relates to the treatment of disorders of the neuroendocrine system, such as cancers of the brain, thyroid, pancreas, gastrointestinal tract, liver, esophagus and lung, including neuroendocrine small cell carcinoma, neuroendocrine tumors of the pituitary gland, neuroendocrine tumors of the adrenal gland, medullary thyroid carcinoma (MTC), C-cell hyperplasia, anaplastic thyroid carcinoma (ATC), parathyroid adenoma, intrathyroid nodule, islet carcinoma, hyalinizing trabecular neoplasm, paraganglioma, pulmonary carcinoid tumor, neuroblastoma, gastrointestinal carcinoid, goblet cell carcinoid, pancreatic carcinoid, gastrinoma, glucagenoma, somatic statinoma, VIPoma, insulinoma, nonfunctioning islet cell tumor, multiple endocrine neoplasia type 1, or pulmonary carcinoid. Yet another aspect relates to the treatment of pulmonary disorders such as cancer of the lung, including small cell lung cancer (SCLC), including squamous cell carcinoma of the lung, adenocarcinoma of the lung, and large cell lung carcinoma, and non-small cell lung cancer (NSCLC). Yet another aspect relates to the treatment of cancer or precancerous lesions of the brain, pancreas, breast, ovary, liver, thyroid, genitourinary, gastrointestinal, and endothelial tissues, including glioma, mixed glioma, glioblastoma multiforme, astrocytoma, anaplastic astrocytoma, glioblastoma, oligodendroglioma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, ependymoma, anaplastic ependymoma, myxopapillary ependymoma, subependymoma, brain stem glioma, optic nerve glioma, as well as forebrain tumors, pancreatic adenocarcinoma, pancreatic ductal adenocarcinoma, pancreatic adenocellulosic carcinoma, pancreatic pseudopapillary neoplasm, intraductal papillary mucinous neoplasm, pancreatic mucinous cystadenocarcinoma, pancreatoblastoma and pancreatic intraepithelial neoplasm, hepatocellular carcinoma, fibrolamellar hepatocellular carcinoma, papillary and follicular thyroid carcinoma, cervical cancer, hormone receptor positive and hormone receptor negative breast cancer, ovarian cancer, gastric cancer, and angiosarcoma. As used herein, the term "treating" or "treatment" refers to one or more of: 1) inhibiting a disease; for example, inhibiting a disease, condition or disorder in an individual experiencing or exhibiting a symptom or symptom of the disease, condition or disorder (i.e., preventing further progression of the symptom and / or symptom); and (2) ameliorating a disease; for example, ameliorating a disease, condition or disorder in an individual experiencing or exhibiting a symptom or symptom of the disease, condition or disorder (i.e., reversing the symptom and / or symptom), such as reducing the severity of the disease. The term "treating" also includes post-treatment care. In some embodiments, administration of a compound of the invention or a pharma- ceutically acceptable salt thereof is effective to prevent a disease, e.g., to prevent a disease, condition or disorder in an individual who may be predisposed to the disease, condition or disorder but has not yet experienced or exhibited any pathology or symptoms of the disease. The compounds of the invention may also be used in human and veterinary medicine, including the treatment of companion animals such as horses, dogs, cats, rabbits, guinea pigs, fish such as carp, birds such as peregrine falcons; and livestock such as cattle, poultry, pigs, sheep, goats, donkeys, yaks and camels. good.
[0360] [Pharmaceutical composition] The present invention further provides pharmaceutical compositions comprising a compound as described herein, or a pharma- ceutically acceptable salt thereof, for use in medicine, e.g., in human or veterinary medicine. In some embodiments, the composition further comprises a pharma- ceutically acceptable carrier. The effective dosage of the compound of the present invention, or its salt, solvate or prodrug thereof, is used in addition to physiologically acceptable carrier, diluent and / or adjuvant to prepare pharmaceutical composition.The dosage of active compound can vary according to the route of administration, age and weight of patient, nature and severity of disease to be treated, and similar factors.The daily dosage can be given as a single dose to be administered at one time, or can be divided into two or more daily dosages, and is usually 0.001-2000mg.It is particularly preferred to administer a daily dosage of 0.1-500mg, for example 0.1-100mg. Suitable modes of administration are local or systemic, including enteral, oral, rectal, and parenteral, as infusion and infusion, intravenous, intraarterial, intraperitoneal, intramuscular, intracardiac, epidural, intracerebral, intraventricular, intraosseous, intraarticular, intraocular, intravitreal, intrathecal, intravaginal, intracavity, intravesical, subcutaneous, intradermal, transdermal, transmucosal, inhalation, intranasal, buccal, sublingual, and intralesional formulations. It is particularly preferred to use oral, parenteral, e.g., intravenous or intramuscular, intranasal formulations, e.g., dry powder or sublingual, of the compounds of the present invention. Conventional galenical formulation forms such as tablets, sugar-coated tablets, capsules, dispersible powders, granules, aqueous solutions, alcohol-containing aqueous solutions, aqueous or oily suspensions, gels, hydrogels, ointments, creams, lotions, shampoos, lip balms, mouthwashes, foams, pastes, tinctures, skin patches and tapes, time release drug delivery systems, electrophoretic skin delivery systems including implants and devices, as well as jet injectors, liposomes and transfersome vesicles, steam, sprays, syrups, juices or occlusions with drops and eye drops or combinations may be used. Solid pharmaceutical forms can contain inactive ingredients and carrier materials such as calcium carbonate, calcium phosphate, sodium phosphate, lactose, starch, mannitol, alginic acid, gelatin, guar gum, magnesium stearate, aluminum stearate, methylcellulose, talc, highly dispersed silicic acid, silicon oils, higher molecular weight fatty acids, (such as stearic acid), gelatin, agar agar or vegetable or animal fats and oils, or solid high molecular weight polymers (such as polyethylene glycol); formulations suitable for oral administration can contain additional flavorings and / or sweeteners, as desired. Liquid pharmaceutical forms may be sterilized and / or may contain auxiliary substances, such as preservatives, stabilizing agents, wetting agents, osmotic agents, emulsifiers, spreading agents, solubilizers, salts, sugars or sugar alcohols, and / or viscosity regulators, for adjusting osmotic pressure or buffering, if appropriate. Examples of such additives are tartaric and citrate buffers, ethanol and sequestering agents (such as ethylenediaminetetraacetic acid and its non-toxic salts). Liquid polyethylene oxide, microcrystalline cellulose, carboxymethylcellulose, polyvinylpyrrolidone, dextran or high molecular weight polymers such as gelatin are suitable for adjusting viscosity. Examples of solid carrier materials are starch, lactose, mannitol, methylcellulose, talc, highly dispersed silicic acid, high molecular weight fatty acids (such as stearic acid), gelatin, agar agar, calcium phosphate, magnesium stearate, animal and vegetable fats, and solid high molecular weight polymers such as polyethylene glycol. Oily suspensions for parenteral or topical application may be vegetable, synthetic or semi-synthetic oils, such as liquid fatty acid esters, in each case having 8 to 22 C atoms in the fatty acid chain, for example palmitic acid, lauric acid, tridecanoic acid, margaric acid, stearic acid, arachidic acid, myristic acid, behenic acid, pentanol, esterified with mono- to trihydric alcohols having 1 to 6 C atoms, such as methanol, ethanol, propanol, butanol, pentanol or their isomers, glycol or glycerol. Examples of such fatty acid esters are commercially available Miglyol, isopropyl myristate, isopropyl palmitate, isopropyl stearate, PEG6-capric acid, caprylic / capric esters of saturated fatty alcohols, polyoxyethylene glycerol trioleate, ethyl oleate, especially waxy fatty acid esters such as artificial ducktail gland fat, coconut fatty acid isopropyl esters, oleyl oleate, decyl oleate, ethyl lactate, dibutyl phthalate, diisopropyl adipate, polyol fatty acid esters. Silicone oils of different viscosities or fatty alcohols such as isotridecyl alcohol, 2-octyldodecanol, cetylstearyl alcohol or oleyl alcohol, or fatty acids such as oleic acid are also suitable. It is further possible to use vegetable oils such as castor oil, almond oil, olive oil, sesame oil, cottonseed oil, peanut oil or soybean oil. Suitable solvents, gelatinizing agents and solubilizing agents are water or water-miscible solvents. Examples of suitable substances are alcohols such as ethanol or isopropyl alcohol, benzyl alcohol, 2-octyldodecanol, polyethylene glycol, phthalates, adipic acid esters, propylene glycol, glycerol, di- or tripropylene glycol, waxes, methyl cellosolve, cellosolve, esters, morpholines, dioxane, dimethylsulfoxide, dimethylformamide, tetrahydrofuran, cyclohexanone, etc. Cellulose ethers such as hydroxypropylmethylcellulose, methylcellulose or ethylcellulose, or soluble starches, which can dissolve or swell in both water or organic solvents, can be used as film formers. Mixtures of gelatinizers and film-forming agents are also entirely possible. In this case, in particular, ionic polymers such as sodium carboxymethylcellulose, polyacrylic acid, polymethacrylic acid and their salts, sodium amylopectin semiglycolate, alginic acid or propylene glycol alginic acid as the sodium salt, gum arabic, xanthan gum, guar gum or carrageenan are used. The following can be used as further formulation auxiliaries: glycerol, paraffin of different viscosities, triethanolamine, collagen, allantoin and novantisolic acid. The use of surfactants, emulsifiers or wetting agents, such as Na lauryl sulfate, fatty alcohol ether sulfate, di-Na-N-lauryl-beta-iminodipropionate, polyethoxylated castor oil or sorbitan monooleate, sorbitan monostearate, polysorbate (e.g. Tween), cetyl alcohol, lecithin, glycerol monostearate, polyoxyethylene stearate, alkylphenol polyglycol ether, cetyltrimethylammonium chloride or mono / dialkyl polyglycol ether orthophosphate monoethanolamine salt, may also be required in the formulation.Stabilizers such as montmorillonite or colloidal silicic acid, such as tocopherol or butyl hydroxyanisole, or preservatives such as p-hydroxybenzoic acid esters, for stabilizing emulsions or preventing the decomposition of active substances such as antioxidants, may also be used to prepare the desired formulation. The preparation for parenteral administration can be in the form of individual dosage units, such as ampoules or vials.Preferably, also use solutions of active compound, preferably aqueous solutions, and especially isotonic solutions and suspensions.These injection forms can be available as ready-to-use preparations, or can be prepared directly before use by mixing active compound, for example lyophilized, with desired solvent or suspension, if appropriate, including other solid carrier substances. Intranasal formulations may be in the form of aqueous or oily solutions or suspensions. They may also be in the form of lyophilisates prepared with appropriate solvents or suspending agents before use. The inhalable formulation may be present as a powder, a solution or a suspension. A suitable formulation is in the form of a powder, for example as a mixture of the active ingredient with a suitable formulation aid, such as lactose. The formulations are manufactured, aliquoted and sealed under customary antibacterial and aseptic conditions. As mentioned above, the compounds of the present invention may be administered as a combination therapy, as a sequential therapy or as a simultaneous combination therapy with further active agents, for example, therapeutically active compounds useful in the treatment of the above-mentioned disorders. These therapeutically active compounds include nucleoside and nucleobase analogs, such as cytarabine, gemcitabine, azathioprine, mercaptopurine, fluorouracil, thioguanine, azacitidine, capecitabine, doxifluridine, platinum-based drugs, such as cisplatin, oxaliplatin, carboplatin and nedaplatin, anthracyclines, such as doxorubicin, epirubicin, valrubicin, idarubicin, daunorubicin, sabarubicin, pixantrone and mitoxantrone, peptide antibiotics, such as actinomycin and bleomycin, albicans, and the like. Killing agents, such as mechlorethamine, chlorambucil, melphalan, nitrosoureas, dacarbazine, temozolomide and cyclophosphamide; mitotic inhibitors including taxanes and vinca alkaloids, such as docetaxel, paclitaxel, abraxane, cabazitaxel, vinblastine, vindesine, vinorelbine and vincristine; topoisomerase inhibitors, such as irinotecan, topotecan, teniposide and etoposide; other cytostatics, such as hydroxyurea and methotrexate; proteosome inhibitors, such as bortezomib, ixazomib;and other targeted therapeutic agents such as kinase inhibitors, cell cycle inhibitors, regulators, i.e., inhibitors and activators of signaling pathways including growth factor signaling, cytokine signaling, NF-kappa B signaling, AP1 signaling, JAK / STAT signaling, EGFR signaling, TGF-beta signaling, Notch signaling, Wnt signaling, Hedgehog signaling, hormone and nuclear receptor signaling, e.g., erlotinib, lapatinib, dasatinib, imatinib, rituximab ... Tinib, afatinib, vemurafenib, dabrafenib, nilotinib, cetuximab, trametinib, palbociclib, cobimetinib, cabozantinib, pegaptanib, crizotinib, olaparib, panitumumab, cabozantinib, ponatinib, regorafenib, entrectinib, ranibizumab, ibrutinib, trastuzumab, rituximab, alemtuzumab, gefitinib, bevacizumab, lenvatinib, bosutinib, axitinib, pazopanib, everolimus, temsirolimus, ruxolitinib, tofacitinib nibs, sorafenib, sunitinib, aflibercept, vandetanib; vismodegib and sonidegib; retinoids such as retinol, tretinoin, isotretinoin, alitretinoin, bexarotene, tazarotene, acitretin, adapalene and etretinate; hormone signalling modulators including estrogen receptor modulators, androgen receptor modulators and aromatase inhibitors, for example raloxifene, tamoxifen, fulvestrant, lasofoxifene, toremifene, bicalutamide, flutamide, anastrozole, letrozole and exemestane; histone deacetylase inhibitors such as vorinostat, romidepsin, panobinostat, belinostat and chidamide; and ingenol mebutate; and other notch enhancers not included in the compounds of the present invention such as valproic acid, resveratrol, hesperetin, chrysin, phenethyl isothiocyanate, thiocoraline, N-methylhemeancidin chloride and notch signaling activating peptides or antibodies;and immune response modifiers including immune checkpoint inhibitors, such as imiquimod, ipilimumab, atezolizumab, ofatumumab, rituximab, nivolumab, and pembrolizumab; and anti-inflammatory agents including glucocorticoids, and nonsteroidal anti-inflammatory agents, such as cortisol-based preparations, dexamethasone, betamethasone, prednisone, prednisolone, methylprednisolone, triamcinolone hexacetonide, mometasone furoate, clobetasol propionate, acetylsalicylic acid, salicylic acid and other salicylates, diflunisal, ibuprofen, dexibuprofen, naproxen, fenoprofen, ketoprofen, dexketoprofen; They may include, but are not limited to, loxoprofen, flurbiprofen, oxaprozin, indomethacin, ketorolac, tolmetin, diclofenac, etodolac, aceclofenac, nabumetone, sulindac, mefenamic acid, meclofenamic acid, flufenamic acid, tolfenamic acid, celecoxib, parecoxib, etoricoxib and firocoxib; and ACE inhibitors; and beta-blockers; and myostatin inhibitors; and PDE-5 inhibitors; and antihistamines. For combination therapy, active ingredients may be formulated as a composition containing several active ingredients in a single dosage form and / or as a kit containing each active ingredient in separate dosage forms. The active ingredients used in combination therapy may be co-administered or administered separately. The compounds of the invention may also be administered as antibody-drug conjugates. The compounds of the invention may be administered in combination with surgery, cryotherapy, electrodessication, radiation therapy, photodynamic therapy, laser therapy, chemotherapy, targeted therapy, immunotherapy, gene therapy, antisense therapy, cell-based transplant therapy, stem cell therapy, physical therapy and occupational therapy.
[0361] [Chemical synthesis] Abbreviation
[0362] JPEG2024164040000166.jpg222158
[0363] [General considerations] The compounds listed in Tables 93 and 94 were identified using precoated silica TLC sheets and common organic solvents such as petroleum ether, ethyl acetate, dichloromethane, methanol, toluene, triethylamine or acetic acid as eluents, preferably as binary or ternary solvent mixtures thereof. UV at wavelengths of 254 or 366 nm. Light and / or common staining solutions such as phosphomolybdic acid, potassium permanganate, or ninhydrin were used to visualize compounds. Reactions were also monitored for completion in this manner. Reactions were performed under an inert atmosphere unless otherwise noted. Dry solvents were used where necessary. All reactions were stirred using a stir plate and magnetic stir bar. The compounds listed in Table 93 were further identified by mass spectrometry using formic acid in the mobile phase for positive ion detection, but no additive for negative ions. Ammonium carbonate was used when molecules were difficult to ionize in the negative mode. Representative compounds and those showing poor ionization in mass spectrometry were also identified by nuclear magnetic resonance spectroscopy (Table 94). Chemical shifts (δ) are reported in parts per million (ppm) relative to the residual solvent peak rounded to the nearest 0.01 ppm for protons and 0.1 ppm for carbons (reference: CHCI3[ 1 H: 7.26 ppm, 13 C: 77.2 ppm], DMSO [ 1 H: 2.50 ppm, 13 C: 39.5 ppm]. Coupling constants (J) are reported in Hz to the nearest 0.1 Hz. Peak multiplicities were indicated as follows: s (singlet), d (doublet), t (triplet), q (quartet), hept (heptet), m (multiplet), and br (broad)].
[0364] [Synthesis of the compounds described] The aforementioned compounds of the present invention falling within the scope of Formula I can be synthesized and purified by one skilled in the art, preferably as shown in Scheme 1, by following the general procedures (A to R) described herein.
[0365] [ka]
[0366] Scheme 1: General synthetic scheme A) To the corresponding mono- or di-substituted phenol (1.0-1.5 equiv) and 4-alkyl ester halo(hetero)aryl (1 equiv) dissolved in DMSO (0.5M) under argon and stirring, K2CO3 (1.5 equiv) was added and the mixture was stirred at room temperature or heated between 40°C and 160°C until complete conversion. The mixture was allowed to warm to room temperature and partitioned between an organic solvent, preferably petroleum ether and water. The aqueous layer was extracted two more times and then the combined organic phases were washed with NaOH (aq, 2M) then brine and dried over Na2SO4. It was dried, filtered and concentrated in vacuo, and the residue was then purified by flash chromatography (SiO2, gradient petroleum ether / AcOEt, DCM / MeOH or petroleum ether / AcOEt / NEt3) to give the desired bi(hetero)aryl ether ethyl esters.
[0367] B) The corresponding bis(hetero)aryl ether alkyl ester (1 equiv) was dissolved in dry THF (0.2 M) under stirring under argon and the resulting solution was cooled to 0° C. in an ice bath. DIBAL-H (2.5 equiv, 1.2 M in toluene) was then added dropwise and the mixture was left stirring at that temperature until complete conversion. The reaction was quenched by the Fieser method, filtered, concentrated in vacuo and the residue was purified by flash chromatography (SiO2, gradient petroleum ether / AcOEt) to give the desired alcohol.
[0368] C) Depending on the scale and substrate, one of these procedures was used. To the corresponding alcohol (1 equiv) dissolved in DCM (0.2 M) under vigorous stirring was added MnO2 (2-4 equiv). The resulting suspension was stirred at room temperature or 40° C. until complete conversion. The reaction was then diluted with AcOEt, filtered through Celite, and concentrated under vacuum. The residue was then purified by flash chromatography (SiO2, gradient petroleum ether / AcOEt) to give the desired aldehyde.
[0369] To the corresponding alcohol (1 equiv) dissolved in DCM or DMSO (0.2M) under vigorous stirring, Dess-Martin periodinane (1.2 equiv) was added. The resulting suspension was stirred at room temperature until complete conversion. The solution was diluted with AcOEt, quenched with aq.sat.NaHC03 and the phases were separated. The aqueous layer was extracted two more times, then the combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated under vacuum. The residue was then purified by flash chromatography (SiO2, gradient petroleum ether / AcOEt) to give the desired aldehyde.
[0370] To a solution of oxalyl chloride (2 equiv) in DCM (0.2 M) at -78 °C, dry DMSO (4 equiv) was added and the mixture was stirred for 30 min. Then a solution of the corresponding alcohol (1 equiv) in DCM (0.2 M) was added followed by freshly distilled NEt3 (8 equiv). The resulting solution was stirred for 1 h and then slowly warmed to room temperature. The solution was diluted with AcOEt, quenched with aq HCl 1 M and the phases were separated. The aqueous layer was extracted two more times and then the combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated under vacuum. The residue was then purified by flash chromatography (SiO2, gradient petroleum ether / AcOEt) to give the desired aldehyde.
[0371] D) To the corresponding aldehyde (1 equiv) dissolved in dry THF (0.2 M) under argon and stirring at 0° C., either TMSCF3 (2 equiv) to give the corresponding secondary alcohol with CF3, then TBAF (1 mol%), or Grignard reagent (2 equiv) to give the corresponding secondary alkyl alcohol, was added. In each case, the resulting solution was left stirring at that temperature until complete conversion. HCl aq (2.5 M) was then added and the reaction was left stirring for an additional hour. The reaction was then partitioned between AcOEt and water. The aqueous layer was extracted two more times, then the combined organic phase was washed with brine, dried over Na2SO4, filtered and concentrated under vacuum. The residue was then purified by flash chromatography (SiO2, gradient petroleum ether / AcOEt) to give the desired secondary alcohol.
[0372] E) To a stirred solution of the corresponding secondary alcohol (1 equiv) in chloroform (0.2 M) at 0°C, Dess-Martin periodinane (1.5 equiv) was added. After the reaction was complete, it was partitioned between AcOEt and NaHCO3aq sat. The aqueous layer was extracted twice more, then the combined organic phases were washed with brine, dried over Na2SO4, filtered and purified. The residue was then purified by flash chromatography (SiO2, gradient petroleum ether / AcOEt) to give the desired ketone.
[0373] F) To a stirred solution of the corresponding ketone (1 equiv) in ethanol (0.2M) was added the amine (2.5-40 equiv) followed by either a catalytic amount of PTSA in the case of aliphatic amines or base (2.5-40 equiv) in the case of hydroxylamines. The reaction was then refluxed for 24-72 hours. After this time, Celite was added and the volatiles were evaporated under vacuum. The residue was then purified by flash chromatography (SiO2, gradient petroleum ether / AcOEt) to give the desired imine.
[0374] G) To a solution of the corresponding aldehyde or crude imine obtained before purification in step (F) in DCM (0.25M) was added sodium borohydride (4 equiv) and the solution was left stirring for a further 2 h. The reaction was then partitioned between AcOEt and NaHCO3aq sat. The aqueous layer was extracted two more times and then the combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated under vacuum. The residue was then purified by flash chromatography (SiO2, gradient petroleum ether / AcOEt) to give the desired product.
[0375] H) To a stirred solution of the corresponding aldehyde (1 equiv) in toluene (0.2M) under argon, the amine (2 equiv) was added followed by TMSCN (2 equiv) and the reaction was stirred for 16 h. The reaction was then partitioned between AcOEt and NaHCO3aq sat. The aqueous layer was extracted two more times and then the combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated under vacuum. The residue was then purified by flash chromatography (SiO2, gradient petroleum ether / AcOEt) to give the desired cyanoamine.
[0376] I) To the corresponding bis(hetero)aryl ether alkyl ester (1 equiv) dissolved in EtOH or THF (0.5 M), NaOH aq 2M (2 equiv) was added and left stirring until the reaction was complete. The reaction was then partitioned between AcOEt and HCl aq (1 M). The aqueous layer was extracted two more times, then the combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated under vacuum. The residue was then purified by flash chromatography (SiO2, gradient petroleum ether / AcOEt) or recrystallization (AcOEt) to give the desired carboxylic acid.
[0377] J) Depending on the amine used, one of these procedures was used. To the corresponding bis(hetero)aryl ether carboxylic acid (1 equiv) suspended in stirred toluene (0.2 M) under argon was added first SOCl2 (2.5 equiv) then DMF (1 mol%) and the mixture was heated to 80 °C for 3 h. The reaction mixture was then evaporated to dryness and the resulting residue was placed again under argon and redissolved in THF (0.2 M). To this was added trimethylamine (2.5 equiv), DMAP (1 mol%) and the corresponding amine or amide (1.2-1.5 equiv) sequentially and the suspension was stirred for 16 h. The reaction was then partitioned between AcOEt and HCl aq (1 M). The aqueous layer was extracted two more times and then the combined organic phase was washed with brine, dried over Na2SO4, filtered and concentrated under vacuum. The residue was then purified by flash chromatography (SiO2, gradient petroleum ether / AcOEt or petroleum ether / AcOEt / AcOH or DCM / MeOH) to give the desired amide.
[0378] To the corresponding bis(hetero)aryl ether carboxylic acid (1 equiv) in DCM (0.2 M) was added NEt3 (3 equiv) and HOBt / EDCI (1.5 equiv / 1.5 equiv) or HATU (1.5 equiv) sequentially. The reaction mixture was then cooled to room temperature. After stirring the mixture for 5 to 60 min, the corresponding amine (1.25 equiv) was added and the mixture was stirred until the reaction was complete. The reaction was then partitioned between AcOEt and HCl aq (1M). The aqueous layer was extracted two more times, then the combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated under vacuum. The residue was then purified by flash chromatography (SiO2, gradient petroleum ether / AcOEt or petroleum ether / AcOEt / AcOH or DCM / MeOH) to give the desired amide.
[0379] To the corresponding bis(hetero)aryl ether carboxylic acid (1 equiv) suspended in stirred toluene (0.2M) under argon, first SOCl2 (2.5 equiv) and then DMF (1 mol%) were added and the mixture was heated to 80°C for 3 h. The reaction mixture was then evaporated to dryness and the resulting residue was again placed under argon and redissolved in toluene (0.2M). This was added to a solution of the corresponding hydroxylamine in aq.sat.NaHCO3 and the reaction mixture was stirred until the reaction was complete. The reaction was then partitioned between AcOEt and aq HCl 1M or water. The aqueous layer was extracted two more times and then the combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated under vacuum. The residue was then purified by flash chromatography (SiO2, gradient petroleum ether / AcOEt or petroleum ether / AcOEt / AcOH or DCM / MeOH) to give the desired amide.
[0380] K) To the corresponding 4-substituted phenol (1 equiv) and 1,4-dibromoaryl (2.5 equiv) dissolved in DMF (0.2 M) was added Cs2CO3 (2 equiv), CuI (10 mol%) and tBuXPos (20 mol%). The mixture was degassed using freeze-pump-thaw method, placed under argon, stirred vigorously and refluxed (165 °C) for 72 h. The mixture was allowed to warm to room temperature and partitioned between petroleum ether and NaOH aq 2M. The aqueous layer was extracted two more times, then the combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated under vacuum. The residue was then purified by flash chromatography (SiO2, gradient petroleum ether / AcOEt) to give the desired bisaryl ether bromide.
[0381] L) To the corresponding 4-substituted phenols (1.2-1.5 equiv) and 1,4-diromo(hetero)aryl (1 equiv) dissolved in DMSO (0.5M) under stirring under argon, K2CO3 (1.5 equiv) was added and the mixture was heated between 80°C and 160°C until complete conversion. The mixture was allowed to warm to room temperature and partitioned between petroleum ether and NaOH aq 2M. The aqueous layer was extracted two more times, then the combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated under vacuum. The residue was then purified by flash chromatography (SiO2, gradient petroleum ether / AcOEt) to give the desired bis(hetero)aryl ether bromides.
[0382] M) The corresponding bi(hetero)aryl ether bromide (1 equiv) was dissolved in dry THF (0.2 M) under stirring under argon and the resulting solution was cooled to -78 °C in a dry ice / acetone bath. Then, n- or t-BuLi (1.1-2.2 equiv, 1.9-2.5 M in hexane or pentane) was added dropwise and the mixture was left stirring at that temperature for 30 min and then at -50 °C until the starting material was completely consumed (monitored by TLC in pentane). The mixture was then cooled back to -78 °C and a solution of the corresponding electrophile (2 equiv, 0.5 M) in dry THF was added and the reaction was allowed to slowly warm to room temperature over 16 h. The reaction was then partitioned between AcOEt and saturated NH4Cl aq.sat., the aqueous layer was extracted two more times, then the combined organic phase was washed with brine, dried over Na2SO4, filtered and concentrated under vacuum. The residue was then purified by flash chromatography (SiO2, gradient petroleum ether / AcOEt / NEt3) to give the desired compound.
[0383] N) The corresponding protected amine compound (1 equiv) dissolved in THF (0.1-0.2M) To this was added HCl (0.5M in MeOH, 2-6 equiv) and the reaction was left stirring until the reaction was complete. The reaction was then either evaporated to dryness to give the desired amine as the HCl salt or the reaction was partitioned between AcOEt and NaHCO3aq sat. The aqueous layer was extracted two more times and then the combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated under vacuum. The residue was then purified by flash chromatography (SiO2, gradient petroleum ether / AcOEt / MeOH or DCM / MeOH) to give the desired free amine.
[0384] O) To the corresponding 4-substituted phenol (1 equiv) and 4-cyano(hetero)haloaryl (2.5 equiv) dissolved in DMSO (0.5M) under stirring under argon, K2CO3 (1.5 equiv) was added and the mixture was heated between 80°C and 160°C until complete conversion. The mixture was allowed to warm to room temperature and partitioned between petroleum ether and NaOH aq 2M. The aqueous layer was extracted two more times, then the combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated under vacuum. The residue was then purified by flash chromatography (SiO2, gradient petroleum ether / AcOEt) to give the desired bis(hetero)aryl ether cyanide.
[0385] P) To the corresponding bis(hetero)aryl ether cyanide (1 equiv) dissolved in THF / MeOH (1:1, 0.1M) at 0°C under argon and stirring was added NaH (1.1 equiv). After 4 h, the ice bath was removed, cyanamide (1.5 equiv) was added and the mixture was stirred for a further 16 h. The reaction was then partitioned between AcOEt and water. The aqueous layer was extracted two more times and then the combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated under vacuum. The residue was then purified by flash chromatography (SiO2, gradient petroleum ether / AcOEt / MeOH) to give the desired amine.
[0386] Q) To the corresponding bis(hetero)aryl ether alcohol, hydroxamic acid or amide (1 equiv) dissolved in THF / DMF (1:0 to 2:8 mixture, 0.2M) under stirring under argon was added NaH, NaOAc or Cs2CO3 (1.2-2 equiv). After 30 min, the alkyl(di)halide or acyl chloride (1.2-2 equiv) was added and, in the case of alkyl(di)bromides, KI (1.2 equiv) was also added. In the case of alkyl(di)bromides, the mixture was then stirred at room temperature or at 50°C for a further 16 h. The reaction was then partitioned between AcOEt and HCl aq (1M). The aqueous layer was extracted two more times and then the combined organic phase was washed with brine, dried over Na2SO4, filtered and concentrated under vacuum. The residue was then purified by flash chromatography (SiO2, gradient petroleum ether / AcOEt / AcOH) to give the desired amide.
[0387] R) To the corresponding bis(hetero)aryletheramide (1 equiv) dissolved in THF (0.2 M) at 0° C. under argon and stirring was added NaBH4 (1.1 equiv). After 1 h, the reaction mixture was then partitioned between AcOEt and NaHCO3 aq sat. The aqueous layer was extracted twice more and then the combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated under vacuum. The residue was then purified by flash chromatography (SiO2, gradient petroleum ether / AcOEt) to give the desired amide.
[0388] S) To the corresponding aldehyde (1 equiv) in dry THF (0.2M) was added the corresponding Wittig reagent (1.5 equiv) at 0°C. To this stirred mixture was added LiHMDS (1.3 equiv, 1M in THF) dropwise. The reaction was stirred until the reaction was complete and then partitioned between AcOEt and HCl aq (1M). The aqueous layer was extracted two more times and then the combined organic phases were washed with aq.sat.NaHCO3, brine, dried over Na2SO4, filtered and concentrated under vacuum. The residue was then purified by flash chromatography (SiO2, gradient petroleum ether / AcOEt) to give the desired olefin.
[0389] T) To add a methyl group to an amine To the corresponding free amine (1 equiv) in acetonitrile (0.2M) was added formaldehyde (6 equiv, 37% w / w in water) followed by NaBH3CN (2 equiv). The reaction mixture was stirred until the reaction was complete, then partitioned between AcOEt and aq.sat.NaHCO3, the aqueous layer was extracted two more times, then the combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated under vacuum. The residue was then purified by flash chromatography (SiO2, gradient DCM / MeOH / NEt3) to give the desired compound.
[0390] To add an isopropyl group to an amine To the corresponding free amine (1 equiv) in acetone (0.2M) was added NaBH3CN (10 equiv) in five portions every 15 min, while maintaining the pH at about 5 with acetic acid. The reaction mixture was then partitioned between AcOEt and aq.sat.NaHCO3, the aqueous layer was extracted two more times, and then the combined organic phases were washed with brine, dried over Na2SO4, filtered, and concentrated under vacuum. The residue was then purified by flash chromatography (SiO2, gradient DCM / MeOH / NEt3) to give the desired compound.
[0391] U) To the corresponding amine (1 equiv) in DCM (0.1M) was added mCPBA (1.2 equiv) and the mixture was stirred at room temperature until complete conversion. The reaction mixture was then partitioned between AcOEt and aq.sat.NaHCO3, the aqueous layer was extracted two more times, and then the combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated under vacuum. The residue was then purified by flash chromatography (SiO2, gradient petroleum ether / AcOEt) to give the desired compound.
[0392] V) To the corresponding nitrile (1 equiv) in ethanol (0.2M) was added hydroxylamine hydrochloride (2.5 equiv) and sodium hydroxide (2.5 equiv). The reaction was heated at 80° C. overnight, then filtered through Celite, concentrated in vacuo, and the residue was purified by flash chromatography (SiO2, gradient petroleum ether / AcOEt) to give the desired compound.
[0393] W) To the corresponding aldehyde (1 equiv) in methanol (0.1M) was added K2CO3 (2 equiv) followed by Ohira-Bestmann reagent (1.1 equiv) and the reaction was stirred until the reaction was complete. The reaction was then partitioned between AcOEt and NaHCO3 aq sat. The aqueous layer was extracted two more times and then the combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated under vacuum. The residue was then purified by flash chromatography (SiO2, gradient petroleum ether / AcOEt) to give the desired alkyne. EXAMPLES
[0394] [Analysis data] The following compounds were synthesized according to the aforementioned protocols and characterized by mass spectrometry (Table 93) or NMR (Table 94).
[0395] [Table 93-1]
[0396] [Table 93-2]
[0397] [Table 93-3]
[0398] [Table 93-4]
[0399] [Table 93-5]
[0400] [Table 93-6]
[0401] [Table 93-7]
[0402] [Table 93-8]
[0403] [Table 93-9]
[0404] [Table 94]
[0405] For illustrative purposes, the synthesis and characterization of the following examples are detailed.
[0406] XPW-0547 4-(4-butylphenoxy)-N-(methylsulfonyl)benzamide
[0407] [ka]
[0408] To 4-(4-butylphenoxy)benzoic acid (104 mg, 0.38 mmol, 1 equiv) suspended in stirred toluene (1.85 mL, 0.2 M) under argon was added first SOCl2 (67 μL, 0.93 mmol, 2.5 equiv) and then DMF (0.3 μL, 3.7 μmol, 1 mol%) and the mixture was heated to 80° C. for 3 h. The reaction mixture was then evaporated to dryness and the resulting residue was placed under argon again and redissolved in THF (1.85 mL, 0.2 M). This was followed by addition of trimethylamine (0.13 mL, 0.93 mmol, 2 0.5 equiv), DMAP (0.45 mg, 3.7 μmol, 1 mol%) and methanesulfonamide (42.3 mg, 0.45 mmol, 1.2 equiv) were added sequentially and the suspension was stirred for 16 h. The reaction was then partitioned between AcOEt and HCl aq (1M). The aqueous layer was extracted twice more and then the combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated under vacuum. The residue was then purified by flash chromatography (SiO2, gradient petroleum ether / AcOEt) to give 118 mg of 4-(4-butylphenoxy)-N-(methylsulfonyl)benzamide (88%).
[0409] MS: m / z[MH] - , calc for [C 18 H 20 NO4S] - = 346.11; found 346.24 1 H-NMR(300MHz DMSO-d6) δ 12.03(s,1H), 7.97(d,J=8.9Hz,2H), 7.32-7.24(m,2H), 7.08-6.97(m,4H), 3.36(s,3H), 2.66-2.56(m,2H), 1.58(tt,J=8.8,6.8Hz,2H), 1.41-1.24(m,2H), 0.92(t,J=7.3Hz,3H). 13 C-NMR(75MHz,DMSO-d6) δ 166.1, 162.1, 153.2, 139.4, 131.4, 130.5, 126.3, 120.4, 117.2, 41.8, 34.6, 33.6, 22.2, 14.3.
[0410] XPW-2890 (6-(4-cyclohexylphenoxy)pyridin-3-yl)(morpholino)methanone
[0411] [ka]
[0412] To 6-(4-cyclohexylphenoxy)nicotinic acid (50 mg, 0.17 mmol, 1 equiv) suspended in stirred toluene (0.85 mL, 0.2 M) under argon was added first SOCl2 (31 μL, 0.43 mmol, 2.5 equiv) and then DMF (0.14 μL, 1.7 μmol, 1 mol%) and the mixture was heated to 80° C. for 3 h. The reaction mixture was then evaporated to dryness and the resulting residue was placed again under argon and redissolved in THF (0.85 mL, 0.2 M). To this was added trimethylamine (9.4 μL, 0.68 mmol, 2.5 equiv), DMAP (0.2 mg, 1.7 μmol, 1 mol%) and morpholine (20 μL, 0.23 mmol, 1.5 equiv) successively and the suspension was stirred for 16 h. The reaction was then partitioned between AcOEt and HCl aq (1 M). The aqueous layer was extracted two more times, then the combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was then purified by flash chromatography (SiO2, gradient petroleum ether / AcOEt) to give 45 mg of (6-(4-cyclohexylphenoxy)pyridin-3-yl)(morpholino)methanone (71%).
[0413] MS: m / z[M+H] + , calc for [C 22 H 27 N2O3] + = 367.20; found 367.32 1H-NMR(300MHz, CDCl3) δ 8.20(d,J=2.3Hz,1H), 7.73(dd,J=8.6,2.2Hz,1H), 7.18(d,J=7.7H) z,2H), 7.06-6.92(m,2H), 6.87(d,J=8.5Hz,1H), 3.63(s,8H), 2.50-2.37(m,1H), 1.89-1.62(m,5H), 1.38-1.08(m,5H). 13 C-NMR(75MHz,CDCl3) δ 167.7, 164.7, 151.2, 146.6, 145.1, 139.5, 128.1, 125.5, 121.0, 111.3, 66.8, 53.4, 44.0, 34.5, 26.9, 26.1.
[0414] XPW-0636 N-Cyano-4-(4-cyclohexylphenoxy)benzamide
[0415] [ka]
[0416] To 4-(4-cyclohexylphenoxy)benzoic acid (60 mg, 0.2 mmol, 1 equiv) suspended in stirred toluene (0.8 mL, 0.2 M) under argon was added first SOCl2 (37 μL, 0.0.5 mmol, 2.5 equiv) then DMF (0.15 μL, 2.0 μmol, 1 mol%) and the mixture was heated to 80° C. for 3 h. The reaction mixture was then evaporated to dryness and the resulting residue was placed again under argon and redissolved in THF (0.8 mL, 0.2 M). To this was added trimethylamine (57 μL, 0.5 mmol, 2.5 equiv), DMAP (0.24 mg, 2.0 μmol, 1 mol%) and cyanamide (12.6 mg, 0.3 mmol, 1.5 equiv) successively and the suspension was stirred for 16 h. The reaction was then partitioned between AcOEt and HCl aq (1 M). The aqueous layer was extracted two more times, then the combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was then purified by flash chromatography (SiO2, gradient petroleum ether / AcOEt) to give 15.4 mg of N-cyano-4-(4-cyclohexylphenoxy)benzamide (24%).
[0417] MS: m / z[MH] - , calc for [C 20 H 19 N2O2] - = 319.15; found 319.28 1 H-NMR(300MHz,CDCl3) δ 7.93(d,J=8.8Hz,2H), 7.31(d,J=8.5Hz,2H), 7.23-6.85(m,4H), 3.37(brs,1H), 2.59-2.51(m,1H) 1.91-1.63(m,5H), 1.57-1.12(m,5H). 13 C-NMR(75MHz,CDCl3) δ 166.5, 161.8, 152.7, 144.2, 130.8, 128.4, 124.8, 119.9, 117.1, 110.0, 43.1, 34.0, 26.3, 25.5.
[0418] XPW-0675 N-hydroxy-4-(4-(2-methoxyethyl)phenoxy)-N-methylbenzamide
[0419] [ka]
[0420] To 4-(4-(2-methoxyethyl)phenoxy)benzoic acid (125 mg, 0.46 mmol, 1 equiv) suspended in stirred toluene (2.3 mL, 0.2 M) under argon was added first SOCl2 (84 μL, 1.15 mmol, 2 equiv) followed by DMF (0.35 μL, 4.6 μmol, 1 mol%) and the mixture was heated to 80° C. for 3 h. The reaction mixture was then evaporated to dryness and the resulting residue was placed again under argon and redissolved in THF (2.3 mL, 0.2 M). To this was added trimethylamine (144 μL, 1.13 mmol, 2.5 equiv), DMAP (0.56 mg, 4.6 μmol, 1 mol%) and N-methylhydroxylamine hydrochloride (58 mg, 0.69 mmol, 1.5 equiv) successively and the suspension was stirred for 16 h. The reaction was then partitioned between AcOEt and HCl aq (1M). The aqueous layer was extracted two more times, then the combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was then purified by flash chromatography (SiO2, gradient petroleum ether / AcOEt) to give 103.1 mg of N-hydroxy-4-(4-(2-methoxyethyl)phenoxy)-N-methylbenzamide (74%).
[0421] MS: m / z[M+H] + , calc for [C 17 H 20 NO4] + = 302.14; found 302.17 1H-NMR(300MHz,CDCl3) δ 10.00(s,1H), 7.73-7.61(m,2H), 7.37-7.20(m,2H), 7.07-6.82(m,4H), 3.55(t,J=6.8Hz,2H), 3.26(s,3H), 3.25(s,3H), 2.82(t,J=6.8Hz,2H). 13 C-NMR(75MHz,CDCl3) δ 168.6, 159.2, 154.3, 135.6, 131.2, 130.9, 129.5, 119.9, 117.1, 73.2, 58.3, 37.9, 35.1.
[0422] XPW-0832 N'-Cyano-6-(4-cyclohexylphenoxy)nicotinimidamide
[0423] [ka]
[0424] 6-(4-Cyclohexylphenoxy)nicotinonitrile (41 mg, 0.15 mmol, 1 equiv) dissolved in THF / MeOH (1:1, 1.5 mL, 0.1 M) at 0 °C under argon and stirring was added to NaH (6.6 mg, 0.17 mmol, 1.1 equiv, 60% in oil) was added. After 4 h, the ice bath was removed, cyanamide (9.5 mg, 0.23 mmol, 1.5 equiv) was added, and the mixture was stirred for an additional 16 h. The reaction was then partitioned between AcOEt and water. The aqueous layer was extracted two more times, then the combined organic phases were washed with brine, dried over Na2SO4, filtered, and concentrated under vacuum. The residue was then purified by flash chromatography (SiO2, gradient petroleum ether / AcOEt / MeOH) to give 32 mg of N'-cyano-6-(4-cyclohexylphenoxy)nicotinimidamide (67%).
[0425] MS: m / z[M+H] + , calc for [C 20 H 22 NO] += 320.18; found 320.27 1 H-NMR(300MHz,DMSO-d6) δ 7.79(d,J=8.9Hz,2H), 7.25-7.17(m,2H), 7.07-6.94(m,4H), 3.83(s,2H), 2.63-2.41(m,1H), 1.94-1.55(m,5H), 1.48-1.16(m,5H). 13 C-NMR(75MHz,DMSO-d6) δ 152.9, 144.9, 129.3, 129.3, 128.4, 124.4, 120.1, 117.4, 116.4, 113.3, 77.5, 44.0, 34.6, 26.9, 26.1.
[0426] XPW-0902: N-(1-(4-(4-((3r,5r,7r)-adamantan-1-yl)phenoxy)phenyl)-2,2,2-trifluoroethyl)-2-methylpropane-2-sulfinamide
[0427] [ka]
[0428] (3r,5r,7r)-1-(4-(4-bromophenoxy)phenyl)adamantane (100 mg, 0.26 mmol, 1 equiv) was dissolved in dry THF (1.3 mL, 0.2 M) under argon and stirring, and the resulting solution was cooled to -78°C in a dry ice / acetone bath. nBuLi (0.11 mL, 0.26 mmol, 1.0 equiv, 2.3 M in pentane) was added dropwise and the mixture was left stirring at that temperature for 30 min and then at -50°C for a further 30 min. The mixture was then cooled back down to -78°C. A solution of 2-methyl-N-(2,2,2-trifluoroethylidene)propane-2-sulfinamide (79 mg, 0.39 mmol, 1.5 equiv) in THF (0.39 mL, 1 M) was added dropwise and the reaction was stirred for 1 h before being allowed to slowly warm to room temperature overnight. The reaction was then partitioned between AcOEt and NH4Cl aq sat., the aqueous layer was extracted two more times, then the combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated under vacuum. The residue was then purified by flash chromatography (SiO2, gradient petroleum ether / AcOEt) to give 81 mg of N-(1-(4-(4-((3r,5r,7r]-adamantan-1-yl)phenoxy)phenyl)-2,2,2-trifluoroethyl)-2-methylpropane-2-sulfinamide (62%).
[0429] MS: m / z[M+H] + , calc for [C 28 H 35 F3NO2S] + = 506.23; found 506.70 1 H NMR(400MHz,CDCl3) δ 7.38-7.32(m,4H), 7.03-6.95(m,4H), 4.83(qd,J=7.1,3.5Hz,1H), 3.88(d,J=3.5Hz ,1H), 2.10(p,J=3.5Hz,3H), 1.91(d,J=2.9Hz,6H), 1.83-1.68(m,6H), 1.23(s,9H). 13 C NMR(101MHz,CDCl3) δ 159.29, 153.59, 147.36, 130.78, 126.31, 125.24, 124.53(q,J=281.3Hz), 119.39, 117.93, 59.87(q,J=30.4Hz), 56.31, 43.33, 36.76, 35.91, 28.95, 22.41. 19 F NMR(376MHz,CDCl3) δ -74.56(d,J=7.2Hz).
[0430] XPW-3052 3-(6-(4-((adamantan-1-yl)phenoxy)pyridin-3-yl)oxetan-3-amine
[0431] [ka]
[0432] To N-(3-(4-(4-((3r,5r,7r)-adamantan-1-yl)phenoxy)phenyl)oxetan-3-yl)-2-methylpropane-2-sulfinamide (31 mg, 0.065 mmol, 1 equiv) in THF (0.32 mL, 0.2 M) was added HCl (0.8 mL, 0.5 M in MeOH, 6 equiv) and the reaction was left stirring until the reaction was complete. The reaction was then cooled to 5° C. for 2 hours and then cooled to 5° C. for 2 hours. The mixture was partitioned between t and NaHCO3aq (1M). The aqueous layer was extracted two more times, then the combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was then purified by flash chromatography (SiO2, gradient DCM / MeOH) to give 17.4 mg of 3-(6-(4-((adamantan-1-yl)phenoxy)pyridin-3-yl)oxetan-3-amine (71%).
[0433] MS: m / z[M+H] + , calc for [C 24 H 29 N2O2] + = 377.22; found 377.34 1H-NMR(300MHz,DMSO-d6) δ 8.33(dd,J=2.6,0.7Hz,1H), 8.02(dd,J=8.6,2.6Hz,1H), 7.50-7.36(m,2H), 7.14-6.96(m,3H), 4.70(d, J=6.3Hz,2H), 4.64(d,J=6.3Hz,2H), 2.65(brs,2H), 2.18-1.99(m,3H), 1.96-1.83(m,6H), 1.75(s,6H). 13 C-NMR(75MHz,DMSO-d6) δ 162.6, 152.3, 147.4, 144.9, 138.0, 136.4, 126.4, 121.0, 111.3, 85.7, 57.6, 43.2, 36.6, 35.9, 28 .8.
[0434] XPW-4642 N-(1-(4-(4-((3r,5r,7r)-adamantan-1-yl)phenoxy)phenyl)-2,2,2-trifluoroethyl)-N,2-dimethylpropane-2-sulfinamide
[0435] [ka]
[0436] To a solution of N-(1-(4-(4-((3r,5r,7r)-adamantan-1-yl)phenoxy)phenyl)-2,2,2-trifluoroethyl)-2-methylpropane-2-sulfinamide (360 mg, 0.71 mmol, 1 equiv) in THF (7.2 mL, 0.1 M) was added Cs2CO3 (464 mg, 1.42 mmol, 2 equiv). After 30 min, iodomethane (0.089 mL, 1.42 mmol, 2 equiv) was added. The mixture was then heated at 50° C. for a further 16 h. The reaction was then partitioned between AcOEt and water. The aqueous layer was extracted two more times, then the combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated under vacuum. The residue was then purified by flash chromatography (SiO2, gradient petroleum ether / AcOEt) to give 300 mg of N-(1-(4-(4-((3r,5r,7r)-adamantan-1-yl)phenoxy)phenyl)-2,2,2-trifluoroethyl)-N,2-dimethylpropane-2-sulfinamide (81%).
[0437] MS: m / z[M+H] + , calc for [C 29 H 37 F3NO2S] + = 520.25; found 520.69 1 H NMR(400MHz,CDCl3) δ 7.42(d,J=8.6Hz,2H), 7.37-7.32(m,2H), 7.02-6.96(m,4H), 4.92(q,J=8.6Hz,1H) , 2.71(s,3H), 2.11(s,3H), 1.91(d,J=2.9Hz,6H), 1.85-1.71(m,6H), 1.20(s,9H). 19 F NMR(376MHz,CDCl3) δ -67.23(d,J=8.2Hz).
[0438] XPW-0028: 1-(4-(4-((3r,5r,7r)-adamantan-1-yl)phenoxy)phenyl)-2,2,2-trifluoro-N-methylethan-1-amine hydrochloride
[0439] [ka]
[0440] To N-(1-(4-(4-((3r,5r,7r)-adamantan-1-yl)phenoxy)phenyl)-2,2,2-trifluoroethyl)-N,2-dimethylpropane-2-sulfinamide (300 mg, 0.58 mmol, 1 equiv) dissolved in THF (5.8 mL, 0.1 M) was added HCl (2.3 mL, 1.15 mmol, 0.5 M in MeOH, 2 equiv) and the reaction was left stirring until the reaction was complete. The reaction was then either evaporated to dryness to give 255 mg of 1-(4-(4-((3r,5r,7r)-adamantan-1-yl)phenoxy)phenyl)-2,2,2-trifluoro-N-methylethan-1-amine as the HCl salt (quantitative).
[0441] MS: m / z[M+H] + , calc for [C 25 H 29 F3NO] + = 416.22; found 416.69 1 H NMR(400MHz,CDCl3) δ 11.04(brs,2H), 7.62(d,J=8.5Hz,2H), 7.43-7.33(m,2H), 7.08(d,J=8.4Hz,2H), 7.05-6.96( m,2H), 4.71-4.36(m,1H), 2.69(s,3H), 2.14(s,3H), 1.94(d,J=2.9Hz,6H), 1.88-1.73(m,6H).
[0442] XPW-0182: N-(1-(4-(4-((3r,5r,7r)-adamantan-1-yl)phenoxy)phenyl)-2,2,2-trifluoroethyl)-N-methylhydroxylamine
[0443] [ka]
[0444] To l-(4-(4-((3r,5r,7r)-adamantan-1-yl)phenoxy)phenyl)-2,2,2-trifluoro-N-methylethan-1-amine hydrochloride (50 mg, 0.12 mmol, 1 equiv) in DCM (1.2 mL, 0.1 M) was added mCPBA (35 mg, 0.144 mmol, 70%, 1.2 equiv) and the mixture was stirred at room temperature for 30 min. The reaction mixture was then partitioned between AcOEt and aq.sat.NaHCO3, the aqueous layer was extracted two more times, then the combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated under vacuum. The residue was then purified by flash chromatography (SiO2, gradient petroleum ether / AcOEt) to give 44.5 mg of N-(1-(4-(4-((3r,5r,7r)-adamantan-1-yl)phenoxy)phenyl)-2,2,2-trifluoroethyl)-N-methylhydroxylamine (86%).
[0445] 1 H NMR(400MHz,CDCl3) δ 7.41-7.33(m,4H), 7.05-6.96(m,4H), 4.32(q,J=7.6Hz,1H), 2.87(s,3H), 2.16-2.07(m,3H), 1.92(d,J=2.9Hz,6H), 1.85-1.67(m,6H). 19 F NMR(376MHz,CDCl3) δ -67.82(d,J=7.5Hz). 13 C NMR(101MHz,CDCl3) δ 159.24, 153.61, 147.38, 131.35, 126.33, 124.40, 124.18(q,J=282.5Hz), 119.37, 117.73, 74.70(q,J=29.0Hz), 50.31, 43.34, 36.76, 35.92, 28.96.
[0446] XPW-0042: 1-(4-(4-((3r,5r,7r)-adamantan-1-yl)phenoxy)phenyl)-2,2,2-trifluoro-N,N-dimethylethan-1-amine
[0447] [ka]
[0448] To l-(4-(4-((3r,5r,7r)-adamantan-1-yl)phenoxy)phenyl)-2,2,2-trifluoro-N-methylethan-1-amine hydrochloride (20 mg, 0.05 mmol, 1 equiv) in acetonitrile (0.25 mL, 0.2 M) was added formaldehyde (0.025 mL, 0.29 mmol, 6 equiv, 37% w / w in water) followed by NaBH3CN (6.1 mg, 0.10 mmol, 2 equiv). The reaction mixture was stirred until the reaction was complete, then partitioned between AcOEt and aq.sat.NaHCO3, the aqueous layer was extracted two more times, then the combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated under vacuum. The residue was then purified by flash chromatography (SiO2, gradient DCM / MeOH) to give 15 mg of 1-(4-(4-((3r,5r,7r)-adamantan-1-yl)phenoxy)phenyl)-2,2,2-trifluoro-N,N-dimethylethan-1-amine (75%).
[0449] MS: m / z[M+H] + , calc for [C 26 H 31 F3NO] + = 430.27; found 430.71 1 H NMR(400MHz,CDCl3) δ 7.39-7.28(m,4H), 7.04-6.93(m,4H), 3.95(q,J=8.7Hz,1H), 2.36(s,6H), 2.10(s,3H), 1.91(d,J=2.9Hz,6H), 1.85-1.69(m,6H). 19 F NMR(376MHz, CDCl3) δ -67.30.
[0450] XPW-0314 2-[4-(4-cyclohexylphenoxy)phenyl]-2-(dimethylamino)acetonitrile
[0451] [ka]
[0452] To a stirred solution of 4-(4-cyclohexylphenoxy)benzaldehyde (50 mg, 0.18 mmol, 1 equiv) in toluene (0.9 mL, 0.2 M) under argon was added dimethylamine (0.18 mL, 0.36 mmol, 2 equiv) followed by TMSCN (0.05 mL, 0.36 mmol, 2 equiv) and the reaction was stirred for 16 h. The reaction was then partitioned between AcOEt and NaHCO3 aq sat. The aqueous layer was extracted two more times and then the combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated under vacuum. The residue was then purified by flash chromatography (SiO2, gradient petroleum ether / AcOEt) to give 29 mg of 2-(4-(4-cyclohexylphenoxy)phenyl)-2-(dimethylamino)acetonitrile (48%).
[0453] MS: m / z[M+H] + , calc for [C 22 H 27 N2O] + = 335.21; found 335.31 1 H-NMR(300MHz,CDCl3) δ 7.46-7.32(m,2H), 7.16-7.07(m,2H), 6.99-6.82(m,4H), 4.75(s,1H), 2.43(dd t,J=11.7,8.2,5.0Hz,1H), 2.27(s,6H), 1.87-1.61(m,5H), 1.42-1.24(m,5H). 13C NMR(75MHz,CDCl3) δ 158.5, 154.2, 143.8, 129.3, 128.1, 119.3, 118.3, 115.0, 62.5, 43.9, 41.7; 34.6, 26.9,
Claims
1. A compound according to formula (I) as defined herein or a salt or solvate thereof. 【Chemistry 1】 (In the formula, R 1 is C 1 -C 12 Preferably C 4 -C 12 Alkyl, C 2 -C 12 Preferably C 4 -C 12 Alkenyl, C 2 -C 12 Preferably C 4 -C 12 Alkynyl, C 3 -C 8 Cycloalkyl, C 5 -C 8 Cycloalkenyl, C 5 -C 12 Bicycloalkyl, C 7 -C 12 Bicycloalkenyl, C 8 -C 14 Tricycloalkyl, -OC 1 -C 12 Preferably, -OC 3 -C 12 Alkyl, -OC 2 -C 12 Preferably, -OC 3 -C 12 Alkenyl, -OC 2 -C 12 Preferably, -OC 3 -C 12 Alkynyl, -OC 3 -C 8 Cycloalkyl, -OC 5 -C 8 Cycloalkenyl, -OC 5 -C 12 Bicycloalkyl, -OC 7 -C 12 Bicycloalkenyl, -OC 8 -C 14 Tricycloalkyl, -SC 1 -C 12 Preferably -SC 3 -C 12 Alkyl, -SC 2 -C 12 Preferably -SC 3 -C 12 Alkenyl, -SC 2 -C 12 Preferably -SC 3 -C 12 Alkynyl, -SC 3 -C 8 Cycloalkyl, -SC 5 -C 8 Cycloalkenyl, -SC 5 -C 12 Bicycloalkyl, -SC 7 -C 12 Bicycloalkenyl, -SC 8 -C 14 Tricycloalkyl, -NHR 7 Or -NR 7 R 8 (In the formula, R 7 and R 8 are independent of each other. 1 -C 12 Preferably C 3 -C 12 Alkyl, C 2 -C 12 Preferably C 3 -C 12 Alkenyl, C 2 -C 12 Preferably C 3 -C 12 Alkynyl, C 3 -C 8 Cycloalkyl, C 5 -C 8 Cycloalkenyl, C 5 -C 12 Bicycloalkyl, C 7 -C 12 Bicycloalkenyl, C 8 -C 14 tricycloalkyl, or R 7 R 8 can form a ring structure together with the N atom, wherein said ring structure containing the N atom is selected from a 3- to 8-membered cyclic structure or a 5- to 12-membered bicyclic structure, and wherein all said ring structures can further contain one or more heteroatoms independently selected from O, S and N in place of the carbon atoms contained in the ring structure, particularly wherein such substitution results in a residue containing at least twice the number of C atoms than heteroatoms independently selected from O, S and N; Here, R 1 , R 7 and R 8 All alkyl, alkenyl and alkynyl residues included in the definition are linear or branched and are unsubstituted or substituted with -F, -Cl, -Br, -I, -CN, -NCO, -NCS, -OH, -NH 2 , -NO 2 , =O, C 3 -C 8 Cycloalkyl, C 5 -C 8 Cycloalkenyl, C 5 -C 12 Bicycloalkyl, C 7 -C 12 Bicycloalkenyl, C 8 -C 14 Tricycloalkyl, linear or branched -OCH 3 -OC etc. 1 -C 5 Alkyl, -OC such as -O(cyclopropyl) 3 -C 5 Cycloalkyl, linear or branched -NH(C 1 -C 5 alkyl), linear or branched -N(C 1 -C 5 Alkyl) (C 1 -C 5 alkyl), -NH(cyclopropyl), etc. 3 -C 5 cycloalkyl), -N(C 3 -C 5 Cycloalkyl) (C 3 -C 5 cycloalkyl), linear or branched -N(C 1 -C 5 Alkyl) (C 3 -C 5 cycloalkyl); Here, R 1 , R 7 and R 8 When the alkyl, alkenyl and alkynyl residues included in the definition of are substituted with one or more substituents that are =O, such substitutions at =O cannot be one of the groups selected from C=O, S=O and N=O attached directly to the aromatic ring; 1 , R 7 and R 8 All cyclic, bicyclic and tricyclic structures, including cycloalkyl, cycloalkenyl, bicycloalkyl, bicycloalkenyl and tricycloalkyl residues included in the definition of 2 , -NO 2 , ═O, linear or branched —CH 3 C etc. 1 -C 5 Alkyl, linear or branched -OCH 3 -OC etc. 1 -C 5 Alkyl, linear or branched -NH(C 1 -C 5 alkyl), linear or branched -N(C 1 -C 5 Alkyl) (C 1 -C 5 alkyl), -NH(cyclopropyl), etc. 3 -C 5 cycloalkyl), -N(C 3 -C 5 Cycloalkyl) (C 3 -C 5 cycloalkyl), linear or branched -N(C 1 -C 5 Alkyl) (C 3 -C 5 cycloalkyl); Here, R 1 , R 7 and R 8 All alkyl, alkenyl and alkynyl residues included in the definition may contain one or more heteroatoms independently selected from O, S and N instead of a carbon atom, and where such substitution results in a residue containing at least twice the number of C atoms than heteroatoms independently selected from O, S and N, and where such substitution cannot be one of the groups selected from C=O, S=O and N=O directly attached to an aromatic ring; Here, R 1 , R 7 and R 8 All cycloalkyl, cycloalkenyl, bicycloalkyl, bicycloalkenyl and tricycloalkyl residues included in the definition of may contain one or more heteroatoms independently selected from O, S and N instead of carbon atoms, and where such a substitution results in a residue containing at least the same number of C atoms as heteroatoms independently selected from O, S and N; Here, R 1 , R 7 and R 8 All alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, bicycloalkyl, bicycloalkenyl and tricycloalkyl residues included in the definition of may be partially or fully halogenated, in particular fluorinated, more in particular perfluorinated; wherein bicyclic and tricyclic moieties include fused, bridged and spiro systems; R 2 -R 5 are each independently -H, -F, -Cl, -Br, -I, -CN, -NCO, -NCS, -OH, or -NH 2 , -NO 2 , linear or branched C 1 -C 4 Alkyl, linear or branched C 2 -C 4 Alkenyl, linear or branched C 2 -C 4 Alkynyl, C 3 -C 6 Cycloalkyl, -CH 2 (C 3 -C 6 cycloalkyl), straight or branched -OC 1 -C 3 Alkyl, -O(cyclopropyl), linear or branched -NH(C 1 -C 3 alkyl), linear or branched -N(C 1 -C 3 Alkyl) (C 1 -C 3 Alkyl), -NH(cyclopropyl), -N(cyclopropyl) 2 , linear or branched -N(C 1 -C 3 alkyl)(cyclopropyl); Here, R 2 -R 5 All alkyl, alkenyl, alkynyl and cycloalkyl residues included in the definition are unsubstituted or substituted with -F, -Cl, -Br, -I, -CH 3 , -CF 3 , —OH and —OCH 3 , -OCF 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 and is substituted with one or more substituents independently selected from Here, R 2 -R 5 All alkyl, alkenyl, alkynyl and cycloalkyl residues included in the definition may contain one or more heteroatoms independently selected from O, S and N in place of a carbon atom, and wherein such substitution cannot be one of the groups selected from C=O and S=O directly attached to the aromatic ring; X 1 -X 4 are N, CR independently of each other. 9 , C.R. 10 , C.R. 11 , C.R. 12 Selected from: R 9 -R 12 are each independently -H, -F, -Cl, -Br, -I, -CN, -NCO, -NCS, -OH, or -NH 2 , -NO 2 , linear or branched C 1 -C 4 Alkyl, Linear or branched C 2 -C 4 Alkenyl, linear or branched C 2 -C 4 Alkynyl, C 3 -C 6 Cycloalkyl, -CH 2 (C 3 -C 6 cycloalkyl), straight or branched -OC 1 -C 3 Alkyl, -O(cyclopropyl), linear or branched -NH(C 1 -C 3 alkyl), linear or branched -N(C 1 -C 3 Alkyl) (C 1 -C 3 Alkyl), -NH(cyclopropyl), -N(cyclopropyl) 2 , linear or branched -N(C 1 -C 3 alkyl)(cyclopropyl); Here, R 9 -R 12 All alkyl, alkenyl, alkynyl and cycloalkyl residues included in the definition are unsubstituted or substituted with -F, -Cl, -Br, -I, -CH 3 , -CF 3 , —OH and —OCH 3 , -OCF 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 and is substituted with one or more substituents independently selected from Here, R 9 -R 12 All alkyl, alkenyl, alkynyl and cycloalkyl residues included in the definition may contain one or more heteroatoms independently selected from O, S and N in place of a carbon atom, and wherein such substitution cannot be one of the groups selected from C=O and S=O directly attached to the aromatic ring; Here, R 9 -R 12 is preferably —H, —F, —Cl, —Br, —CH 3 , -CF 3 , -OH, -OCH 3 , -OCF 3 , cyclopropyl, oxiranyl, -C(CH 3 ) 3 , -N(CH 3 ) 2 , -NH 2 , -CN, -CH 2 OCH 3 , -OCH(CH 3 ) 2 , -CH 2 N.H. 2 , -CH 2 N (CH 3 ) 2 , -CH 2 OH, -NO 2 , -CH 2 -N-morpholinyl; R 6 is -H, C 1 -C 8 Preferably C 1 -C 4 Alkyl, C 2 -C 8 Preferably C 2 -C 4 Alkenyl, C 2 -C 8 Preferably C 2 -C 4 Alkynyl, C 3 -C 6 Cycloalkyl, C 5 -C 6 Cycloalkenyl, C 5 -C 12 Bicycloalkyl, C 7 -C 12 Bicycloalkenyl, C 8 -C 14 tricycloalkyl, and aromatic and heteroaromatic residues preferably 6-membered aromatic rings and 5- to 6-membered heteroaromatic rings; and wherein the bicyclic and tricyclic moieties include fused, bridged and spiro systems; Here, R 6 The cycloalkyl, cycloalkenyl, bicycloalkyl, bicycloalkenyl, tricycloalkyl, aromatic and heteroaromatic residues included in the definition of 1 Alkylene or C 2 Alkylene or C 3 R via an alkylene linker 6 can be attached to the N to which is attached; Here, R 6 All aromatic and heteroaromatic residues included in the definition are unsubstituted or substituted with -F, -Cl, -Br, -I, -CN, -NCO, -NCS, -OH, -NH 2 , -NO 2 , linear or branched C 1 -C 3 Alkyl, C 2 -C 3 Alkenyl, C 2 -C 3 Alkynyl, cyclopropyl, straight or branched -OCH 3 -OC etc. 1 -C 3 Alkyl, -O(cyclopropyl), linear or branched -NH(C 1 -C 3 alkyl), linear or branched -N(C 1 -C 3 Alkyl) (C 1 -C 3 Alkyl), -NH(cyclopropyl), -N(cyclopropyl) 2 , linear or branched -N(C 1 -C 3 substituted with one or more substituents independently selected from: Here, R 6 All alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, bicycloalkyl, bicycloalkenyl and tricycloalkyl residues, as well as alkylene linkers, included within the definition may be linear or branched, unsubstituted or substituted with -F, -Cl, -Br, -I, -CN, -NCO, -NCS, -OH, -NH 2 , ═O, linear or branched C 1 -C 3 Alkyl, C 2 -C 3 Alkenyl, C 2 -C 3 Alkynyl, cyclopropyl, straight or branched -OCH 3 -OC etc. 1 -C 3 Alkyl, -O(cyclopropyl), linear or branched -NH(C 1 -C 3 alkyl), linear or branched -N(C 1 -C 3 Alkyl) (C 1 -C 3 Alkyl), -NH(cyclopropyl), -N(cyclopropyl) 2 , linear or branched -N(C 1 -C 3 substituted with one or more substituents independently selected from: Here, R 6 All alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, bicycloalkyl, bicycloalkenyl, tricycloalkyl and and heteroaromatic residues, as well as alkylene linkers, can contain one or more heteroatoms independently selected from O, S and N in place of carbon atoms; Here, R 6 is preferably —H, —CH 3 , -CH 2 CH 3 , n-propyl, isopropyl, cyclopropyl, -CF 3 and -CF 2 CF 3 , benzyl, tert-butyl, phenyl, cyclohexyl, 1-phenylethyl, 2,2-dimethyl-1-phenylpropyl, (1-naphthyl)-methyl, 4-methoxybenzyl, 4-trifluoromethylbenzyl, tetrahydropyranyl; Here, R 2 -R 6 and R 9 -R 12 All alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, bicycloalkyl, bicycloalkenyl, tricycloalkyl, aromatic and heteroaromatic residues included in the definition of may be partially or fully halogenated, in particular fluorinated, more in particular perfluorinated; Y is -H, linear or branched C 1 -C 6 Alkyl, linear or branched C 2 -C 6 Alkenyl, linear or branched C 2 -C 6 Alkynyl, C 3 -C 6 Cycloalkyl, C 5 -C 6 Cycloalkenyl, -OH, linear or branched -OC 1 -C 6 Alkyl, linear or branched -OC 2 -C 6 Alkenyl, linear or branched -OC 2 -C 6 Alkynyl, -OC 3 -C 6 Cycloalkyl, -OC 5 -C 6 Cycloalkenyl, -CN, aromatic and heteroaromatic residues preferably 6-membered aromatic rings and 5- to 6-membered heteroaromatic rings, -S(O)R 13 and -S(O) 2 R 13 (In the formula, R 13 is a linear or branched C 1 -C 6 Alkyl, linear or branched C 2 -C 6 Alkenyl, linear or branched C 2 -C 6 Alkynyl, C 3 -C 6 Cycloalkyl, C 5 -C 6 Cycloalkenyl, -CF 3 , and -C 6 H 4 CH 3 is selected from wherein all cycloalkyl, cycloalkenyl, aromatic and heteroaromatic residues included in the definition of Y are optionally C 1 Alkylene or C 2 Alkylene or C 3 Alkylene or -O- or -O-CH 2 - or -O-CH 2 -CH 2 - can be linked to N to which Y is attached via a linker; wherein all aromatic and heteroaromatic residues included in the definition of Y are unsubstituted or are selected from the group consisting of -F, -Cl, -Br, -I, -CN, -NCO, -NCS, -OH, -NH 2 , -NO 2 , linear or branched C 1 -C 3 Alkyl, C 2 -C 3 Alkenyl, C 2 -C 3 Alkynyl, cyclopropyl, straight or branched -OCH 3 -OC etc. 1 -C 3 Alkyl, -O(cyclopropyl), linear or branched -NH(C 1 -C 3 alkyl), linear or branched -N(C 1 -C 3 Alkyl) (C 1 -C 3 Alkyl), -NH(cyclopropyl), -N(cyclopropyl) 2 , linear or branched -N(C 1 -C 3 Y is substituted with one or more substituents independently selected from the group consisting of -alkyl, -cyclopropyl ... 2 , ═O, linear or branched C 1 -C 3 Alkyl, C 2 -C 3 Alkenyl, C 2 -C 3 Alkynyl, cyclopropyl, straight or branched -OCH 3 -OC etc. 1 -C 3 Alkyl, -O(cyclopropyl), linear or branched -NH(C 1 -C 3 alkyl), linear or branched -N(C 1 -C 3 Alkyl) (C 1 -C 3 Alkyl), -NH(cyclopropyl), -N(cyclopropyl) 2 , linear or branched -N(C 1 -C 3 substituted with one or more substituents independently selected from: wherein all alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and heteroaromatic residues, as well as alkylene linkers, included within the definition of Y can contain one or more heteroatoms independently selected from O, S and N in place of carbon atoms; wherein all alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aromatic and heteroaromatic residues, as well as alkylene linkers included in the definition of Y, may be partially or fully halogenated, in particular fluorinated, more in particular perfluorinated; Here, Y is R 6 and together with the N atom of formula I can form a ring structure, wherein said ring structure containing the N atom of formula I is selected from a 3-membered ring, a 4-membered ring, a 5-membered ring, a 6-membered ring, from a 5- to 12-membered bicyclic residue, from an 8- to 14-membered tricyclic residue, and from a heteroaromatic residue, wherein all rings, bicyclics, tricyclics, and heteroaromatic residues can further contain one or more heteroatoms independently selected from O, S, and N in place of carbon atoms contained in the ring structure, and wherein all rings, bicyclics, tricyclics, and heteroaromatic residues are unsubstituted or substituted with -F, -Cl, -Br, -I, -CN, -NCO, -NCS, -OH, -OCH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , =O, -CH 3 , -CF 3 , morpholinyl; and wherein the bicyclic and tricyclic moieties include fused, bridged and spiro systems; Z 1 and Z 2 is selected from the following groups: 【Chemistry 2】 Here, Z 1 is a linear or branched C 1 -C 3 Alkyl, preferably -CH 3 , cyclopropyl, oxiranyl, N-methyl-aziridinyl, thiiranyl, -CN, -N 3 , -CF 3 , -CF 2 CF 3 and wherein Z 2 is -H and linear or branched C 1 -C 3 Alkyl, preferably -CH 3 , -CF 3 , -CF 2 CF 3 (Ia); Or here, Z 1 and Z 2 are together =O, =S, =NR 14 (Ib); where R 14 is -H, -OH, -OCH 3 , -CN, -S(O)C(CH 3 ) 3 , -S(O) 2 CH 3 , -S(O) 2 CF 3 , linear or branched C 1 -C 3 Alkyl, preferably -CH 3 , cyclopropyl, -CF 3 , -CF 2 CF 3 , -CH 2 CF 3 , -C 6 H 5 , -CH 2 C 6 H 5 Selected from: Or here, Z 1 and Z 2 taken together form a cyclic residue including the carbon atom to which they are attached (Ic); where the cyclic residue is selected from a 3-, 4-, 5-, and 6-membered ring, where all rings can optionally contain one or more heteroatoms independently selected from O, S, and N in place of the carbon atoms contained in the ring structure; where all rings are unsubstituted or substituted with -F, -Cl, -Br, -I, -CN, -NCO, -NCS, -OH, -OCH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , =O, -CH 3 and -CF 3 and is substituted with one or more substituents independently selected from Here, Z 1 and Z 2 All alkyl and cyclic residues included in the definition may be partially or fully halogenated, particularly fluorinated, more particularly perfluorinated.
2. 2. The compound of claim 1 according to formula (Ia) or a salt or solvate thereof:
3. 2. The compound of claim 1 according to formula (Ib) or a salt or solvate thereof:
4. 2. The compound of claim 1 according to formula (Ic) or a salt or solvate thereof:
5. A compound according to any one of claims 1 to 4, provided that: (i) The compounds shown in Table 1 are excluded; (ii) excluding the compounds shown in Table 2; and / or (iii) The compounds shown in Table 3 are excluded.
6. R 1 is methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, iso-propyl, sec-butyl, tert-butyl, tert-pentyl, tert-octyl, 3-pentyl, -CF 3 , -CF 2 CF 3 , -(CF 2 ) 2 CF 3 , -CH(CF 3 ) 2 , -CH 2 SCH 3 , -CH 2 CH 2 SCH 3 , -CH 2 SCH 2 CH 3 , -CH 2 CH 2 SCH 2 CH 3 , methoxymethyl, methoxyethyl, methoxypropyl, ethoxymethyl, ethoxyethyl, propoxymethyl, dimethylaminomethyl, dimethylaminoethyl, diethylaminomethyl, ethylmethylaminomethyl, cyclopropyl, methylcyclopropyl, ethylcyclopropyl, trifluoromethylcyclopropyl, perfluoroethylcyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, bicyclopentyl, bicyclohexyl, bicycloheptyl, preferably nor Bornyl, bicyclooctyl, bicyclooctenyl, bicyclononyl, methylbicyclononyl, adamantyl, tricyclodecyl, oxiranyl, oxetanyl, tetrahydrofuranyl, methyltetrahydrofuranyl, trimethyltetrahydrofuranyl, tetrahydropyranyl, aziridinyl, N-methylaziridinyl, azetidinyl, N-methylazetidinyl, difluoroazetidinyl, pyrrolidinyl, N-methylpyrrolidinyl, piperidinyl, N-methylpiperidinyl, difluoropiperidinyl, thiiranyl, thietanylic aryl, tetrahydrothiophenyl, tetrahydrothiopyranyl, dioxanyl, piperazinyl, dimethylpiperazinyl, dithianly, morpholinyl, N-methylmorpholinyl, thiomorpholinyl, N-methylthiomorpholinyl, oxa-azaspiroheptyl, N-methyloxa-azaspiroheptyl, azaspiroheptyl, N-methylazaspiroheptyl, thia-azaspiroheptyl, N-methylthia-azaspiroheptyl, difluorothia-azaspiroheptyl, azaspirooctyl, N-methylaza Zaspirooctyl, oxa-azaspirooctyl, N-methyloxa-azaspirooctyl, oxa-azaspirononyl, N-methyloxa-azaspirononyl, azaspirononyl, N-methylazaspirononyl, oxa-azaspirodecyl, N-methyloxa-azaspirodecyl, azaspirodecyl, N-methylazaspirodecyl, dihydro-oxazinyl, N-methyldihydro-oxazinyl, oxazolidinyl, N-methyloxazolidinyl, dioxolanyl, imidazolidinyl, N-methylimidazolidinyl, N,N-dimethylimidazolidinyl, azepanyl, N-methylazepanyl, azaspirohexyl, N-methylazaspirohexyl, oxa-azadispirodecyl, N-methyloxa-azadispirodecyl, azadispirodecyl, N-methylazadispirodecyl, oxa-azabicyclooctyl, N-methyloxa-azabicyclooctyl, azabicyclooctyl, N-methylazabicyclooctyl, azabicycloheptyl, N-methylazabicycloheptyl, azabicyclononyl, N-methylazabicyclononyl, azaadamantyl, -O(adamantyl), oxa The compound according to any one of claims 1 to 5, selected from cer-azabicyclononyl, N-methyloxa-azabicyclononyl, oxa-azabicycloheptyl, N-methyloxa-azabicycloheptyl, diazabicyclooctyl, N-methyldiazabicyclooctyl, N,N-dimethyldiazabicyclooctyl, diazabicycloheptyl, N-methyldiazabicycloheptyl, N,N-dimethyldiazabicycloheptyl; 4-oxocyclohexyl; 3-oxocyclopentyl; 2-oxocyclobutyl, and 4-oxobicyclo[4.1.0]heptan-1-yl.
7. R 1 But, C 4 -C 12 Alkyl, C 4 -C 12 Alkenyl, C 4 -C 12 Compounds according to any one of claims 1 to 6, selected from alkynyl, cyclic, bicyclic and tricyclic residues, where the alkyl, alkenyl and alkynyl residues are preferably branched and include: 【Chemistry 3】
8. R 2 -R 3 are each -H, and R 4 is preferably -H or -F, and / or R 5 -H, -F, -Cl, -Br, -CH 3 , -CF 3 , -CH=CH 2 , -C≡CH, -CH 2 OH, -CH 2 N.H.C.H. 3 , -OH, -OCH 3 , -OCF 3 , Sik propyl, oxiranyl, -CH 2 -N-morpholinyl, -C(CH 3 ) 3 , -CH 2 OCH 3 , -NO 2 , -CN, -NH 2 , -N(CH 3 ) 2 , -OCH(CH 3 ) 2 , -CH 2 N.H. 2 , -CH 2 N (CH 3 ) 2 The compound according to any one of claims 1 to 7,
9. The substituent R as defined in formula (I) 1 From R 5 The compound according to any one of claims 1 to 8, wherein the six-membered aromatic ring to which is attached is selected from the following: 【Chemistry 4】
10. X defined in formula (I) 1 -X 4 The compound according to any one of claims 1 to 9, wherein the six-membered aromatic ring is selected from the following: 【Chemistry 5】
11. Y is -H, -CH 3 , -CH 2 CH 3 , n-propyl, isopropyl, cyclopropyl, cyclohexyl, tetrahydropyranyl, -CF 3 , -CF 2 CF 3 , -OH, -OCH 3 , -OCH 2 CH 3 , -OCH 2 (cyclopropyl), -CN, -S(O)C(CH 3 ) 3 , -S(O) 2 CH 3 , -S(O) 2 CF 3 , -S(O) 2 C 6 H 4 CH 3 , -OCH 2 C 6 H 5 and -OC 6 H 5 and R 6 is -H or -CH 3 or benzyl, Y is preferably -OH, -OCH 3 , -OCH 2 CH 3 , -OCH 2 The compound according to any one of claims 1 to 10, which is (cyclopropyl).
12. R containing an N atom of formula I 6 The compound of any one of claims 1 to 11, wherein the ring structure of Y taken together is selected from aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, difluoropiperidinyl, morpholinyl, morpholinylazetidinyl, hydroxyazetidinyl, azetidinonyl, azetidinyl, difluoroazetidinyl, azaspirohexyl, azaspiroheptyl, difluoroazaspiroheptyl, hydroxyazaspiroheptyl, methylhydroxyazaspiroheptyl, trifluoromethylhydroxyazaspiroheptyl, azaspirooctyl, azaspirononyl, oxa-azaspiroheptyl, oxa-azaspirooctyl, oxa-azaspirononyl, thia-azaspiroheptyl, oxazolidinyl, tetrahydro-oxazinyl, isoxazolidinyl, oxazinane, isoxazolidine, piperazine.
13. R containing an N atom of formula I 6 The compound of any one of claims 1 to 12, wherein the ring structure of Y taken together is selected from the following: 【Chemistry 6】
14. Z 1 Ga-CH 3 , -CF 3 , —CN, cyclopropyl; and / or Z 2 is preferably —H, —CH 3 and -CF 3 A compound according to any one of claims 1 to 13, for example 【Chemistry 7】
15. Z 1 and Z 2 are preferably taken together as ═O or ═NR 14 where R 14 is preferably -H, -CH 3 , cyclopropyl, -OH, -OCH 3 The compound of any one of claims 1 to 13, selected from -CN. 【Chemistry 8】
16. Z 1 and Z 2 together form a 3- or 4-membered cyclic moiety containing the carbon atom to which they are attached, wherein the cyclic moiety is preferably selected from cyclopropyl, cyclobutyl, oxiranyl, oxetanyl, aziridinyl, azetidinyl and thietanyl; and wherein the cyclic moiety is optionally preferably -F, -OH, -OCH 3 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , =O, -CH 3 and -CF 3 and wherein the cyclic residue is even more preferably 【Chemistry 9】 The compound according to any one of claims 1 to 13, selected from:
17. 17. The compound according to any one of claims 1 to 16, wherein Y is selected from residues contained in the general formula of Y bonded to the N to which Y is bonded via an oxygen atom.
18. R 1 R contains 4 or more, preferably 6 or more, and even more preferably 7 or more carbon atoms. 1 and R 1 The compound of any one of claims 1 to 17, wherein does not contain a heteroatom.
19. R 1 20. The compound of claim 18, wherein is selected from cyclic, bicyclic and tricyclic structures.
20. R 1 Cyclohexyl, norbornyl, bicyclooctyl, bicyclononyl, methylbicyclo 20. The compound of claim 18 or 19 selected from cyclononyl, tricyclodecyl and adamantyl.
21. R 1 R contains 4 or more, preferably 6 or more, and even more preferably 7 or more carbon atoms. 1 and R 1 R 1 18. The compound of any one of claims 1 to 17, comprising one or more, preferably one to two heteroatoms independently selected from O, S and N in place of the carbon atoms contained in
22. R 1 22. The compound of claim 21, wherein is selected from tetrahydropyranyl, N-methylpiperidinyl, morpholinyl, 4-oxocyclohexyl, azabicycloheptyl, N-methylazabicycloheptyl, oxa-azabicycloheptyl, N-methyldiazabicycloheptyl, azabicyclooctyl, diazabicyclooctyl, N-methyldiazabicyclooctyl, oxa-azabicyclooctyl, azabicyclononyl, azaadamantyl, and -O(adamantyl).
23. The compound of any one of claims 1 to 22, wherein the compound has the following structure (I-1): 【Chemistry 10】 (In the formula, Z 1 and Z 2 is as defined in general formula (I), including general formula (Ia), general formula (Ib) and general formula (Ic), including substituents and preferred definitions, with the optional proviso that in the case of general formula (Ib), Z 1 and Z 2 are not combined to equal O. R 14 is as defined in general formula (Ib), including the substituents and preferred definitions; Y, R 2 -R 6 , R 9 -R 13 and X 1 -X 4 are as defined in general formula (I), including substituents and preferred definitions.
24. The compound of any one of claims 1 to 23, wherein the compound has the following structure (I-4): 【Chemistry 11】 (In the formula, R 6 is as defined in general formula (I), including the substituents and preferred definitions, with the proviso that R 6 is different from -H, Z 1 and Z 2 is as defined in general formula (I), including general formula (Ia), general formula (Ib) and general formula (Ic), including substituents and preferred definitions; R 14 is as defined in general formula (Ib), including the substituents and preferred definitions; R 1 -R 5 , R 7 -R 12 and X 1 -X 4 are as defined in general formula (I), including substituents and preferred definitions.
25. 25. The compound of any one of claims 1 to 24, wherein the compound has the following structure (Ib-1): 【Chemistry 12】 (In the formula, R 1 is as defined in general formula (I), including the substituents and preferred definitions; R 1 contains six or more carbon atoms, optionally substituted independently with heteroatoms selected from O, S and N as defined in general formula (I), and R 1 is selected from cyclic, bicyclic and tricyclic structures; R 5 is as defined in general formula (I), including the substituents and preferred definitions, with the proviso that R 5 is different from -H, Z 1 , Z 2 and R 14 is as defined in general formula (Ib), including the substituents and preferred definitions; R 2 -R 4 , R 6 -R 13 , X 1 -X 4 and Y is as defined in general formula (I), including the substituents and preferred definitions.
26. 26. The compound of any one of claims 1 to 25, wherein the compound has the following structure (Ib-2): 【Chemistry 13】 (In the formula, R 1 is as defined in general formula (I), including the substituents and preferred definitions; R 1 contains six or more carbon atoms, optionally substituted independently with heteroatoms selected from O, S and N as defined in general formula (I), and R 1 is selected from cyclic, bicyclic and tricyclic structures; Z 1 , Z 2 and R 14 is as defined in general formula (Ib), including the substituents and preferred definitions; R 2 -R 13 , X 1 -X 3 and Y is as defined in general formula (I), including the substituents and preferred definitions.
27. A compound shown in any one of Tables 6 to 54, or a salt or solvate thereof.
28. A compound according to any one of claims 1 to 27 for use in medicine, such as human or veterinary medicine.
29. 30. A compound according to any one of claims 1 to 27 for use in the treatment of a disorder associated with, accompanied by and / or caused by dysfunctional Notch signalling.
30. 28. A compound according to any one of claims 1 to 27 for use as an enhancer of Notch signalling.
31. 30. A compound of any one of claims 1 to 27 for use in the treatment of hyperproliferative disorders, including malignant and non-malignant hyperproliferative disorders.
32. 28. A compound according to any one of claims 1 to 27 for use in the treatment of cancers such as non-melanoma skin cancers including squamous cell carcinoma and basal cell carcinoma and precancerous lesions including actinic keratosis, skin and / or mucosal disorders with defective keratinization and / or abnormal keratinocyte proliferation, skin and / or mucosal diseases associated with, accompanied by and / or caused by viral infections, diseases and malignant, non-malignant and hyperproliferative disorders of the skin, mucous membranes, skin and mucosal adnexa, cornea and epithelial tissues including atopic dermatitis and acne, and in promoting wound healing of the skin and mucous membranes.
33. 28. A compound according to any one of claims 1 to 27 for use in hyperproliferative disorders, cancer or precancerous lesions of the skin, oral mucosa, tongue, lung, stomach, breast, medullary thyroid cancer, cancer of the neuroendocrine system such as brain, pancreas, liver, thyroid and urogenital tract including cervical and ovarian cancer.
34. Treatment of malignant and non-malignant muscle diseases, including muscular dystrophies, or muscle regeneration, or muscle 30. A compound according to any one of claims 1 to 27 for use in hyperproliferative disorders of muscle, such as hyperplasia and muscle hypertrophy.
35. 28. A compound according to any one of claims 1 to 27 for use in the treatment of immune system related disorders including disorders of the hematopoietic system including the vasculature such as malignancies of the myeloid system, e.g. acute and chronic myeloid leukemia and acute and chronic promyelocytic leukemia, and malignancies of the lymphoid system, e.g. acute and chronic T-cell leukemia and acute and chronic B-cell leukemia and cutaneous T-cell lymphoma, and cancers of the hematopoietic and vascular systems such as leukemias and lymphomas.
36. 30. A compound of any one of claims 1 to 27 for use in therapeutic immune system related applications including immunotherapy and other immunotherapies such as for use as an immunological adjuvant or vaccine adjuvant.
37. A method of treating a hyperproliferative disorder comprising administering to a subject, particularly a human subject, in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 27.
38. A method for treating disorders related to, accompanied by and / or caused by dysfunctional Notch signaling, comprising administering to a subject, particularly a human subject, a therapeutically effective amount of a compound of any one of claims 1 to 27.
